

**CUMULATIVE
SUPPLEMENT 6
JUNE 2003**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23rd EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2003

HYMAN, PHELPS
&MCNAMARA, P.C.
WASHINGTON, DC

DEMCO

1.0
1.1
1.2
1.3
1.4
1.5
1.6

DRU

PA

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23RD EDITION

Cumulative Supplement 6

June 2003

CONTENTS

	PAGE
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Nitroglycerin, Film, Extended Release; Transdermal 23 rd Annual Edition	v
1.4 Availability of the Edition.....	vi
1.5 Report of Counts for the Prescription Drug Product List.....	vii
1.6 Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

THE UNIVERSITY OF CHICAGO
DEPARTMENT OF CHEMISTRY

LABORATORY REPORT

EXPERIMENT 1

DATE

NAME

1.1

1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
1.10
1.11
1.12
1.13
1.14
1.15
1.16
1.17
1.18
1.19
1.20
1.21
1.22
1.23
1.24
1.25
1.26
1.27
1.28
1.29
1.30
1.31
1.32
1.33
1.34
1.35
1.36
1.37
1.38
1.39
1.40
1.41
1.42
1.43
1.44
1.45
1.46
1.47
1.48
1.49
1.50
1.51
1.52
1.53
1.54
1.55
1.56
1.57
1.58
1.59
1.60
1.61
1.62
1.63
1.64
1.65
1.66
1.67
1.68
1.69
1.70
1.71
1.72
1.73
1.74
1.75
1.76
1.77
1.78
1.79
1.80
1.81
1.82
1.83
1.84
1.85
1.86
1.87
1.88
1.89
1.90
1.91
1.92
1.93
1.94
1.95
1.96
1.97
1.98
1.99
2.00

1.1

1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
1.10
1.11
1.12
1.13
1.14
1.15
1.16
1.17
1.18
1.19
1.20
1.21
1.22
1.23
1.24
1.25
1.26
1.27
1.28
1.29
1.30
1.31
1.32
1.33
1.34
1.35
1.36
1.37
1.38
1.39
1.40
1.41
1.42
1.43
1.44
1.45
1.46
1.47
1.48
1.49
1.50
1.51
1.52
1.53
1.54
1.55
1.56
1.57
1.58
1.59
1.60
1.61
1.62
1.63
1.64
1.65
1.66
1.67
1.68
1.69
1.70
1.71
1.72
1.73
1.74
1.75
1.76
1.77
1.78
1.79
1.80
1.81
1.82
1.83
1.84
1.85
1.86
1.87
1.88
1.89
1.90
1.91
1.92
1.93
1.94
1.95
1.96
1.97
1.98
1.99
2.00

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

CUMULATIVE SUPPLEMENT 6
June 2003

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 23rd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BAYER CORP (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
BAYER CORP CONSUMER CARE DIV (BAYER CORP CONSUMER)	BAYER CORP CONSUMER CARE LLC (BAYER)
BAYER CORP PHARMACEUTICALS DIV (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
ESI LEDERLE INC (ESI LEDERLE)	CLONMEL HEALTHCARE INC (CLONMEL HEALTHCARE)
LEK SERVICES INC (LEK SVCS)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO (LEK LJUBLJANA)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK PHARMACEUTICAL AND CHEMICAL DD (LEK PHARM)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
ORGANON INC (ORGANON INC)	ORGANON USA INC (ORGANON USA INC)
ORGANON INC SUB AKZO INC (ORGANON)	ORGANON USA INC (ORGANON USA INC)
ORGANON INC SUB AKZO NOBEL INC (ORGANON INC)	ORGANON USA INC (ORGANON USA INC)
SIDMAK LABORATORIES INC (SIDMAK LABS)	PLIVA INC (PLIVA)
SYNTEX (USA) INC LLC (SYNTEX USA INC)	ROCHE PALO ALTO LLC (ROCHE PALO)
WALLACE LABORATORIES DIV CARTER WALLACE INC (WALLACE LABS)	MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC (MEDPOINTE PHARM HLC)
WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC (WALLACE PHARMS)	MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC (MEDPOINTE PHARM HLC)

1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL 23RD ANNUAL EDITION

The *Approved Drug Products with Therapeutic Equivalence Evaluations 23rd annual edition*, page 3-265 omitted the 3 character Therapeutic Equivalence (TE) Codes for Nitroglycerin, Film, Extended Release; Transdermal products. The correct codes are listed below by product name, applicant holder, TE code, strength, NDA number, and product number.

<u>PRODUCT</u> <u>NAME</u>	<u>APPLICANT</u>	<u>TE</u> <u>CODE</u>	<u>STRENGTH</u>	<u>NDA</u>	<u>PRODUCT</u>
MINITRAN	3M	AB1	0.1MG/HR	N89771	001
MINITRAN	3M	AB1	0.2MG/HR	N89772	001
MINITRAN	3M	AB1	0.4MG/HR	N89773	001
MINITRAN	3M	AB1	0.6MG/HR	N89774	001
NITRO-DUR	KEY PHARMS	AB1	0.1MG/HR	N20145	001
NITRO-DUR	KEY PHARMS	AB1	0.2MG/HR	N20145	002
NITRO-DUR	KEY PHARMS	AB1	0.4MG/HR	N20145	004
NITRO-DUR	KEY PHARMS	AB1	0.6MG/HR	N20145	005
NITROGLYCERIN	HERCON LABS	AB2	0.2MG/HR	N89884	001
NITROGLYCERIN	HERCON LABS	AB2	0.4MG/HR	N89885	001
NITROGLYCERIN	HERCON LABS	AB2	0.6MG/HR	N89886	001
NITROGLYCERIN	MYLAN	AB2	0.1MG/HR	N75033	001
NITROGLYCERIN	MYLAN	AB2	0.2MG/HR	N74609	001
NITROGLYCERIN	MYLAN	AB2	0.4MG/HR	N74607	001

1.4 AVAILABILITY OF THE EDITION

The 23rd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$108.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
<http://www.fda.gov/cder/orange/adp.htm>

The Internet version of the monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>

There are ASCII text files of the Orange Book drug product data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 23rd annual edition of the 2002 Orange Book Patent and Exclusivity List is at
<http://www.fda.gov/cder/orange/23bookpub.pdf>

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
<http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
<http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.htm>

The current listing of the Orphan Product Designations and Approvals is available at
<http://www.fda.gov/orphan/designat/list.htm>

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2002) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2002</u>	<u>JUN 2003</u>	<u>SEP 2003</u>	<u>DEC 2003</u>
DRUG PRODUCTS LISTED	10465	10514		
SINGLE SOURCE	2420 (23.1%)	2417 (23.0%)		
MULTISOURCE	7939 (75.9%)	7989 (76.0%)		
THERAPEUTICALLY	7659 (73.2%)	7708 (73.3%)		
EQUIVALENT				
NOT THERAPEUTICALLY	280 (2.7%)	281 (2.7%)		
EQUIVALENT				
EXCEPTIONS ¹	106 (1.0%)	108 (1.0%)		
NEW MOLECULAR ENTITIES	6	6		
APPROVED				
NUMBER OF APPLICANTS	598	604		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION; ORAL

ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE

+ MIKART 325MG/15ML;50MG/15ML;40MG/15ML N40387 001 JAN 31, 2003 JAN NEWA

TABLET; ORAL

BUTALBITAL, APAP, AND CAFFEINE

AB AXIOM PHARM 325MG;50MG;40MG N89536 001 FEB 16, 1988 MAY CAHN

FIORICET

AB + WATSON PHARMS 325MG;50MG;40MG N88616 001 NOV 09, 1984 APR CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

AB + WATSON PHARMS 325MG;50MG;40MG;30MG N20232 001 JUL 30, 1992 MAR CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

>D> CAPSULE; ORAL

>D> PHENAPHEN W/ CODEINE NO. 3

>D> + ROBINS AH 325MG;30MG N84445 001 JUN DISC

>A> @ 325MG;30MG N84445 001 JUN DISC

>D> PHENAPHEN W/ CODEINE NO. 4

>D> + ROBINS AH 325MG;60MG N84446 001 JUN DISC

>A> @ 325MG;60MG N84446 001 JUN DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA ANDRX PHARMS 300MG;15MG N40443 001 JAN 22, 2003 JAN NEWA

AA 300MG;30MG N40443 002 JAN 22, 2003 JAN NEWA

AA 300MG;60MG N40443 003 JAN 22, 2003 JAN NEWA

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA RANBAXY 300MG;60MG N87083 001 JAN CAHN

ACETAMINOPHEN W/ CODEINE PHOSPHATE #3

AA RANBAXY 300MG;30MG N85868 001 JAN CAHN

CODRIX

+ ANDRX PHARMS 500MG;30MG N40441 001 MAR 27, 2003 MAR NEWA

+ 500MG;15MG N40447 001 FEB 26, 2003 FEB NEWA

+ 500MG;60MG N40488 001 MAR 28, 2003 MAR NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

AA ABLE 650MG;7.5MG N40474 001 JAN 02, 2003 JAN NEWA

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ABLE 500MG;7.5MG N40490 001 MAY 21, 2003 MAY NEWA

AA ANDRX PHARMS 500MG;5MG N40493 001 MAY 28, 2003 MAY NEWA

AA 660MG;10MG N40495 001 MAY 28, 2003 MAY NEWA

AA 750MG;7.5MG N40494 001 MAY 28, 2003 MAY NEWA

AA AXIOM PHARM 500MG;5MG N40236 001 SEP 25, 1997 MAY CAHN

AA 650MG;10MG N40240 001 NOV 26, 1997 MAY CAHN

AA 650MG;7.5MG N40240 002 NOV 26, 1997 MAY CAHN

AA 750MG;7.5MG N40236 002 SEP 25, 1997 MAY CAHN

AA MIKART 325MG;7.5MG N40432 001 JAN 22, 2003 JAN NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	AXIOM PHARM	500MG;5MG	N40219 001	JAN 22, 1998	MAY	CAHN
----	-------------	-----------	------------	--------------	-----	------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

DIAMOX

>A>	@ DURAMED PHARM BARR	500MG	N12945 001		JUN	CAHN
>A>	+	500MG	N12945 003	APR 25, 1995	JUN	CAHN
>D>	@ LEDERLE	500MG	N12945 001		JUN	CAHN
>D>	+	500MG	N12945 003	APR 25, 1995	JUN	CAHN

TABLET; ORAL

>A>	AB DURAMED PHARM BARR	125MG	N08943 001		JUN	CAHN
>A>	AB +	250MG	N08943 002		JUN	CAHN
>D>	AB LEDERLE	125MG	N08943 001		JUN	CAHN
>D>	AB +	250MG	N08943 002		JUN	CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

>A>	AP + DURAMED PHARM BARR	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990	JUN	CAHN
>D>	AP + LEDERLE	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990	JUN	CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

>D>	+ BAYER PHARMS	2%;1%;EQ 0.35% BASE	N50238 001		JUN	DISC
>A>	@	2%;1%;EQ 0.35% BASE	N50238 001		JUN	DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB	AAIPHARMA	200MG	N74833 001	APR 22, 1997	APR	CAHN
----	-----------	-------	------------	--------------	-----	------

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

>A>	+ AMERSHAM HLTH	10MG/ML	N20899 001	DEC 31, 1997	JUN	CAHN
>D>	+ MALLINCKRODT	10MG/ML	N20899 001	DEC 31, 1997	JUN	CAHN

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	NOVEX	EQ 0.5% BASE	N76391 001	APR 01, 2003	APR	NEWA
>A>	@ CLONMEL HLTHCARE	EQ 2MG BASE	N72859 001	DEC 20, 1989	JUN	DISC
>A>	@	EQ 4MG BASE	N72860 001	DEC 20, 1989	JUN	DISC
>D>	AB LEDERLE	EQ 2MG BASE	N72859 001	DEC 20, 1989	JUN	DISC
>D>	AB	EQ 4MG BASE	N72860 001	DEC 20, 1989	JUN	DISC

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP + AKORN

EQ 0.5MG BASE/ML

N19353 001 DEC 29, 1986 MAR CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

>A> + SANOFI SYN RES

10MG

N21287 001 JUN 12, 2003 JUN NEWA

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

>A> AB VINTAGE PHARMS

100MG

N75798 001 JUN 27, 2003 JUN NEWA

>A> AB

300MG

N75798 002 JUN 27, 2003 JUN NEWA

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

JANSSEN ORTHO

+

EQ 6.25MG BASE

N21001 001 MAY 07, 2001 APR CAHN

EQ 12.5MG BASE

N21001 002 MAY 07, 2001 APR CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

>D> + SABEX 2002

2 IU/ML;20MG/ML;12UGM/ML;40
IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/
ML;0.8MG/ML;0.72MG/ML;0.8MG/ML;660
IU/ML;0.03MG/ML

N21163 001 MAY 18, 2000 JUN CPOT

>A> +

2 IU/ML;40MG/ML;12UGM/ML;40
IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/
ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660
IU/ML;0.03MG/ML

N21163 001 MAY 18, 2000 JUN CPOT

INJECTABLE; IV (INFUSION)

>A> + SABEX 2002

2 IU/ML;40MG/ML;12UGM/ML;40
IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/
ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660
IU/ML;30UGM/ML

N21559 001 JUN 16, 2003 JUN NEWA

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

CERNEVIT-12

@ BAXTER HLTHCARE

11.2
IU/VIAL;125MG/VIAL;60UGM/VIAL;200
IU/VIAL;5.5MG/VIAL;414UGM/VIAL;46MG
/VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14
MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL

N20924 001 APR 06, 1999 MAR DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

>A>	@	CLONMEL HLTHCARE	0.25MG	N74174 001	OCT 19, 1993	JUN	DISC
>A>	@		0.5MG	N74174 002	OCT 19, 1993	JUN	DISC
>A>	@		1MG	N74174 003	OCT 19, 1993	JUN	DISC
>A>	@		2MG	N74174 004	OCT 19, 1993	JUN	DISC
>D>	AB	LEDERLE	0.25MG	N74174 001	OCT 19, 1993	JUN	DISC
>D>	AB		0.5MG	N74174 002	OCT 19, 1993	JUN	DISC
>D>	AB		1MG	N74174 003	OCT 19, 1993	JUN	DISC
>D>	AB		2MG	N74174 004	OCT 19, 1993	JUN	DISC

TABLET, EXTENDED RELEASE; ORAL

XANAX XR

		PHARMACIA AND UPJOHN	0.5MG	N21434 001	JAN 17, 2003	JAN	NEWA
			1MG	N21434 002	JAN 17, 2003	JAN	NEWA
			2MG	N21434 003	JAN 17, 2003	JAN	NEWA
	+		3MG	N21434 004	JAN 17, 2003	JAN	NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HCL

AB		GENEVA PHARMS	100MG	N71293 001	FEB 18, 1987	APR	CAHN
----	--	---------------	-------	------------	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB		ALTANA	0.1%	N76065 001	MAY 15, 2003	MAY	NEWA
AB		TARO PHARM INDS	0.1%	N76229 001	MAY 31, 2002	MAY	CTEC
AT			0.1%	N76229 001	MAY 31, 2002	APR	NEWA
AT	+	FUJISAWA HLTHCARE	0.1%	N18116 002		APR	CFTG
AB	+		0.1%	N18116 002		MAY	CTEC

OINTMENT; TOPICAL

AMCINONIDE

AB		TARO PHARM INDS	0.1%	N76367 001	MAR 19, 2003	MAR	NEWA
----	--	-----------------	------	------------	--------------	-----	------

AMINO ACIDS

INJECTABLE; INJECTION

PREMASOL 10% IN PLASTIC CONTAINER

>A>		BAXTER HLTHCARE	10% (10GM/100ML)	N75880 002	JUN 19, 2003	JUN	NEWA
>A>		PREMASOL 6% IN PLASTIC CONTAINER					
>A>		BAXTER HLTHCARE	6% (6GM/100ML)	N75880 001	JUN 19, 2003	JUN	NEWA

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

>D>	AP	ELKINS SINN	250MG/ML	N18590 001	OCT 29, 1982	JUN	DISC
>A>	@		250MG/ML	N18590 001	OCT 29, 1982	JUN	DISC

AMINOPHYLLINE

INJECTABLE; INJECTION

>D> AP AMINOPHYLLINE 25MG/ML
 >A> AP + ABBOTT 25MG/ML
 >D> AP + ELKINS SINN 25MG/ML
 >A> @ 25MG/ML

N87601 001 JUL 23, 1982 JUN CRLD
 N87601 001 JUL 23, 1982 JUN CRLD
 N87239 001 JUN DISC
 N87239 001 JUN DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AP AMIODARONE HCL 50MG/ML
 AP APOTEX 50MG/ML
 AP + CORDARONE 50MG/ML
 AP + WYETH PHARMS INC 50MG/ML
 AB TABLET; ORAL 200MG
 AB WYETH PHARMS INC 200MG

N76394 001 APR 25, 2003 APR NEWA
 N20377 001 AUG 03, 1995 MAR CAHN
 N18972 001 DEC 24, 1985 MAR CAHN

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

>D> ENDEP 40MG/ML
 >D> + ROCHE 40MG/ML
 >A> @ 40MG/ML

N85749 001 JUN DISC
 N85749 001 JUN DISC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10 10MG;2MG
 @ SCHERING
 ETRAFON 2-25 25MG;2MG
 @ SCHERING
 ETRAFON-FORTE 25MG;4MG
 @ SCHERING

N14713 007 MAR DISC
 N14713 004 MAR DISC
 N14713 006 MAR DISC

AMMONIUM LACTATE

CREAM; TOPICAL

AB AMMONIUM LACTATE EQ 12% BASE
 AB TARO

N75883 001 APR 10, 2003 APR NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

>D> WYMOX
 >D> AB WYETH AYERST 125MG/5ML
 >A> @ 125MG/5ML
 >D> AB 250MG/5ML
 >A> @ 250MG/5ML

N62131 001 JUN DISC
 N62131 001 JUN DISC
 N62131 002 JUN DISC
 N62131 002 JUN DISC

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

PREVPAC

+ TAP PHARM 500MG;500MG;30MG

N50757 001 DEC 02, 1997 MAY CDFR

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	RANBAXY	200MG/5ML;EQ 28.5MG BASE/5ML	N65132 001	MAR 19, 2003	MAR	NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	N65132 002	MAR 19, 2003	MAR	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

	ADDERALL XR 10					
	SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	JAN	CAHN
	ADDERALL XR 15					
	SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	JAN	CAHN
	ADDERALL XR 20					
	SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	JAN	CAHN
	ADDERALL XR 25					
	SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	JAN	CAHN
	ADDERALL XR 30					
+	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	JAN	CAHN
	ADDERALL XR 5					
	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005	MAY 22, 2002	JAN	CAHN
	TABLET; ORAL					
	ADDERALL 12.5					
AB	SHIRE LABS	3.125MG;3.125MG;3.125MG;3.125MG	N11522 012	AUG 31, 2000	MAR	CFTG
	ADDERALL 15					
AB	SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N11522 013	AUG 31, 2000	MAR	CFTG
	ADDERALL 7.5					
AB	SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	MAR	CFTG
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	N40456 001	MAY 06, 2003	MAY	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40456 002	MAY 06, 2003	MAY	NEWA
AB		5MG;5MG;5MG;5MG	N40456 003	MAY 06, 2003	MAY	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40456 004	MAY 06, 2003	MAY	NEWA
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB	BARR	1.875MG;1.875MG;1.875MG;1.875MG	N40422 005	MAR 19, 2003	MAR	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	N40422 006	MAR 19, 2003	MAR	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	N40422 007	MAR 19, 2003	MAR	NEWA

AMPICILLIN SODIUM

INJECTABLE; INJECTION

>D>	OMNIPEN-N					
>D>	AP + WYETH AYERST	EQ 125MG BASE/VIAL	N60626 001		JUN	DISC
>A>	@	EQ 125MG BASE/VIAL	N60626 001		JUN	DISC
>D>	AP +	EQ 250MG BASE/VIAL	N60626 002		JUN	DISC
>A>	@	EQ 250MG BASE/VIAL	N60626 002		JUN	DISC
>D>	AP +	EQ 500MG BASE/VIAL	N60626 003		JUN	DISC
>A>	@	EQ 500MG BASE/VIAL	N60626 003		JUN	DISC
>D>	AP +	EQ 1GM BASE/VIAL	N60626 004		JUN	DISC
>A>	@	EQ 1GM BASE/VIAL	N60626 004		JUN	DISC
>D>	AP +	EQ 2GM BASE/VIAL	N60626 005		JUN	DISC
>A>	@	EQ 2GM BASE/VIAL	N60626 005		JUN	DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION

TOTACILLIN-N

>D>	AP	GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	N60677 001		JUN	CRLD
>A>	AP +		EQ 125MG BASE/VIAL	N60677 001		JUN	CRLD
>D>	AP		EQ 250MG BASE/VIAL	N60677 002		JUN	CRLD
>A>	AP +		EQ 250MG BASE/VIAL	N60677 002		JUN	CRLD
>D>	AP		EQ 500MG BASE/VIAL	N60677 003		JUN	CRLD
>A>	AP +		EQ 500MG BASE/VIAL	N60677 003		JUN	CRLD
>D>	AP		EQ 1GM BASE/VIAL	N60677 004		JUN	CRLD
>A>	AP +		EQ 1GM BASE/VIAL	N60677 004		JUN	CRLD
>D>	AP		EQ 2GM BASE/VIAL	N60677 005		JUN	CRLD
>A>	AP +		EQ 2GM BASE/VIAL	N60677 005		JUN	CRLD

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

OMNIPEN (AMPICILLIN)

>D>	AB	WYETH AYERST	250MG	N60624 001		JUN	DISC
>A>		@	250MG	N60624 001		JUN	DISC
>D>	AB		500MG	N60624 002		JUN	DISC
>A>		@	500MG	N60624 002		JUN	DISC

FOR SUSPENSION; ORAL

>D>	AB	WYETH AYERST	100MG/ML	N60625 001		JUN	DISC
>A>		@	100MG/ML	N60625 001		JUN	DISC
>D>	AB		125MG/5ML	N60625 002		JUN	DISC
>A>		@	125MG/5ML	N60625 002		JUN	DISC
>D>	AB		250MG/5ML	N60625 003		JUN	DISC
>A>		@	250MG/5ML	N60625 003		JUN	DISC

PRINCIPEN

>D>	AB	APOTHECON	EQ 100MG BASE/ML	N61394 001		JUN	CTEC
>A>			EQ 100MG BASE/ML	N61394 001		JUN	CTEC

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

		GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999	MAR	CMFD
	+		150MG	N21007 002	APR 15, 1999	MAR	CMFD

SOLUTION; ORAL

	+	GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999	MAR	CMFD
--	---	-----------------	---------	------------	--------------	-----	------

APREPITANT

CAPSULE; ORAL

EMEND

		MERCK	80MG	N21549 001	MAR 26, 2003	MAR	NEWA
	+		125MG	N21549 002	MAR 26, 2003	MAR	NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

>A>	+	ENCYSIVE	100MG/ML	N20883 001	JUN 30, 2000	JUN	CAHN
>D>	+	TX BIOTECH	100MG/ML	N20883 001	JUN 30, 2000	JUN	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
 NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
 HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
 M.V.I.-12

>D>	AP +	AAIPHARMA	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3 6MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML					
>A>	+		10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3 6MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809 004	AUG 08, 1985	JUN	CTEC	
				N08809 004	AUG 08, 1985	JUN	CTEC	

ASPIRIN; BUTALBITAL; CAFFEINE
 CAPSULE; ORAL

FIORINAL

	AB +	WATSON PHARMS	325MG;50MG;40MG	N17534 005	APR 16, 1986	MAR	CAHN	
		TABLET; ORAL						
	AB +	WATSON PHARMS	325MG;50MG;40MG	N17534 003	APR 16, 1986	MAR	CAHN	

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
 CAPSULE; ORAL

FIORINAL W/CODEINE NO 3

	AB +	WATSON PHARMS	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990	MAR	CAHN	
--	------	---------------	----------------------	------------	--------------	-----	------	--

ASPIRIN; MEPROBAMATE

TABLET; ORAL
 EQUAGESIC

>D>	AB +	WOMEN FIRST HLTHCARE	325MG;200MG	N11702 003	DEC 29, 1983	JUN	CTEC	
>A>	+		325MG;200MG	N11702 003	DEC 29, 1983	JUN	CTEC	
>D>		MICRAININ						
>A>	@	MEDPOINTE PHARM HLC	325MG;200MG	N84978 001		JUN	DISC	
>D>	AB	WALLACE PHARMS	325MG;200MG	N84978 001		JUN	DISC	

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

>D>	AB	IVAX PHARMS	325MG;400MG	N87211 001	DEC 22, 1982	JUN	CRLD	
>A>	AB +		325MG;400MG	N87211 001	DEC 22, 1982	JUN	CRLD	
>D>		ROBAXISAL						
>D>	AB +	ROBINS AH	325MG;400MG	N12281 001		JUN	DISC	
>A>	@		325MG;400MG	N12281 001		JUN	DISC	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE
 TABLET; ORAL

OXYCODONE AND ASPIRIN

AA		AXIOM PHARM	325MG;4.5MG;0.38MG	N40260 001	JUL 17, 1998	MAY	CAHN	
----	--	-------------	--------------------	------------	--------------	-----	------	--

>A> ASPIRIN; PRAVASTATIN SODIUM
 >A> TABLET; ORAL
 >A> PRAVIGARD PAC (COPACKAGED)
 >A> BRISTOL MYERS SQUIBB 81MG;20MG N21387 001 JUN 24, 2003 JUN NEWA
 >A> 81MG;40MG N21387 002 JUN 24, 2003 JUN NEWA
 >A> 81MG;80MG N21387 003 JUN 24, 2003 JUN NEWA
 >A> 325MG;20MG N21387 004 JUN 24, 2003 JUN NEWA
 >A> 325MG;40MG N21387 005 JUN 24, 2003 JUN NEWA
 >A> + 325MG;80MG N21387 006 JUN 24, 2003 JUN NEWA

>A> ATAZANAVIR SULFATE
 >A> CAPSULE; ORAL
 >A> REYATAZ
 >A> BRISTOL MYERS SQUIBB EQ 100MG BASE N21567 001 JUN 20, 2003 JUN NEWA
 >A> EQ 150MG BASE N21567 002 JUN 20, 2003 JUN NEWA
 >A> + EQ 200MG BASE N21567 003 JUN 20, 2003 JUN NEWA

ATOMOXETINE HYDROCHLORIDE
 CAPSULE; ORAL
 STRATTERA
 @ LILLY 5MG N21411 001 NOV 26, 2002 MAY DISC

AZATHIOPRINE
 TABLET; ORAL
 AZASAN
 AAIPHARMA LLC 25MG N75252 002 FEB 03, 2003 FEB NEWA
 AB 50MG N75252 001 JUN 07, 1999 FEB NEWA
 75MG N75252 003 FEB 03, 2003 FEB NEWA
 100MG N75252 004 FEB 03, 2003 FEB NEWA

AZELASTINE HYDROCHLORIDE
 SOLUTION/DROPS; OPHTHALMIC
 OPTIVAR
 + MEDPOINTE 0.05% N21127 001 MAY 22, 2000 APR CAHN

BECLOMETHASONE DIPROPIONATE
 AEROSOL, METERED; INHALATION
 BECLOVENT
 @ GLAXOSMITHKLINE 0.042MG/INH N18153 001 MAR DISC
 AEROSOL, METERED; NASAL
 BECONASE
 @ GLAXOSMITHKLINE 0.042MG/INH N18584 001 MAR DISC
 VANCENASE
 @ SCHERING 0.042MG/INH N18521 001 MAR DISC

BETAMETHASONE
 TABLET; ORAL
 CELESTONE
 @ SCHERING 0.6MG N12657 003 FEB DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

AB + SAVAGE LABS EQ 0.05% BASE N19138 001 JUN 26, 1984 MAY CRLD

DIPROSONE

@ SCHERING EQ 0.05% BASE N17536 001 MAY DISC

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ALTANA EQ 0.05% BASE N75276 001 MAY 13, 2003 MAY NEWA

DIPROLENE

AB + SCHERING EQ 0.05% BASE N19408 002 NOV 22, 1991 MAY CFTG

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

>A> AB DURAMED PHARM BARR 5MG N19982 002 JUL 31, 1992 JUN CAHN

>A> AB + 10MG N19982 001 JUL 31, 1992 JUN CAHN

>D> AB WYETH PHARMS INC 5MG N19982 002 JUL 31, 1992 JUN CAHN

AB 5MG N19982 002 JUL 31, 1992 MAR CAHN

>D> AB + 10MG N19982 001 JUL 31, 1992 JUN CAHN

AB + 10MG N19982 001 JUL 31, 1992 MAR CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

>A> AB DURAMED PHARM BARR 2.5MG;6.25MG N20186 003 MAR 26, 1993 JUN CAHN

>A> AB 5MG;6.25MG N20186 001 MAR 26, 1993 JUN CAHN

>A> AB + 10MG;6.25MG N20186 002 MAR 26, 1993 JUN CAHN

>D> AB WYETH PHARMS INC 2.5MG;6.25MG N20186 003 MAR 26, 1993 JUN CAHN

AB 2.5MG;6.25MG N20186 003 MAR 26, 1993 MAR CAHN

>D> AB 5MG;6.25MG N20186 001 MAR 26, 1993 JUN CAHN

AB 5MG;6.25MG N20186 001 MAR 26, 1993 MAR CAHN

>D> AB + 10MG;6.25MG N20186 002 MAR 26, 1993 JUN CAHN

AB + 10MG;6.25MG N20186 002 MAR 26, 1993 MAR CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS

VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL

N21602 001 MAY 13, 2003 MAY NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

>D> AP ELKINS SINN 50MG/ML N70545 001 MAY 14, 1986 JUN DISC

>A> @ 50MG/ML N70545 001 MAY 14, 1986 JUN DISC

>D> AP 50MG/ML N70546 001 MAY 14, 1986 JUN DISC

>A> @ 50MG/ML N70546 001 MAY 14, 1986 JUN DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

+ BAUSCH AND LOMB 0.2%

N76260 001 MAY 28, 2003 MAY NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
 DIMETANE-DX
 @ ROBINS AH 2MG/5ML;10MG/5ML;30MG/5ML N19279 001 AUG 24, 1984 MAR DISC
 MYPHETANE DX
 AA + MORTON GROVE 2MG/5ML;10MG/5ML;30MG/5ML N88811 001 JUN 07, 1985 MAR CTEC

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
 DUOCAINE
 + AMPAHSTAR 0.375% (37.5MG/10ML);1% (100MG/10ML) N21496 001 MAY 23, 2003 MAY NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
 BUSPIRONE HCL
 AB EGIS 15MG N75119 003 JAN 23, 2003 JAN NEWA

BUSULFAN

INJECTABLE; INJECTION
 BUSULFEX
 >A> + ESP PHARMA 6MG/ML N20954 001 FEB 04, 1999 JUN CAHN
 >D> + ORPHAN MEDCL 6MG/ML N20954 001 FEB 04, 1999 JUN CAHN

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL
 CAFCIT
 >A> + MEAD JOHNSON EQ 10MG BASE/ML N20793 001 SEP 21, 1999 JUN CAHN
 >D> + OPR DEVELOP LP EQ 10MG BASE/ML N20793 001 SEP 21, 1999 JUN CAHN

CALCITRIOL

INJECTABLE; INJECTION
 CALCITRIOL
 AP AAIPHARMA 0.001MG/ML N75766 001 FEB 20, 2003 FEB NEWA
 AP 0.002MG/ML N75766 002 FEB 20, 2003 FEB NEWA
 AP GENZIA SICOR PHARMS 0.001MG/ML N75823 001 MAR 31, 2003 MAR NEWA
 AP 0.002MG/ML N75823 002 MAR 31, 2003 MAR NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL
 ELLIOTTS B SOLUTION

+ QOL MEDCL 0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML
 ;1.9MG/ML;7.3MG/ML;0.2MG/ML N20577 001 SEP 27, 1996 MAY CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

>A> TABLET; ORAL
 >A> STALEVO 100 N21485 002 JUN 11, 2003 JUN NEWA
 >A> ORION PHARMA INC 25MG;200MG;100MG
 >A> STALEVO 150 N21485 003 JUN 11, 2003 JUN NEWA
 >A> + ORION PHARMA INC 37.5MG;200MG;150MG

CARBIDOPA; ENTACAPONE; LEVODOPA

>A>	TABLET; ORAL						
>A>	STALEVO 50						
>A>	ORION PHARMA INC	12.5MG;200MG;50MG		N21485 001	JUN 11, 2003	JUN	NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

+ MIKART 4MG/5ML

N40458 001 APR 25, 2003 APR NEWA

TABLET; ORAL

+ MIKART 4MG

N40442 001 MAR 19, 2003 MAR NEWA

CARVEDILOL

TABLET; ORAL

COREG

+ GLAXOSMITHKLINE 12.5MG
25MG

N20297 002 SEP 14, 1995 APR CRLD

N20297 001 SEP 14, 1995 APR CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB RANBAXY EQ 125MG BASE/5ML

N65115 001 MAR 26, 2003 MAR NEWA

AB EQ 250MG BASE/5ML

N65115 002 MAR 26, 2003 MAR NEWA

AB EQ 500MG BASE/5ML

N65115 003 MAR 26, 2003 MAR NEWA

DURICEF

AB WARNER CHILCOTT EQ 125MG BASE/5ML

N50527 002 MAR CFTG

AB EQ 250MG BASE/5ML

N50527 003 MAR CFTG

AB + EQ 500MG BASE/5ML

N50527 001 MAR CFTG

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

+ PURDUE PHARMA LP 200MG

N21222 001 AUG 29, 2001 MAY CAHN

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

@ LEDERLE 100MG/5ML

N50622 001 APR 28, 1989 APR DISC

TABLET; ORAL

@ LEDERLE 200MG

N50621 001 APR 28, 1989 APR DISC

@ 400MG

N50621 002 APR 28, 1989 APR DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN IN PLASTIC CONTAINER

+ MERCK EQ 20MG BASE/ML

N63182 001 JAN 25, 1993 MAR CRLD

+ EQ 40MG BASE/ML

N63182 002 JAN 25, 1993 MAR CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	RANBAXY	EQ 125MG BASE	N65118 001	APR 25, 2003	APR	NEWA
AB		EQ 250MG BASE	N65118 002	APR 25, 2003	APR	NEWA
AB		EQ 500MG BASE	N65118 003	APR 25, 2003	APR	NEWA

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM

+	BRISTOL	EQ 1GM BASE/VIAL	N62464 001	MAY 07, 1984	MAR	CRLD
+		EQ 2GM BASE/VIAL	N62464 002	MAY 07, 1984	MAR	CRLD
+		EQ 4GM BASE/VIAL	N62464 003	MAY 07, 1984	MAR	CRLD
	KEFLIN					
@	LILLY	EQ 1GM BASE/VIAL	N50482 001		MAR	DISC
@		EQ 2GM BASE/VIAL	N50482 002		MAR	DISC
@		EQ 4GM BASE/VIAL	N50482 003		MAR	DISC

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC

CHLORAMPHENICOL

AT	+	ALTANA	1%	N60133 001		MAY	CRLD
		CHLOROMYCETIN					
	@	PARKEDALE	1%	N50156 001		MAY	DISC
>D>		CHLOROPTIC S.O.P.					
>D>	AT	ALLERGAN	1%	N61187 001		JUN	DISC
>A>		@	1%	N61187 001		JUN	DISC
>D>		SOLUTION/DROPS; OPHTHALMIC					
>D>		CHLOROPTIC					
>D>	+	ALLERGAN	0.5%	N50091 001		JUN	DISC
>A>		@	0.5%	N50091 001		JUN	DISC
		SOLUTION/DROPS; OTIC					
		CHLOROMYCETIN					
	@	PARKEDALE	0.5%	N50205 001		MAY	DISC

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HCL

>D>	+	SANOFI SYNTHELABO	EQ 40MG BASE/ML	N06002 002		JUN	DISC
>A>		@	EQ 40MG BASE/ML	N06002 002		JUN	DISC

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

@	MERCK	150MG;250MG	N16016 001		MAY	DISC
	ALDOCLOR-250					
@	MERCK	250MG;250MG	N16016 002		MAY	DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

>A>	AP	BAXTER HLTHCARE	25MG/ML	N83329 001		JUN	CAHN
-----	----	-----------------	---------	------------	--	-----	------

>D>	AP	ELKINS SINN PHARM	25MG/ML	N83329 001	JUN	CAHN	
		TABLET; ORAL					
>D>	BP	LEDERLE	10MG	N84803 001	JUN	DISC	
>A>	@		10MG	N84803 001	JUN	DISC	
		<u>CHLORTHALIDONE</u>					
		TABLET; ORAL					
		THALITONE					
	@	MONARCH PHARMS	25MG	N19574 002	FEB 12, 1992	MAY DISC	
		<u>CICLOPIROX</u>					
		SHAMPOO; TOPICAL					
		LOPROX					
	+	MEDICIS	1%	N21159 001	FEB 28, 2003	FEB NEWA	
		<u>CLADRIBINE</u>					
		INJECTABLE; INJECTION					
		LEUSTATIN					
AP	+	ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993	APR CTEC	
		<u>CLEMASTINE FUMARATE</u>					
		SYRUP; ORAL					
		CLEMASTINE FUMARATE					
>D>	AA	TEVA	EQ 0.5MG BASE/5ML	N73399 001	JUN 30, 1994	JUN CRLD	
>A>	AA	+	EQ 0.5MG BASE/5ML	N73399 001	JUN 30, 1994	JUN CRLD	
>D>		TAVIST					
>D>	AA	+	NOVARTIS	EQ 0.5MG BASE/5ML	N18675 001	JUN 28, 1985	JUN DISC
>A>	@		EQ 0.5MG BASE/5ML	N18675 001	JUN 28, 1985	JUN DISC	
		<u>CLINDAMYCIN HYDROCHLORIDE</u>					
		CAPSULE; ORAL					
		CLINDAMYCIN HCL					
AB		WATSON LABS	EQ 300MG BASE	N63083 002	MAR 18, 2003	MAR NEWA	
		<u>CLOFIBRATE</u>					
		CAPSULE; ORAL					
		ATROMID-S					
>D>	AB	+	WYETH AYERST	500MG	N16099 002	JUN DISC	
>A>	@		500MG	N16099 002	JUN	DISC	
		<u>CLONAZEPAM</u>					
		TABLET, ORALLY DISINTEGRATING; ORAL					
		KLONOPIN RAPIDLY DISINTEGRATING					
		ROCHE	0.125MG	N20813 001	DEC 23, 1997	APR CMFD	
			0.25MG	N20813 002	DEC 23, 1997	APR CMFD	
			0.5MG	N20813 003	DEC 23, 1997	APR CMFD	
		+	1MG	N20813 004	DEC 23, 1997	APR CMFD	
			2MG	N20813 005	DEC 23, 1997	APR CMFD	
		<u>CLORAZEPATE DIPOTASSIUM</u>					
		CAPSULE; ORAL					
		CLORAZEPATE DIPOTASSIUM					
>A>	@	CLONMEL HLHCARE	3.75MG	N71742 001	DEC 14, 1987	JUN DISC	

>A>	@	7.5MG	N71743 001	DEC 14, 1987	JUN	DISC	
>A>	@	15MG	N71744 001	DEC 14, 1987	JUN	DISC	
>D>	AB	LEDERLE	3.75MG	N71742 001	DEC 14, 1987	JUN	DISC
>D>	AB		7.5MG	N71743 001	DEC 14, 1987	JUN	DISC
>D>	AB		15MG	N71744 001	DEC 14, 1987	JUN	DISC

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

>D>		PHENERGAN VC W/ CODEINE		N08306 005	APR 02, 1984	JUN	DISC
>D>	AA +	WYETH AYERST	10MG/5ML;5MG/5ML;6.25MG/5ML	N08306 005	APR 02, 1984	JUN	DISC
>A>	@		10MG/5ML;5MG/5ML;6.25MG/5ML				
		PROMETH VC W/ CODEINE					
>D>	AA	ALPHARMA	10MG/5ML;5MG/5ML;6.25MG/5ML	N88764 001	OCT 31, 1984	JUN	CRLD
>A>	AA +		10MG/5ML;5MG/5ML;6.25MG/5ML	N88764 001	OCT 31, 1984	JUN	CRLD

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

>D>		PHENERGAN W/ CODEINE		N08306 004	APR 02, 1984	JUN	DISC
>D>	AA +	WYETH AYERST	10MG/5ML;6.25MG/5ML	N08306 004	APR 02, 1984	JUN	DISC
>A>	@		10MG/5ML;6.25MG/5ML				
		PROMETH W/ CODEINE					
>D>	AA	ALPHARMA	10MG/5ML;6.25MG/5ML	N88763 001	OCT 31, 1984	JUN	CRLD
>A>	AA +		10MG/5ML;6.25MG/5ML	N88763 001	OCT 31, 1984	JUN	CRLD

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL

COLESTID

+ PHARMACIA AND UPJOHN	1GM	N20222 001	JUL 19, 1994	MAY	CRLD
------------------------	-----	------------	--------------	-----	------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

COPPER T MODEL TCU 380A

+ FEI	309MG/COPPER	N18680 001	NOV 15, 1984	MAR	CAHN
-------	--------------	------------	--------------	-----	------

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

BP + PHARMACIA AND UPJOHN	25MG	N08126 001		APR	CRLD
---------------------------	------	------------	--	-----	------

CORTONE

@ MERCK	25MG	N07750 003		APR	DISC
---------	------	------------	--	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

>A>	+ AMPAHSTAR	0.25MG/VIAL	N16750 001		JUN	CAHN
>D>	+ ORGANON	0.25MG/VIAL	N16750 001		JUN	CAHN

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

CROMOPTIC

@ KING PHARMS	4%	N75088 001	APR 27, 1999	MAY	DISC
---------------	----	------------	--------------	-----	------

CYANOCOBALAMINGEL, METERED; NASAL
NASCOBAL

>D>	+	NASTECH PHARM	0.5MG/INH	N19722 001	NOV 05, 1996	JUN	CAHN
>A>	+	QUESTCOR PHARMS	0.5MG/INH	N19722 001	NOV 05, 1996	JUN	CAHN
INJECTABLE; INJECTION							
CYANOCOBALAMIN							
>D>	AP	ELKINS SINN	1MG/ML	N80515 002		JUN	DISC
>A>		@	1MG/ML	N80515 002		JUN	DISC
>D>	AP	WYETH AYERST	0.1MG/ML	N80554 001		JUN	DISC
>A>		@	0.1MG/ML	N80554 001		JUN	DISC
>D>	AP		1MG/ML	N80554 002		JUN	DISC
>A>		@	1MG/ML	N80554 002		JUN	DISC

CYCLOBENZAPRINE HYDROCHLORIDETABLET; ORAL
FLEXERIL

AA	MCNEIL CONS SPECLT	5MG	N17821 001			MAR	CMFD
		5MG	N17821 001			APR	CTEC

CYCLOSPORINECAPSULE; ORAL
GENGRAF

AB1	ABBOTT	25MG	N65003 001	MAY 12, 2000	FEB	CTNA
BX		50MG	N65003 002	MAY 12, 2000	FEB	CTNA
AB1		100MG	N65003 003	MAY 12, 2000	FEB	CTNA

EMULSION; OPHTHALMIC
RESTASIS

+	ALLERGAN	0.05%	N50790 001	DEC 23, 2002	MAR	CMS1
---	----------	-------	------------	--------------	-----	------

CYTARABINEINJECTABLE; INJECTION
CYTOSAR-U

>A>	AP	+	GENSIA SICOR PHARMS	100MG/VIAL	N16793 001		JUN	CAHN
>A>	AP	+		500MG/VIAL	N16793 002		JUN	CAHN
>A>	AP	+		1GM/VIAL	N16793 003	DEC 21, 1987	JUN	CAHN
>A>	AP	+		2GM/VIAL	N16793 004	DEC 21, 1987	JUN	CAHN
>D>	AP	+	PHARMACIA AND UPJOHN	100MG/VIAL	N16793 001		JUN	CAHN
>D>	AP	+		500MG/VIAL	N16793 002		JUN	CAHN
>D>	AP	+		1GM/VIAL	N16793 003	DEC 21, 1987	JUN	CAHN
>D>	AP	+		2GM/VIAL	N16793 004	DEC 21, 1987	JUN	CAHN

DALFOPRISTIN; QUINUPRISTININJECTABLE; IV (INFUSION)
SYNERCID

+	KING PHARMS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	FEB	CAHN
@		420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	FEB	CAHN

DEMECLOCYCLINE HYDROCHLORIDETABLET; ORAL
DECLOMYCIN

@	WYETH PHARMS INC	75MG	N50261 001			MAR	CAHN
---	------------------	------	------------	--	--	-----	------

		150MG	N50261 002	MAR	CAHN
+		300MG	N50261 003	MAR	CAHN
<u>DESIRUDIN</u>					
INJECTABLE; SUBCUTANEOUS					
IPRIVASK					
+	AVENTIS PHARMS	15MG/VIAL	N21271 001	APR 04, 2003	APR NEWA
<u>DESMOPRESSIN ACETATE</u>					
SPRAY, METERED; NASAL					
DESMOPRESSIN ACETATE					
AB	+	FERRING	0.01MG/SPRAY	N21333 001	SEP 16, 2002 MAY CMS1
MINIRIN					
>D>	AB	+	FERRING	0.01MG/SPRAY	N21333 001 SEP 16, 2002 JUN CTNA
>A>	AB	+		0.01MG/SPRAY	N21333 001 SEP 16, 2002 JUN CTNA
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>					
TABLET; ORAL-21					
ORTHO-CEPT					
	@	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 001	DEC 14, 1992 MAR DISC
TABLET; ORAL-28					
AB	+	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 002	DEC 14, 1992 MAR CRLD
<u>DEXAMETHASONE</u>					
ELIXIR; ORAL					
DECADRON					
	@	MERCK	0.5MG/5ML	N12376 002	APR DISC
HEXADROL					
AA	+	ORGANON	0.5MG/5ML	N12674 001	APR CRLD
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>					
INJECTABLE; INJECTION					
DEXAMETHASONE SODIUM PHOSPHATE					
AP		AM PHARM	EQ 10MG PHOSPHATE/ML	N40491 001	APR 11, 2003 APR NEWA
<u>DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE</u>					
SOLUTION/DROPS; OPHTHALMIC					
NEODECADRON					
	@	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001	MAY DISC
<u>DEXTROAMPHETAMINE SULFATE</u>					
CAPSULE, EXTENDED RELEASE; ORAL					
DEXTROAMPHETAMINE SULFATE					
AB		MALLINCKRODT	5MG	N76353 001	MAY 06, 2003 MAY NEWA
AB			10MG	N76353 002	MAY 06, 2003 MAY NEWA
AB			15MG	N76353 003	MAY 06, 2003 MAY NEWA
<u>DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE</u>					
SYRUP; ORAL					
PHENERGAN W/ DEXTROMETHORPHAN					
>D>	AA	+	WYETH AYERST	15MG/5ML;6.25MG/5ML	N11265 002 APR 02, 1984 JUN DISC
>A>		@		15MG/5ML;6.25MG/5ML	N11265 002 APR 02, 1984 JUN DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

- PROMETH W/ DEXTROMETHORPHAN

>D>	AA	ALPHARMA	15MG/5ML;6.25MG/5ML	N88762 001	OCT 31, 1984	JUN	CRLD
>A>	AA	+	15MG/5ML;6.25MG/5ML	N88762 001	OCT 31, 1984	JUN	CRLD

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

>D>	AP	ELKINS SINN	5MG/ML	N70311 001	DEC 16, 1985	JUN	DISC
>A>		@	5MG/ML	N70311 001	DEC 16, 1985	JUN	DISC
>D>	AP		5MG/ML	N70312 001	DEC 16, 1985	JUN	DISC
>A>		@	5MG/ML	N70312 001	DEC 16, 1985	JUN	DISC
>D>	AP		5MG/ML	N70313 001	DEC 16, 1985	JUN	DISC
>A>		@	5MG/ML	N70313 001	DEC 16, 1985	JUN	DISC

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

@ MERCK

50MG

N11366 001

MAY DISC

DICLOXACILLIN SODIUM

CAPSULE; ORAL

PATHOCIL

>D>	AB	WYETH AYERST	EQ 250MG BASE	N50011 002		JUN	DISC
>A>		@	EQ 250MG BASE	N50011 002		JUN	DISC
>D>	AB		EQ 500MG BASE	N50011 003	MAR 28, 1983	JUN	DISC
>A>		@	EQ 500MG BASE	N50011 003	MAR 28, 1983	JUN	DISC

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

>D>	AB	+	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001		JUN	CTEC
>A>		+		EQ 62.5MG BASE/5ML	N61455 001		JUN	CTEC
>D>			PATHOCIL					
>D>	AB		WYETH AYERST	EQ 62.5MG BASE/5ML	N50092 001		JUN	DISC
>A>		@		EQ 62.5MG BASE/5ML	N50092 001		JUN	DISC

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HCL (PRESERVATIVE-FREE)

>A>	AP	BEDFORD	10MG/ML	N40465 001	JUN 30, 2003	JUN	NEWA
-----	----	---------	---------	------------	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

>D>	AP	WYETH AYERST	0.25MG/ML	N84386 001		JUN	DISC
>A>		@	0.25MG/ML	N84386 001		JUN	DISC
	AB	CARACO	0.125MG	N76363 001	JAN 31, 2003	JAN	NEWA
	AB		0.25MG	N76363 002	JAN 31, 2003	JAN	NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP	+	XCEL PHARMS	1MG/ML	N05929 001		APR	CFTG
		DIHYDROERGOTAMINE MESYLATE					
>A>	AP	BEDFORD	1MG/ML	N40453 001	JUN 09, 2003	JUN	NEWA
		DIHYDROERGOTAMINE MESYLATE					
AP		PADDOCK	1MG/ML	N40475 001	APR 28, 2003	APR	NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TAZTIA XT

AB4		ANDRX PHARMS	120MG	N75401 001	APR 10, 2003	APR	NEWA
AB4			180MG	N75401 002	APR 10, 2003	APR	NEWA
AB4			240MG	N75401 003	APR 10, 2003	APR	NEWA
AB4			300MG	N75401 004	APR 10, 2003	APR	NEWA
AB4			360MG	N75401 005	APR 10, 2003	APR	NEWA

TIAZAC

AB4	+	BIOVAIL	120MG	N20401 001	SEP 11, 1995	APR	CFTG
AB4	+		180MG	N20401 002	SEP 11, 1995	APR	CFTG
AB4	+		240MG	N20401 003	SEP 11, 1995	APR	CFTG
AB4	+		300MG	N20401 004	SEP 11, 1995	APR	CFTG
AB4	+		360MG	N20401 005	SEP 11, 1995	APR	CFTG

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

	+	BIOVAIL	120MG	N21392 001	FEB 06, 2003	FEB	NEWA
	+		180MG	N21392 002	FEB 06, 2003	FEB	NEWA
	+		240MG	N21392 003	FEB 06, 2003	FEB	NEWA
	+		300MG	N21392 004	FEB 06, 2003	FEB	NEWA
	+		360MG	N21392 005	FEB 06, 2003	FEB	NEWA
	+		420MG	N21392 006	FEB 06, 2003	FEB	NEWA

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

	@	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996	MAY	DISC
	@		EQ 180MG HCL	N20506 002	OCT 04, 1996	MAY	DISC
	@		EQ 240MG HCL	N20506 003	OCT 04, 1996	MAY	DISC

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

>D>	AP	+	STERIS	50MG/ML	N80615 001		JUN	CTEC
>A>		+		50MG/ML	N80615 001		JUN	CTEC
>D>	AP	+	WYETH AYERST	50MG/ML	N84316 001		JUN	DISC
>A>		@		50MG/ML	N84316 001		JUN	DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

>A>	AP		BAXTER HLTHCARE	50MG/ML	N80817 002		JUN	CAHN
>D>	AP		ELKINS SINN	50MG/ML	N80817 002		JUN	CAHN

>D>	AP	WYETH AYERST	50MG/ML		N80577 001			
>A>		@	50MG/ML		N80577 001		JUN DISC	
<u>DOBUTAMINE HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
DOBUTAMINE HCL								
>D>	AP	ELKINS SINN	EQ 12.5MG BASE/ML		N74381 001	SEP 26, 1996	JUN DISC	
>A>		@	EQ 12.5MG BASE/ML		N74381 001	SEP 26, 1996	JUN DISC	
<u>DOPAMINE HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
DOPAMINE HCL								
>A>		@ BAXTER HLHCARE	40MG/ML		N18398 001		JUN DISC	
>A>		@	80MG/ML		N18398 002	MAR 22, 1982	JUN DISC	
>D>	AP +	ELKINS SINN	40MG/ML		N18398 001		JUN DISC	
>D>	AP +		80MG/ML		N18398 002	MAR 22, 1982	JUN DISC	
<u>DOXAPRAM HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
DOPRAM								
AP +		BAXTER HLHCARE CORP	20MG/ML		N14879 001		JAN CAHN	
DOXAPRAM HCL								
AP		BEDFORD	20MG/ML		N76266 001	JAN 10, 2003	JAN NEWA	
<u>DOXYCYCLINE</u>								
CAPSULE; ORAL								
DOXYCYCLINE								
AB		AXIOM PHARM	EQ 50MG BASE		N65041 001	APR 28, 2000	MAY CAHN	
AB			EQ 100MG BASE		N65041 002	APR 28, 2000	MAY CAHN	
<u>DOXYCYCLINE HYCLATE</u>								
CAPSULE; ORAL								
DOXYCYCLINE HYCLATE								
AB		AXIOM PHARM	EQ 50MG BASE		N61717 001		MAY CAHN	
AB			EQ 100MG BASE		N61717 002		MAY CAHN	
CAPSULE, COATED PELLETS; ORAL								
DORYX								
FAULDING								
			EQ 75MG BASE		N50582 002	AUG 13, 2001	FEB NEWA	
INJECTABLE; INJECTION								
DOXY 100								
+		AM PHARM PARTNERS	EQ 100MG BASE/VIAL		N62475 001	DEC 09, 1983	MAR CRLD	
+		AM PHARM PARTNERS	EQ 200MG BASE/VIAL		N62475 002	DEC 09, 1983	MAR CRLD	
VIBRAMYCIN								
		@ PFIZER	EQ 100MG BASE/VIAL		N50442 002		MAR DISC	
		@	EQ 200MG BASE/VIAL		N50442 001		MAR DISC	
TABLET; ORAL								
DOXYCYCLINE HYCLATE								
AB		AXIOM PHARM	EQ 100MG BASE		N62269 002	NOV 08, 1982	MAY CAHN	
DOXYCYCLINE HYLATE								
		@ AXIOM PHARM	EQ 50MG BASE		N62269 003		MAY CAHN	

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

REVERSOL

a ORGANON

10MG/ML

N89624 001 MAY 13, 1988 MAY DISC

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAX

PFIZER IRELAND

EQ 20MG BASE

N21016 001 DEC 26, 2002 MAR CAHN

+

EQ 40MG BASE

N21016 002 DEC 26, 2002 MAR CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB IVAX PHARMS

5MG;12.5MG

N75736 001 MAR 25, 2003 MAR NEWA

AB

10MG;25MG

N75736 002 MAR 25, 2003 MAR NEWA

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+ ROCHE

90MG/VIAL

N21481 001 MAR 13, 2003 MAR NEWA

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

+ AVENTIS

300MG/3ML

N20164 009 JAN 23, 2003 JAN NEWA

EPINEPHRINE

INJECTABLE; IM-SC

TWINJECT

+ HOLLISTER STIER LABS

0.3MG /DELIVERY

N20800 001 MAY 30, 2003 MAY NEWA

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

a DENTSPLY PHARM

0.005MG/ML;1.5%

N21384 001 MAR DISC

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

>D> AP ELKINS SINN

0.01MG/ML;1%

N80406 001

JUN DISC

>D> AP

0.01MG/ML;2%

N80406 002

JUN DISC

>A> a

0.01MG/ML;1%

N80406 001

JUN DISC

>A> a

0.01MG/ML;2%

N80406 002

JUN DISC

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ HARVEST PHARMS

2MG

N87693 001 FEB 24, 1983 MAR CAHN

ERYTHROMYCIN

SOLUTION; TOPICAL
STATICIN

+ WESTWOOD SQUIBB 1.5%

N50526 001

APR CTEC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

>D> ERYTHROMYCIN
>D> AP ELKINS SINN EQ 1GM BASE/VIAL
>A> @ EQ 1GM BASE/VIAL

N62563 002 MAR 28, 1985 JUN DISC
N62563 002 MAR 28, 1985 JUN DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

>A> + BAXTER HLTHCARE CORP 10MG/ML
>A> + BAXTER HLTHCARE CORP 20MG/ML
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
>A> + BAXTER HLTHCARE CORP 2GM/100ML
BREVIBLOC IN PLASTIC CONTAINER
>A> + BAXTER HLTHCARE CORP 1GM/100ML

N19386 006 FEB 25, 2003 JUN NEWA
N19386 007 MAY 28, 2003 JUN NEWA
N19386 005 JAN 27, 2003 MAR NEWA
N19386 004 FEB 16, 2001 MAR NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

>A> BX + BERLEX LABS 0.0375MG/24HR
>A> + 0.06MG/24HR

N20375 005 MAY 27, 2003 JUN NEWA
N20375 006 MAY 27, 2003 JUN NEWA

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

+ GALEN LTD 0.05MG/24HR
+ 0.1MG/24HR

N21367 001 MAR 20, 2003 MAR NEWA
N21367 002 MAR 20, 2003 MAR NEWA

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

@ PHARMACIA AND UPJOHN 2MG/ML;50MG/ML

N17968 001 MAY WDAG

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

+ KING PHARMS 1MG;1MG;0.09MG

N21040 001 OCT 22, 1999 MAY CTNA

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC 0.625MG/GM

N20216 001

MAR CAHN

INJECTABLE; INJECTION

+ WYETH PHARMS INC 25MG/VIAL

N10402 001

MAR CAHN

TABLET; ORAL

WYETH PHARMS INC 0.3MG

N04782 003

MAR CAHN

+ WYETH PHARMS INC 0.625MG

N04782 004

MAR CAHN

	0.9MG	N04782 005	JAN 26, 1984	MAR	CAHN
+	1.25MG	N04782 001		MAR	CAHN
	2.5MG	N04782 002		MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

	TABLET; ORAL-28				
	PREMPHASE (PREMARIN;CYCRIN 14/14)				
	@ WYETH PHARMS INC	0.625MG;0.625MG;5MG	N20303 002	DEC 30, 1994	MAR CAHN
	PREMPHASE 14/14				
+	WYETH PHARMS INC	0.625MG;0.625MG;5MG	N20527 002	NOV 17, 1995	MAR CAHN
	PREMPRO				
>A>	+	WYETH PHARMS INC	0.3MG;1.5MG	N20527 005	JUN 04, 2003 JUN NEWA
	+		0.45MG;1.5MG	N20527 004	MAR 12, 2003 MAR NEWA
	+		0.625MG;0.625MG;2.5MG;2.5MG	N20527 001	NOV 17, 1995 MAR CAHN
	+		0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998 MAR CAHN
	PREMPRO (PREMARIN;CYCRIN)				
	@ WYETH PHARMS INC	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	MAR CAHN

ESTROGENS, ESTERIFIED

	TABLET; ORAL				
	MENEST				
	MONARCH PHARMS	0.3MG	N84951 001		JAN CRLD

ETHACRYNIC ACID

	TABLET; ORAL				
	EDECIN				
+	MERCK	25MG	N16092 001		MAY CRLD
@		50MG	N16092 002		MAY DISC

ETHAMBUTOL HYDROCHLORIDE

	TABLET; ORAL				
	ETHAMBUTOL HCL				
>D>	AB	WEST WARD	400MG	N75095 002	NOV 30, 1999 JUN CRLD
>A>	AB	+	400MG	N75095 002	NOV 30, 1999 JUN CRLD
>D>		MYAMBUTOL			
>D>	AB	LEDERLE	100MG	N16320 001	JUN DISC
>A>		@	100MG	N16320 001	JUN DISC
>D>	AB	+	400MG	N16320 003	JUN DISC
>A>		@	400MG	N16320 003	JUN DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

	TABLET; ORAL-21				
	ALESSE				
AB1	+	WYETH PHARMS INC	0.02MG;0.1MG	N20683 001	MAR 27, 1997 MAR CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB1		BARR	0.02MG;0.1MG	N75862 001	APR 29, 2003 APR NEWA
	NORDETTE-21				
AB	+	WYETH PHARMS INC	0.03MG;0.15MG	N18668 001	MAY 10, 1982 MAR CAHN
	TRIPHASIL-21				
AB	+	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG; ;0.075MG	N19192 001	NOV 01, 1984 MAR CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

ALESSE

AB1	WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	MAR 27, 1997	MAR	CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	BARR	0.02MG;0.1MG	N75862 002	APR 29, 2003	APR	NEWA
	NORDETTE-28					
AB	WYETH PHARMS INC	0.03MG;0.15MG	N18782 001	JUL 21, 1982	MAR	CAHN
	TRIPHASIL-28					
AB	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG; ;0.075MG	N19190 001	NOV 01, 1984	MAR	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

TRI-NORINYL 21-DAY

@ WATSON LABS

0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG

N18977 001 APR 13, 1984 MAR CPOT

@

0.035MG,0.035MG;0.5MG,1MG

N18977 001 APR 13, 1984 FEB DISC

TABLET; ORAL-28

ORTHO-NOVUM 7/7/7-28

AB + ORTHO MCNEIL PHARM

0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG

N18985 002 APR 04, 1984 FEB CRLD

OVCON-35

+ WARNER CHILCOTT

0.035MG;0.4MG

N17716 001

JAN CRLD

OVCON-50

+ WARNER CHILCOTT

0.05MG;1MG

N17576 001

JAN CRLD

TRI-NORINYL 28-DAY

+ WATSON LABS

0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG

N18977 002 APR 13, 1984 MAR CPOT

+

0.035MG,0.035MG;0.5MG,1MG

N18977 002 APR 13, 1984 JAN CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

+ GALEN CHEM

0.005MG;1MG

N21065 002 OCT 15, 1999 MAY CAHN

TABLET; ORAL-21

ESTROSTEP 21

@ GALEN CHEM

0.02MG;0.03MG;0.035MG;1MG;1MG;1MG

N20130 001 OCT 09, 1996 APR CAHN

JUNEL 1.5/30

AB BARR

0.03MG;1.5MG

N76381 001 MAY 30, 2003 MAY NEWA

JUNEL 1/20

AB BARR

0.02MG;1MG

N76380 001 MAY 30, 2003 MAY NEWA

LOESTRIN 21 1.5/30

+ GALEN CHEM

0.03MG;1.5MG

N17875 001

APR CAHN

AB +

0.03MG;1.5MG

N17875 001

MAY CFTG

LOESTRIN 21 1/20

+ GALEN CHEM

0.02MG;1MG

N17876 001

APR CAHN

AB +

0.02MG;1MG

N17876 001

MAY CFTG

TABLET; ORAL-28

ESTROSTEP FE

+ GALEN CHEM

0.02MG;0.03MG;0.035MG;1MG;1MG;1MG

N20130 002 OCT 09, 1996 APR CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

LOESTRIN FE 1.5/30

AB + GALEN CHEM 0.03MG;1.5MG N17355 001 APR CAHN

LOESTRIN FE 1/20

AB + GALEN CHEM 0.02MG;1MG N17354 001 APR CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

AB + WYETH PHARMS INC 0.03MG;0.3MG N17612 001 MAR CAHN

OGESTREL 0.5/50-21

AB WATSON LABS 0.05MG;0.5MG N75406 001 DEC 15, 1999 FEB CAHN

OVRAL

AB + WYETH PHARMS INC 0.05MG;0.5MG N16672 001 MAR CAHN

TABLET; ORAL-28

LO/OVRAL-28

AB WYETH PHARMS INC 0.03MG;0.3MG N17802 001 MAR CAHN

OGESTREL 0.5/50-28

AB WATSON LABS 0.05MG;0.5MG N75406 002 DEC 15, 1999 FEB CAHN

OVRAL-28

AB WYETH PHARMS INC 0.05MG;0.5MG N16806 001 MAR CAHN

ETHIONAMIDE

TABLET; ORAL

TRECATOR-SC

+ WYETH PHARMS INC 250MG N13026 002 MAR CAHN

ETHOTOIN

TABLET; ORAL

PEGANONE

+ OVATION PHARMS 250MG N10841 001 MAR CAHN

a 500MG N10841 003 MAR CAHN

ETIDRONATE DISODIUM

TABLET; ORAL

ETIDRONATE DISODIUM

AB GENPHARM 200MG N75800 001 JAN 24, 2003 JAN NEWA

AB 400MG N75800 002 JAN 24, 2003 JAN NEWA

ETODOLAC

CAPSULE; ORAL

LODINE

AB WYETH PHARMS INC 200MG N18922 002 JAN 31, 1991 MAR CAHN

AB + 300MG N18922 003 JAN 31, 1991 MAR CAHN

TABLET; ORAL

AB WYETH PHARMS INC 400MG N18922 004 JUL 29, 1993 MAR CAHN

AB + 500MG N18922 005 JUN 28, 1996 MAR CAHN

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB TARO 400MG N76174 001 MAR 13, 2003 MAR NEWA

AB		500MG					
AB		600MG	N76174	002	MAR 13, 2003	MAR	NEWA
	LODINE XL		N76174	003	MAR 13, 2003	MAR	NEWA
AB +	WYETH PHARMS INC	400MG	N20584	001	OCT 25, 1996	MAR	CAHN
AB +		500MG	N20584	003	JAN 20, 1998	MAR	CAHN
AB +		600MG	N20584	002	OCT 25, 1996	MAR	CAHN
<u>FAMOTIDINE</u>							
INJECTABLE; INJECTION							
FAMOTIDINE PRESERVATIVE FREE							
>A>	AP	BAXTER HLTHCARE	10MG/ML	N75486	001	APR 16, 2001	JUN CAHN
>D>	AP	ESI LEDERLE	10MG/ML	N75486	001	APR 16, 2001	JUN CAHN
<u>FELBAMATE</u>							
SUSPENSION; ORAL							
FELBATOL							
	+	MEDPOINTE	600MG/5ML	N20189	003	JUL 29, 1993	MAR CAHN
TABLET; ORAL							
		MEDPOINTE	400MG	N20189	001	JUL 29, 1993	MAR CAHN
	+		600MG	N20189	002	JUL 29, 1993	MAR CAHN
<u>FENOFIBRATE</u>							
CAPSULE; ORAL							
FENOFIBRATE (MICRONIZED)							
		TEVA	67MG	N75753	001	SEP 03, 2002	MAR CTEC
			134MG	N75753	002	APR 09, 2002	MAR CTEC
	+		200MG	N75753	003	APR 09, 2002	MAR CRLD
TRICOR (MICRONIZED)							
	@	ABBOTT	67MG	N19304	002	FEB 09, 1998	MAR DISC
	@		134MG	N19304	003	JUN 30, 1999	MAR DISC
	@		200MG	N19304	004	JUN 30, 1999	MAR DISC
<u>FLAVOXATE HYDROCHLORIDE</u>							
TABLET; ORAL							
URISPAS							
	+	ORTHO MCNEIL PHARM	100MG	N16769	001		MAR CAHN
<u>FLECAINIDE ACETATE</u>							
TABLET; ORAL							
FLECAINIDE ACETATE							
>A>	AB	GENEVA PHARMS	50MG	N76030	001	OCT 28, 2002	JUN CAHN
>A>	AB		100MG	N76030	002	OCT 28, 2002	JUN CAHN
>A>	AB		150MG	N76030	003	OCT 28, 2002	JUN CAHN
>D>	AB	GENEVA PHARMS TECH	50MG	N76030	001	OCT 28, 2002	JUN CAHN
>D>	AB		100MG	N76030	002	OCT 28, 2002	JUN CAHN
>D>	AB		150MG	N76030	003	OCT 28, 2002	JUN CAHN
	AB	RANBAXY	50MG	N76421	001	MAR 28, 2003	MAR NEWA
	AB		100MG	N76421	002	MAR 28, 2003	MAR NEWA
	AB		150MG	N76421	003	MAR 28, 2003	MAR NEWA
	AB	ROXANE	50MG	N76278	001	JAN 14, 2003	JAN NEWA
	AB		100MG	N76278	002	JAN 14, 2003	JAN NEWA
	AB		150MG	N76278	003	JAN 14, 2003	JAN NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB	BARR	0.1MG	N40425 001	JAN 21, 2003	JAN	NEWA
----	------	-------	------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1	ALPHARMA US PHARM	0.05%	N73085 001	FEB 14, 1992	MAY	CTEC
AB1	FOUGERA	0.05%	N73030 001	OCT 17, 1994	MAY	CTEC
AB1	TARO	0.05%	N19117 001	JUN 26, 1984	MAY	CTEC
AB1		0.05%	N71500 001	JUN 10, 1987	MAY	CTEC
AB1	TEVA	0.05%	N72488 001	FEB 06, 1989	MAY	CTEC

FLUOCINONIDE EMULSIFIED BASE

AB2	ALPHARMA US PHARM	0.05%	N74204 001	JUN 13, 1995	MAY	CTEC
>D>	AB2	DRAXIS HLTH	N72494 001	JAN 19, 1989	JUN	CAHN
	AB2		N72494 001	JAN 19, 1989	MAY	CTEC
>A>	AB2	TARO	N72494 001	JAN 19, 1989	JUN	CAHN
	AB2	TEVA	N72490 001	FEB 07, 1989	MAY	CTEC

LIDEX

AB1 +	MEDICIS	0.05%	N16908 002		MAY	CTEC
-------	---------	-------	------------	--	-----	------

LIDEX-E

AB2 +	MEDICIS	0.05%	N16908 003		MAY	CRLD
-------	---------	-------	------------	--	-----	------

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

@	NOVARTIS	25%	N17869 001		JAN	DISC
---	----------	-----	------------	--	-----	------

FLUOROURACIL

SOLUTION; TOPICAL

>D>		FLUROPLEX				
>D>	+	ALLERGAN HERBERT	1%	N16765 001	JUN	DISC
>A>	@		1%	N16765 001	JUN	DISC

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@	KING PHARMS	25MG/ML	N74966 001	APR 16, 1998	MAY	DISC
---	-------------	---------	------------	--------------	-----	------

FLURANDRENOLIDE

LOTION; TOPICAL

CORDRAN

+	OCLASSEN	0.05%	N13790 001		MAY	CTEC
---	----------	-------	------------	--	-----	------

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	GENPHARM	125MG	N76224 001	MAY 09, 2003	MAY	NEWA
----	----------	-------	------------	--------------	-----	------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	GENEVA PHARMS	25MG	N75887 001	JAN 05, 2001	APR	CAHN
AB		50MG	N75887 002	JAN 05, 2001	APR	CAHN
AB		100MG	N75887 003	JAN 05, 2001	APR	CAHN

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

>D>	AP	AM PHARM PARTNERS	5MG/ML	N89202 001	FEB 18, 1986	JUN	CRLD
>A>	AP	+	5MG/ML	N89202 001	FEB 18, 1986	JUN	CRLD
>D>		FOLVITE					
>D>	AP	+ WYETH PHARMS INC	5MG/ML	N05897 008		JUN	DISC
>A>		@	5MG/ML	N05897 008		JUN	DISC
	AP	+	5MG/ML	N05897 008		MAR	CAHN
		TABLET; ORAL					
		@ WYETH PHARMS INC	1MG	N05897 004		MAR	CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

>A>		@ BAXTER HLTHCARE	10MG/ML	N18267 001		JUN	DISC
>D>	AP	ELKINS SINN	10MG/ML	N18267 001		JUN	DISC

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

REMINYL

	+	JANSSEN PHARMA	EQ 4MG BASE	N21169 001	FEB 28, 2001	APR	CRLD
			EQ 12MG BASE	N21169 003	FEB 28, 2001	APR	CRLD

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

>D>		ROCHE PALO	250MG	N20460 001	DEC 22, 1994	JUN	CFTG
>A>	AB		250MG	N20460 001	DEC 22, 1994	JUN	CFTG
>D>		+	500MG	N20460 002	DEC 12, 1997	JUN	CFTG
>A>	AB	+	500MG	N20460 002	DEC 12, 1997	JUN	CFTG
>A>		GANCICLOVIR					
>A>	AB	RANBAXY	250MG	N76457 001	JUN 27, 2003	JUN	NEWA
>A>	AB		500MG	N76457 002	JUN 27, 2003	JUN	NEWA

GATIFLOXACIN

INJECTABLE; INJECTION

TEQUIN

+	BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)	N21062 001	DEC 17, 1999	APR	CRLD
+		EQ 2MG /ML(400MG/200ML)	N21062 002	DEC 17, 1999	APR	CRLD
+		EQ 10MG /ML(200MG)	N21062 003	DEC 17, 1999	APR	CRLD

SOLUTION/DROPS; OPHTHALMIC

ZYMAR

+	ALLERGAN	0.3%	N21493 001	MAR 28, 2003	MAR	NEWA
---	----------	------	------------	--------------	-----	------

<u>GEFITINIB</u>						
TABLET; ORAL						
IRESSA						
+ ASTRAZENECA	250MG	N21399 001	MAY 05, 2003	MAY	NEWA	
<u>GEMIFLOXACIN MESYLATE</u>						
TABLET; ORAL						
FACTIVE						
+ GENESOFT PHARMS	EQ 320MG BASE	N21158 001	APR 04, 2003	MAY	CAHN	
+ LG LIFE	EQ 320MG BASE	N21158 001	APR 04, 2003	APR	NEWA	
<u>GEMTUZUMAB OZOGAMICIN</u>						
INJECTABLE; INJECTION						
MYLOTARG						
+ WYETH PHARMS INC	5MG/VIAL	N21174 001	MAY 17, 2000	MAR	CAHN	
<u>GENTAMICIN SULFATE</u>						
CREAM; TOPICAL						
GARAMYCIN						
@ SCHERING	EQ 0.1% BASE	N60462 001		FEB	DISC	
GENTAMICIN SULFATE						
AT + FOUGERA	EQ 0.1% BASE	N62531 001	JUL 05, 1984	FEB	CRLD	
INJECTABLE; INJECTION						
>D> AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356 001	MAR 04, 1982	JUN	CRLD
>A> AP	+	EQ 10MG BASE/ML	N62356 001	MAR 04, 1982	JUN	CRLD
>A>	@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N62251 002		JUN	DISC
>A>	@	EQ 40MG BASE/ML	N62251 001		JUN	DISC
>D> AP	+ ELKINS SINN	EQ 10MG BASE/ML	N62251 002		JUN	DISC
>D> AP		EQ 40MG BASE/ML	N62251 001		JUN	DISC
OINTMENT; OPHTHALMIC						
GARAMYCIN						
@ SCHERING	EQ 0.3% BASE	N50425 001		APR	DISC	
GENTAMICIN SULFATE						
+ AKORN	EQ 0.3% BASE	N64093 001	AUG 31, 1995	APR	CRLD	
<u>GLIMEPIRIDE</u>						
TABLET; ORAL						
AMARYL						
+ AVENTIS PHARMS	1MG	N20496 001	NOV 30, 1995	JAN	CRLD	
	4MG	N20496 003	NOV 30, 1995	JAN	CRLD	
<u>GONADORELIN HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
FACTREL						
+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001	SEP 30, 1982	MAY	CAHN	
@	EQ 0.2MG BASE/VIAL	N18123 002	SEP 30, 1982	MAY	CAHN	
@	EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	MAY	CAHN	
<u>GONADOTROPIN, CHORIONIC</u>						
INJECTABLE; INJECTION						
A.P.L.						
>D> AP	+ WYETH AYERST	5,000 UNITS/VIAL	N17055 001		JUN	DISC

>A>	@	5,000 UNITS/VIAL	N17055 001		JUN	DISC
>D>	AP +	10,000 UNITS/VIAL	N17055 002		JUN	DISC
>A>	@	10,000 UNITS/VIAL	N17055 002		JUN	DISC
<u>GREPAFLOXACIN HYDROCHLORIDE</u>						
TABLET; ORAL						
RAXAR						
	@ OTSUKA	EQ 200MG BASE	N20695 001	NOV 06, 1997	MAY	DISC
	@	EQ 400MG BASE	N20695 002	MAY 14, 1998	MAY	DISC
	@	EQ 600MG BASE	N20695 003	MAY 14, 1998	MAY	DISC
<u>GUANABENZ ACETATE</u>						
TABLET; ORAL						
GUANABENZ ACETATE						
>D>	AB	WATSON LABS	EQ 8MG BASE	N74025 002	FEB 28, 1994	JUN CRLD
>A>	AB +		EQ 8MG BASE	N74025 002	FEB 28, 1994	JUN CRLD
>D>		WYTENSIN				
>D>	AB	WYETH AYERST	EQ 4MG BASE	N18587 001	SEP 07, 1982	JUN DISC
>A>	@		EQ 4MG BASE	N18587 001	SEP 07, 1982	JUN DISC
>D>	AB +		EQ 8MG BASE	N18587 002	SEP 07, 1982	JUN DISC
>A>	@		EQ 8MG BASE	N18587 002	SEP 07, 1982	JUN DISC
<u>HALOPERIDOL DECANOATE</u>						
INJECTABLE; INJECTION						
HALOPERIDOL DECANOATE						
	@ KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000	MAY	DISC
	@	EQ 100MG BASE/ML	N75176 002	FEB 09, 2000	MAY	DISC
<u>HEPARIN SODIUM</u>						
INJECTABLE; INJECTION						
HEP-LOCK						
>A>	AP +	BAXTER HLTHCARE	10 UNITS/ML	N17037 007		JUN CAHN
>A>	AP +		100 UNITS/ML	N17037 006		JUN CAHN
>D>	AP +	ELKINS SINN	10 UNITS/ML	N17037 007		JUN CAHN
>D>	AP +		100 UNITS/ML	N17037 006		JUN CAHN
HEP-LOCK U/P						
>A>	AP	BAXTER HLTHCARE	10 UNITS/ML	N17037 010	JUN 10, 1983	JUN CAHN
>A>	AP		100 UNITS/ML	N17037 011	JUN 10, 1983	JUN CAHN
>D>	AP	ELKINS SINN	10 UNITS/ML	N17037 010	JUN 10, 1983	JUN CAHN
>D>	AP		100 UNITS/ML	N17037 011	JUN 10, 1983	JUN CAHN
HEPARIN LOCK FLUSH						
	@ BAXTER HLTHCARE CORP	10 UNITS/ML	N17007 008		MAY	CAHN
	@	100 UNITS/ML	N17007 009		MAY	CAHN
HEPARIN SODIUM						
>A>	AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17037 001		JUN CAHN
>A>	AP		5,000 UNITS/ML	N17037 002		JUN CAHN
>A>	AP		5,000 UNITS/0.5ML	N17037 013	APR 07, 1986	JUN CAHN
>A>	AP		10,000 UNITS/ML	N17037 003		JUN CAHN
	@ BAXTER HLTHCARE CORP	1,000 UNITS/ML	N17007 001		MAY	CAHN
	@	2,500 UNITS/ML	N17007 007		MAY	CAHN
	@	5,000 UNITS/ML	N17007 002		MAY	CAHN
	@	5,000 UNITS/0.5ML	N17007 010		MAY	CAHN
	@	7,500 UNITS/ML	N17007 003		MAY	CAHN

		@	10,000 UNITS/ML	N17007 004		MAY	CAHN
		@	15,000 UNITS/ML	N17007 005		MAY	CAHN
		@	20,000 UNITS/ML	N17007 006		MAY	CAHN
>D>	AP	ELKINS SINN	1,000 UNITS/ML	N17037 001		JUN	CAHN
>D>	AP		5,000 UNITS/ML	N17037 002		JUN	CAHN
>D>	AP		5,000 UNITS/0.5ML	N17037 013	APR 07, 1986	JUN	CAHN
>D>	AP		10,000 UNITS/ML	N17037 003		JUN	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		AXIOM PHARM	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999	MAY	CAHN
----	--	-------------	-------------------	------------	--------------	-----	------

>A> HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

>A> TABLET; ORAL

>A> BENICAR HCT

>A>		SANKYO	12.5MG;20MG	N21532 002	JUN 05, 2003	JUN	NEWA
-----	--	--------	-------------	------------	--------------	-----	------

>A>			12.5MG;40MG	N21532 003	JUN 05, 2003	JUN	NEWA
-----	--	--	-------------	------------	--------------	-----	------

>A>	+		25MG;40MG	N21532 005	JUN 05, 2003	JUN	NEWA
-----	---	--	-----------	------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB		WYETH PHARMS INC	25MG;40MG	N18031 001		MAR	CAHN
----	--	------------------	-----------	------------	--	-----	------

INDERIDE-80/25

AB	+	WYETH PHARMS INC	25MG;80MG	N18031 002		MAR	CAHN
----	---	------------------	-----------	------------	--	-----	------

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		TEVA	7.5MG;200MG	N76023 001	APR 11, 2003	APR	NEWA
----	--	------	-------------	------------	--------------	-----	------

VICOPROFEN

AB	+	ABBOTT	7.5MG;200MG	N20716 001	SEP 23, 1997	APR	CFTG
----	---	--------	-------------	------------	--------------	-----	------

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

@	MERCK		EQ 50MG BASE/ML	N12052 001		APR	DISC
---	-------	--	-----------------	------------	--	-----	------

>D> HYDROCORTISONE; NEOMYCIN SULFATE

>D> CREAM; TOPICAL

>D> NEO-CORT-DOME

>D>	+	BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N50237 006	JUN 05, 1984	JUN	DISC
-----	---	--------------	-----------------------	------------	--------------	-----	------

>A>		@	0.5%;EQ 3.5MG BASE/GM	N50237 006	JUN 05, 1984	JUN	DISC
-----	--	---	-----------------------	------------	--------------	-----	------

>D>	+		1%;EQ 3.5MG BASE/GM	N50237 005	JUN 05, 1984	JUN	DISC
-----	---	--	---------------------	------------	--------------	-----	------

>A>		@	1%;EQ 3.5MG BASE/GM	N50237 005	JUN 05, 1984	JUN	DISC
-----	--	---	---------------------	------------	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT		ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001	AUG 25, 1983	FEB	CMFD
----	--	-------	-------------------------------------	------------	--------------	-----	------

SUSPENSION/DROPS; OPHTHALMIC

AT		ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	FEB	CMFD
----	--	-----------------	-------------------------------------	------------	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

SUSPENSION/DROPS; OTIC

AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001	NOV 06, 1985	FEB	CMFD
----	-----------------	-------------------------------------	------------	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

>D> DIUCARDIN

>D>	AB	WYETH AYERST	50MG	N83383 001		JUN	DISC
-----	----	--------------	------	------------	--	-----	------

>A>		@	50MG	N83383 001		JUN	DISC
-----	--	---	------	------------	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HCL

AP	FAULDING	10MG/ML	N76444 001	APR 25, 2003	APR	NEWA
----	----------	---------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D> HYDROXYZINE

>D>	AP	ELKINS SINN	50MG/ML	N85551 002		JUN	DISC
-----	----	-------------	---------	------------	--	-----	------

>A>		@	50MG/ML	N85551 002		JUN	DISC
-----	--	---	---------	------------	--	-----	------

>D> HYDROXYZINE HCL

>D>	AP	ELKINS SINN	25MG/ML	N85551 001		JUN	DISC
-----	----	-------------	---------	------------	--	-----	------

>A>		@	25MG/ML	N85551 001		JUN	DISC
-----	--	---	---------	------------	--	-----	------

TABLET; ORAL

ATARAX

@ PFIZER

		10MG	N10392 001		FEB	DISC
--	--	------	------------	--	-----	------

@

		25MG	N10392 004		FEB	DISC
--	--	------	------------	--	-----	------

@

		50MG	N10392 006		FEB	DISC
--	--	------	------------	--	-----	------

@

		100MG	N10392 005		FEB	DISC
--	--	-------	------------	--	-----	------

HYDROXYZINE HCL

AB +	SIDMAK LABS NJ	10MG	N88617 001	JAN 10, 1986	FEB	CRLD
------	----------------	------	------------	--------------	-----	------

AB +		25MG	N88618 001	JAN 10, 1986	FEB	CRLD
------	--	------	------------	--------------	-----	------

AB +		50MG	N88619 001	JAN 10, 1986	FEB	CRLD
------	--	------	------------	--------------	-----	------

	@	100MG	N81054 001	SEP 25, 1995	FEB	DISC
--	---	-------	------------	--------------	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

+	ROCHE	EQ 2.5MG BASE	N21455 001	MAY 16, 2003	MAY	NEWA
---	-------	---------------	------------	--------------	-----	------

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

>D>		NOVARTIS	50MG	N21335 001	MAY 10, 2001	JUN	DISC
-----	--	----------	------	------------	--------------	-----	------

>A>		@	50MG	N21335 001	MAY 10, 2001	JUN	DISC
-----	--	---	------	------------	--------------	-----	------

TABLET; ORAL

NOVARTIS

		100MG	N21588 001	APR 18, 2003	APR	NEWA
--	--	-------	------------	--------------	-----	------

+		400MG	N21588 002	APR 18, 2003	APR	NEWA
---	--	-------	------------	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

>D>		IOPAMIDOL		N74629 001	NOV 06, 1996	JUN	DISC
>D>	AP	ELKINS SINN PHARM	41%	N74629 001	NOV 06, 1996	JUN	DISC
>A>		@	41%	N74629 004	MAR 31, 1998	JUN	DISC
>D>	AP		51%	N74629 004	MAR 31, 1998	JUN	DISC
>A>		@	51%	N74629 002	NOV 06, 1996	JUN	DISC
>D>	AP		61%	N74629 002	NOV 06, 1996	JUN	DISC
>A>		@	61%	N74629 003	NOV 06, 1996	JUN	DISC
>D>	AP		76%	N74629 003	NOV 06, 1996	JUN	DISC
>A>		@	76%				

IOVERSOL

INJECTABLE; INJECTION

		OPTIRAY 240		N20923 001	MAY 28, 1998	JUN	DISC
>D>	+	MALLINCKRODT	51%	N20923 001	MAY 28, 1998	JUN	DISC
>A>		@	51%				
		OPTIRAY 300		N20923 004	MAY 13, 1999	JUN	NEWA
>A>	+	MALLINCKRODT	64%				
		OPTIRAY 320		N20923 002	MAY 29, 1998	JUN	DISC
>D>	+	MALLINCKRODT	68%	N20923 002	MAY 29, 1998	JUN	DISC
>A>		@	68%				

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

ATROVENT

AB	+	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N20393 001	OCT 20, 1995	MAR	CFTG
AB	+		0.042MG/SPRAY	N20394 001	OCT 20, 1995	MAR	CFTG
		IPRATROPIUM BROMIDE		N76025 001	MAR 31, 2003	MAR	NEWA
AB		BAUSCH AND LOMB	0.021MG/SPRAY	N76103 001	MAR 31, 2003	MAR	NEWA
AB			0.042MG/SPRAY	N75552 001	MAR 31, 2003	MAR	NEWA
AB		DEY	0.021MG/SPRAY	N75553 001	MAR 31, 2003	MAR	NEWA
AB			0.042MG/SPRAY	N76156 001	APR 18, 2003	APR	NEWA
AB		NOVEX	0.021MG/SPRAY	N76155 001	APR 18, 2003	APR	NEWA
AB			0.042MG/SPRAY				

ISONIAZID

TABLET; ORAL

ISONIAZID

		@ AXIOM PHARM	100MG	N80136 001		MAY	CAHN
AA			300MG	N83633 001		MAY	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL

>A>		@ BAXTER HLTHCARE	0.2MG/ML	N83486 001		JUN	DISC
>D>	AP	ELKINS SINN	0.2MG/ML	N83486 001		JUN	DISC

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

>D>	BC	SCHWARZ PHARMA	40MG	N19790 001	SEP 02, 1988	JUN	CRLD
-----	----	----------------	------	------------	--------------	-----	------

>A>	BC +	40MG	N19790 001	SEP 02, 1988	JUN	CRLD
>D>	ISORDIL					
>D>	BC + WYETH AYERST	40MG	N12882 002	JUL 29, 1988	JUN	DISC
>A>	@	40MG	N12882 002	JUL 29, 1988	JUN	DISC
	TABLET; ORAL					
>A>	AB BIOVAIL	5MG	N12093 007	JUL 29, 1988	JUN	CAHN
>A>	AB	10MG	N12093 002	JUL 29, 1988	JUN	CAHN
>A>	AB	20MG	N12093 006	JUL 29, 1988	JUN	CAHN
>A>	AB +	30MG	N12093 005	JUL 29, 1988	JUN	CAHN
>A>	AB	40MG	N12093 001	JUL 29, 1988	JUN	CAHN
>D>	AB WYETH PHARMS INC	5MG	N12093 007	JUL 29, 1988	JUN	CAHN
	AB	5MG	N12093 007	JUL 29, 1988	MAR	CAHN
>D>	AB	10MG	N12093 002	JUL 29, 1988	JUN	CAHN
	AB	10MG	N12093 002	JUL 29, 1988	MAR	CAHN
>D>	AB	20MG	N12093 006	JUL 29, 1988	JUN	CAHN
	AB	20MG	N12093 006	JUL 29, 1988	MAR	CAHN
>D>	AB +	30MG	N12093 005	JUL 29, 1988	JUN	CAHN
	AB +	30MG	N12093 005	JUL 29, 1988	MAR	CAHN
>D>	AB	40MG	N12093 001	JUL 29, 1988	JUN	CAHN
	AB	40MG	N12093 001	JUL 29, 1988	MAR	CAHN
	TABLET; SUBLINGUAL					
>A>	AB BIOVAIL	2.5MG	N12940 004	JUL 29, 1988	JUN	CAHN
>A>	AB	5MG	N12940 003	JUL 29, 1988	JUN	CAHN
>A>	+	10MG	N12940 005	JUL 29, 1988	JUN	CAHN
>D>	AB WYETH PHARMS INC	2.5MG	N12940 004	JUL 29, 1988	JUN	CAHN
	AB	2.5MG	N12940 004	JUL 29, 1988	MAR	CAHN
>D>	AB	5MG	N12940 003	JUL 29, 1988	JUN	CAHN
	AB	5MG	N12940 003	JUL 29, 1988	MAR	CAHN
>D>	+	10MG	N12940 005	JUL 29, 1988	JUN	CAHN
	+	10MG	N12940 005	JUL 29, 1988	MAR	CAHN

ISOTRETINOIN

CAPSULE; ORAL

CLARAVIS

AB	BARR	10MG	N76356 001	APR 11, 2003	APR	NEWA
AB		20MG	N76135 002	APR 11, 2003	APR	NEWA
AB		40MG	N76135 001	APR 11, 2003	APR	NEWA
>A>	SOTRET					
>A>	RANBAXY	30MG	N76503 001	JUN 20, 2003	JUN	NEWA

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

RELIANT PHARMS

		2.5MG	N19546 001	DEC 20, 1990	MAY	CAHN
	+	5MG	N19546 002	DEC 20, 1990	MAY	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	DYNACIRC CR					
	+	5MG	N20336 001	JUN 01, 1994	MAY	CAHN
	+	10MG	N20336 002	JUN 01, 1994	MAY	CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

>D>	AB	TEVA	75MG	N73517 001	DEC 22, 1992	JUN	CRLD
>A>	AB	+	75MG	N73517 001	DEC 22, 1992	JUN	CRLD
>D>		ORUDIS					
>D>	AB	WYETH AYERST	25MG	N18754 001	JUL 31, 1987	JUN	DISC
>A>		@	25MG	N18754 001	JUL 31, 1987	JUN	DISC
>D>	AB		50MG	N18754 002	JAN 09, 1986	JUN	DISC
>A>		@	50MG	N18754 002	JAN 09, 1986	JUN	DISC
>D>	AB	+	75MG	N18754 003	JAN 09, 1986	JUN	DISC
>A>		@	75MG	N18754 003	JAN 09, 1986	JUN	DISC

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

AB	WYETH PHARMS INC	100MG	N19816 003	FEB 08, 1995	MAR	CAHN
AB		150MG	N19816 002	FEB 08, 1995	MAR	CAHN
AB	+	200MG	N19816 001	SEP 24, 1993	MAR	CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ACULAR LS

+	ALLERGAN	0.4%	N21528 001	MAY 30, 2003	MAY	NEWA
---	----------	------	------------	--------------	-----	------

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	VISTAPHARM	10GM/15ML	N74138 001	SEP 30, 1992	MAR	CAHN
----	------------	-----------	------------	--------------	-----	------

LEFLUNOMIDE

TABLET; ORAL

ARAVA

+	AVENTIS PHARMS	20MG	N20905 002	SEP 10, 1998	MAR	CRLD
	@	100MG	N20905 003	SEP 10, 1998	MAR	DISC

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

>D>	AP	ELKINS SINN	EQ 50MG BASE/VIAL	N70480 001	JAN 02, 1987	JUN	DISC
>A>		@	EQ 50MG BASE/VIAL	N70480 001	JAN 02, 1987	JUN	DISC
>D>	AP		EQ 100MG BASE/VIAL	N81224 001	JUN 03, 1994	JUN	DISC
>A>		@	EQ 100MG BASE/VIAL	N81224 001	JUN 03, 1994	JUN	DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

+	ATRIX	30MG/VIAL	N21488 001	FEB 13, 2003	FEB	NEWA
---	-------	-----------	------------	--------------	-----	------

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

+	MEDPOINTE	EQ 0.5% BASE	N21114 001	FEB 23, 2000	MAR	CAHN
---	-----------	--------------	------------	--------------	-----	------

LEVONORGESTREL

IMPLANT; IMPLANTATION

>D>		LEVONORGESTREL						
>D>	BX +	WYETH PHARMS INC	75MG/IMPLANT	N20627 001	AUG 15, 1996	JUN	DISC	
>A>		@	75MG/IMPLANT	N20627 001	AUG 15, 1996	JUN	DISC	
	BX +		75MG/IMPLANT	N20627 001	AUG 15, 1996	MAR	CAHN	
		NORPLANT II						
>D>	BX	POPULATION COUNCIL	75MG/IMPLANT	N20544 001	NOV 01, 1996	JUN	CRLD	
>A>	BX +		75MG/IMPLANT	N20544 001	NOV 01, 1996	JUN	CRLD	
>D>		NORPLANT SYSTEM IN PLASTIC CONTAINER						
>D>	+	WYETH PHARMS INC	36MG/IMPLANT	N20088 001	DEC 10, 1990	JUN	DISC	
>A>		@	36MG/IMPLANT	N20088 001	DEC 10, 1990	JUN	DISC	
	+		36MG/IMPLANT	N20088 001	DEC 10, 1990	MAR	CAHN	

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ ICN

2MG

N08720 001 DEC 19, 1991 FEB DISC

LEVORPHANOL TARTRATE

+ ROXANE

2MG

N74278 001 MAR 31, 2000 FEB CRLD

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

BX		ALARA PHARM	0.025MG	N21342 001	MAR 01, 2002	APR	CAHN	
BX			0.05MG	N21342 002	MAR 01, 2002	APR	CAHN	
BX			0.075MG	N21342 003	MAR 01, 2002	APR	CAHN	
BX			0.088MG	N21342 004	MAR 01, 2002	APR	CAHN	
BX			0.1MG	N21342 005	MAR 01, 2002	APR	CAHN	
BX			0.112MG	N21342 006	MAR 01, 2002	APR	CAHN	
BX			0.125MG	N21342 007	MAR 01, 2002	APR	CAHN	
BX			0.15MG	N21342 008	MAR 01, 2002	APR	CAHN	
BX			0.175MG	N21342 009	MAR 01, 2002	APR	CAHN	
BX			0.2MG	N21342 010	MAR 01, 2002	APR	CAHN	
BX +			0.3MG	N21342 011	MAR 01, 2002	APR	CAHN	
>A>		LEVOLET						
>A>	BX	VINTAGE PHARMS	0.025MG	N21137 001	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.05MG	N21137 002	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.075MG	N21137 003	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.088MG	N21137 004	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.1MG	N21137 005	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.112MG	N21137 006	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.125MG	N21137 007	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.137MG	N21137 008	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.15MG	N21137 009	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.175MG	N21137 010	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.2MG	N21137 011	JUN 06, 2003	JUN	NEWA	
>A>	BX		0.3MG	N21137 012	JUN 06, 2003	JUN	NEWA	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

>D>	AP	ELKINS SINN	1%	N80407 001			JUN	DISC
>A>		@	1%	N80407 001			JUN	DISC
>D>	AP		2%	N80407 002			JUN	DISC
>A>		@	2%	N80407 002			JUN	DISC
>D>	AP	WYETH AYERST	1%	N83083 001			JUN	DISC
>A>		@	1%	N83083 001			JUN	DISC
>D>	AP		2%	N83083 002			JUN	DISC
>A>		@	2%	N83083 002			JUN	DISC

LIDOCAINE HCL PRESERVATIVE FREE

>D>	AP	ELKINS SINN	1%	N84625 001			JUN	DISC
>A>		@	1%	N84625 001			JUN	DISC
>D>	AP		2%	N84625 002			JUN	DISC
>A>		@	2%	N84625 002			JUN	DISC

JELLY; TOPICAL

LIDOCAINE HCL

AT		AKORN	2%	N40433 001	FEB 12, 2003		FEB	NEWA
----	--	-------	----	------------	--------------	--	-----	------

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB		RANBAXY	30MG	N75944 006	FEB 11, 2003		FEB	NEWA
>A>	AB	WEST WARD	30MG	N76063 006	JUN 27, 2003		JUN	NEWA
		ZESTRIL						
AB		ASTRAZENECA	30MG	N19777 006	JAN 20, 1999		APR	CRLD

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB		ROXANE	150MG	N17812 002	JAN 28, 1987		FEB	CTEC
AB		WEST WARD	150MG	N76243 002	FEB 24, 2003		FEB	NEWA

TABLET, EXTENDED RELEASE; ORAL

ESKALITH CR

>D>	+	GLAXOSMITHKLINE	450MG	N18152 001	MAR 29, 1982		JUN	CFTG
>A>	AB	+	450MG	N18152 001	MAR 29, 1982		JUN	CFTG
>A>		LITHIUM CARBONATE						
AB		ABLE	300MG	N76382 001	APR 21, 2003		APR	NEWA
>A>	AB	WEST WARD	450MG	N76490 001	JUN 17, 2003		JUN	NEWA

LORATADINE

SYRUP; ORAL

CLARITIN

@ SCHERING 1MG/ML

N20641 001 OCT 10, 1996 MAY DISC

TABLET; ORAL

@ SCHERING 10MG

N19658 001 APR 12, 1993 MAY DISC

TABLET, ORALLY DISINTEGRATING; ORAL

CLARITIN REDITABS

@ SCHERING 10MG

N20704 001 DEC 23, 1996 MAY DISC

<u>LORAZEPAM</u>									
		CONCENTRATE; ORAL							
		LORAZEPAM INTENSOL							
		+	ROXANE	2MG/ML		N72755 001	JUN 28, 1991	MAY	CRLD
			INJECTABLE; INJECTION						
			ATIVAN						
	AP	+	BAXTER HLTHCARE CORP	2MG/ML		N18140 001		FEB	CAHN
	AP	+		4MG/ML		N18140 002		FEB	CAHN
			TABLET; ORAL						
>A>	AB		BIOVAIL	0.5MG		N17794 001		JUN	CAHN
>A>	AB			1MG		N17794 002		JUN	CAHN
>A>	AB	+		2MG		N17794 003		JUN	CAHN
>D>	AB		WYETH AYERST	0.5MG		N17794 001		JUN	CAHN
>D>	AB			1MG		N17794 002		JUN	CAHN
>D>	AB	+		2MG		N17794 003		JUN	CAHN
<u>MECAMYLAMINE HYDROCHLORIDE</u>									
		TABLET; ORAL							
		INVERSINE							
		+	TARGACEPT	2.5MG		N10251 001		APR	CAHN
<u>MECLOFENAMATE SODIUM</u>									
		CAPSULE; ORAL							
		MECLOFENAMATE SODIUM							
	AB	+	MYLAN	EQ 100MG BASE		N71081 001	SEP 03, 1986	MAY	CRLD
			MECLOMEN						
		@	PARKE DAVIS	EQ 50MG BASE		N18006 001		MAY	DISC
		@		EQ 100MG BASE		N18006 002		MAY	DISC
<u>MEFLOQUINE HYDROCHLORIDE</u>									
		TABLET; ORAL							
		MEFLOQUINE HCL							
	AB		GENEVA PHARMS	250MG		N76175 001	FEB 20, 2002	APR	CAHN
<u>MEGESTROL ACETATE</u>									
		SUSPENSION; ORAL							
		MEGESTROL ACETATE							
	AB		COPLY PHARM	40MG/ML		N75681 001	MAY 05, 2003	MAY	NEWA
<u>MENOTROPINS (FSH;LH)</u>									
		INJECTABLE; INJECTION							
		REPRONEX							
	BX	+	FERRING	75 IU/VIAL;75 IU/VIAL		N21047 001	AUG 27, 1999	MAY	CRLD
		@		150 IU/VIAL;150 IU/VIAL		N21047 002	AUG 27, 1999	MAY	DISC
<u>MEPERIDINE HYDROCHLORIDE</u>									
		INJECTABLE; INJECTION							
		MEPERIDINE HCL							
	AP		BAXTER HLTHCARE CORP	25MG/ML		N80455 007		MAY	CAHN
	AP			50MG/ML		N80455 008		MAY	CAHN
	AP			75MG/ML		N80455 009		MAY	CAHN
	AP			100MG/ML		N80455 010		MAY	CAHN

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HCL

TABLET; ORAL

AA	AXIOM PHARM	50MG	N80448 001	MAY	CAHN
AA		100MG	N80448 002	MAY	CAHN
>D>	AA	WYETH AYERST	50MG	N80454 001	JUN DISC
>A>	@	50MG	N80454 001	JUN	DISC

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@ BAXTER HLTHCARE CORP 25MG/ML;25MG/ML

N11730 001 MAY CAHN

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

@ BAXTER HLTHCARE CORP EQ 15MG BASE/ML

N08248 002 FEB CAHN

@ EQ 30MG BASE/ML

N08248 001 FEB CAHN

MEPROBAMATE

TABLET; ORAL

EQUANIL

>D>	AA +	WYETH AYERST	200MG	N10028 005	JUN DISC
>A>	@		200MG	N10028 005	JUN DISC
>D>	AA +		400MG	N10028 004	JUN DISC
>A>	@		400MG	N10028 004	JUN DISC

MEPROBAMATE

>D>	AA	ROXANE	600MG	N84332 001	JUN CRLD
>A>	+		600MG	N84332 001	JUN CRLD
>D>		MILTOWN			
>D>	AA +	MEDPOINTE	600MG	N83919 001	JUN DISC
	AA +		600MG	N83919 001	APR CAHN
>A>	@	MEDPOINTE PHARM HLC	600MG	N83919 001	JUN DISC

MESORIDAZINE BESYLATE

TABLET; ORAL

SERENTIL

>D>		NOVARTIS	EQ 10MG BASE	N16774 001	JUN DISC
>A>	@		EQ 10MG BASE	N16774 001	JUN DISC
>D>			EQ 50MG BASE	N16774 003	JUN DISC
>A>	@		EQ 50MG BASE	N16774 003	JUN DISC

METAXALONE

TABLET; ORAL

SKELAXIN

>D>		ELAN PHARMS	400MG	N13217 001	JUN CAHN
>D>	+		800MG	N13217 003	AUG 30, 2002 JUN CAHN
>A>		JONES PHARMA INC	400MG	N13217 001	JUN CAHN
>A>	+		800MG	N13217 003	AUG 30, 2002 JUN CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL
 METFORMIN HCL
 AB PUREPAC PHARM 1GM
 TABLET, EXTENDED RELEASE; ORAL
 GLUCOPHAGE XR
 + BRISTOL MYERS SQUIBB 750MG

N76033 003 JAN 24, 2002 FEB CMS1

N21202 004 APR 11, 2003 APR NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
 AVANDAMET
 SB PHARMCO
 500MG;EQ 1MG BASE
 500MG;EQ 2MG BASE
 +
 500MG;EQ 4MG BASE

N21410 001 OCT 10, 2002 APR CAHN

N21410 002 OCT 10, 2002 APR CAHN

N21410 003 OCT 10, 2002 APR CAHN

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION
 DOLOPHINE HCL
 + AAIPHARMA 10MG/ML
 + ROXANE 10MG/ML

N21624 001 APR CAHN

N21624 001 FEB CMS1

METHAZOLAMIDE

TABLET; ORAL
 METHAZOLAMIDE
 >D> AB MIKART 50MG
 >A> AB + 50MG
 >D> NEPTAZANE
 >D> AB LEDERLE 25MG
 >A> @ 25MG
 >D> AB + 50MG
 >A> @ 50MG

N40062 002 JAN 27, 1994 JUN CRLD

N40062 002 JAN 27, 1994 JUN CRLD

N11721 002 NOV 25, 1991 JUN DISC

N11721 002 NOV 25, 1991 JUN DISC

N11721 001 JUN DISC

N11721 001 JUN DISC

METHENAMINE HIPPURATE

TABLET; ORAL
 METHENAMINE HIPPURATE
 >A> AB COREPHARMA 1GM

N76411 001 JUN 20, 2003 JUN NEWA

METHIMAZOLE

TABLET; ORAL
 TAPAZOLE
 >D> AB + LILLY 10MG
 >A> AB 10MG

N07517 004 JUN CRLD

N07517 004 JUN CRLD

METHOCARBAMOL

TABLET; ORAL
 METHOCARBAMOL
 AA ABLE 500MG
 AA 750MG
 AA LANNETT 500MG
 >D> AA LEDERLE 500MG
 >A> @ 500MG
 >D> AA 750MG

N40413 001 MAR 17, 2003 MAR NEWA

N40413 002 MAR 17, 2003 MAR NEWA

N84756 002 MAR 31, 2003 MAR NEWA

N85961 001 JUN DISC

N85961 001 JUN DISC

N85963 001 JUN DISC

>A>	@	750MG		N85963 001		JUN	DISC
AA	VINTAGE PHARMS	500MG		N40489 001	JAN 29, 2003	JAN	NEWA
AA		750MG		N40489 002	JAN 29, 2003	JAN	NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE LPF

AP	+	WYETH PHARMS INC	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982	MAR	CAHN
		METHOTREXATE SODIUM					
		@ WYETH PHARMS INC	EQ 2.5MG BASE/ML	N11719 004		MAR	CAHN
	+		EQ 20MG BASE/VIAL	N11719 001		MAR	CAHN
AP	+		EQ 25MG BASE/ML	N11719 005		MAR	CAHN
		@	EQ 50MG BASE/VIAL	N11719 003		MAR	CAHN
		@	EQ 100MG BASE/VIAL	N11719 006		MAR	CAHN
		METHOTREXATE SODIUM PRESERVATIVE FREE					
AP	+	WYETH PHARMS INC	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	MAR	CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

PAMINE FORTE

+	BRADLEY PHARMS	5MG		N08848 002	MAR 25, 2003	MAR	NEWA
---	----------------	-----	--	------------	--------------	-----	------

METHYLCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

>D>	@	MEDPOINTE PHARM HLC	5MG	N17364 001		JUN	DISC
>D>	AB	WALLACE LABS	5MG	N17364 001		JUN	DISC

METHYLDOPA

TABLET; ORAL

ALDOMET

@	MERCK	125MG		N13400 003		MAY	DISC
@		250MG		N13400 001		MAY	DISC

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

>D>	AP	ELKINS SINN	50MG/ML	N70291 001	JUL 01, 1986	JUN	DISC
>A>	@		50MG/ML	N70291 001	JUL 01, 1986	JUN	DISC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

>A>	+	CELLTECH PHARMS	30MG	N21259 002	JUN 19, 2003	JUN	NEWA
-----	---	-----------------	------	------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

METHYLIN

		MALLINCKRODT	2.5MG	N21475 001	APR 15, 2003	APR	NEWA
			5MG	N21475 002	APR 15, 2003	APR	NEWA
	+		10MG	N21475 003	APR 15, 2003	APR	NEWA

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

+	MCNEIL CONS SPECT	18MG		N21121 001	AUG 01, 2000	MAY	CAHN
+		27MG		N21121 004	APR 01, 2002	MAY	CAHN

	+		36MG		N21121 002	AUG 01, 2000	MAY	CAHN
	+		54MG		N21121 003	DEC 08, 2000	MAY	CAHN
<u>METHYLPREDNISOLONE ACETATE</u>								
>D>								
>D>								
>D>	+	PHARMACIA AND UPJOHN	0.25%		N12421 001		JUN	DISC
>A>	@		0.25%		N12421 001		JUN	DISC
<u>METHYSERGIDE MALEATE</u>								
>D>								
>D>								
>D>								
>D>	+	NOVARTIS	2MG		N12516 001		JUN	DISC
>A>	@		2MG		N12516 001		JUN	DISC
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>								
AA		VISTAPHARM	EQ 5MG BASE/5ML		N75051 001	JAN 26, 2001	APR	CAHN
>D>	AB	LEDERLE	EQ 10MG BASE		N72639 001	MAY 09, 1991	JUN	DISC
>A>	@		EQ 10MG BASE		N72639 001	MAY 09, 1991	JUN	DISC
<u>METRONIDAZOLE</u>								
>A>	AB	ABLE	250MG		N76519 001	JUN 27, 2003	JUN	NEWA
>A>	AB		500MG		N76519 002	JUN 27, 2003	JUN	NEWA
>D>	+	GD SEARLE LLC	750MG		N20868 001	NOV 26, 1997	JUN	CFTG
>A>	AB		750MG		N20868 001	NOV 26, 1997	JUN	CFTG
>A>								
>A>	AB	ABLE	750MG		N76462 001	JUN 25, 2003	JUN	NEWA
<u>MEZLOCILLIN SODIUM MONOHYDRATE</u>								
>D>								
>D>								
>D>								
>D>	+	BAYER PHARMS	EQ 1GM BASE/VIAL		N50549 001		JUN	DISC
>A>	@		EQ 1GM BASE/VIAL		N50549 001		JUN	DISC
>D>	+		EQ 2GM BASE/VIAL		N50549 002		JUN	DISC
>A>	@		EQ 2GM BASE/VIAL		N50549 002		JUN	DISC
>D>	+		EQ 3GM BASE/VIAL		N50549 003		JUN	DISC
>A>	@		EQ 3GM BASE/VIAL		N50549 003		JUN	DISC
>D>	+		EQ 4GM BASE/VIAL		N50549 004		JUN	DISC
>A>	@		EQ 4GM BASE/VIAL		N50549 004		JUN	DISC
>D>	+		EQ 20GM BASE/VIAL		N50549 005	MAR 02, 1988	JUN	DISC
>A>	@		EQ 20GM BASE/VIAL		N50549 005	MAR 02, 1988	JUN	DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

>A>	AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	N75243 001	JUN 20, 2000	JUN	CAHN
>A>	AP		EQ 5MG BASE/ML	N75243 002	JUN 20, 2000	JUN	CAHN
>D>	AP	ESI LEDERLE	EQ 1MG BASE/ML	N75243 001	JUN 20, 2000	JUN	CAHN
>D>	AP		EQ 5MG BASE/ML	N75243 002	JUN 20, 2000	JUN	CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>A>	AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	JUN	CAHN
>A>	AP	BIONICHE (CANADA)	EQ 1MG BASE/ML	N76428 001	JUN 16, 2003	JUN	NEWA
>D>	AP	ESI LEDERLE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	JUN	CAHN
AP	+	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB		WYETH PHARMS INC	EQ 50MG BASE	N50649 001	MAY 31, 1990	MAR	CAHN
AB			EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	CAHN
AB	+		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CAHN

INJECTABLE; INJECTION

+ WYETH PHARMS INC

EQ 100MG BASE/VIAL

N50444 001 MAR CAHN

TABLET; ORAL

MINOCYCLINE HCL

PAR PHARM

+

EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASEN65131 001 APR 16, 2003 APR NEWA
N65131 002 APR 16, 2003 APR NEWA
N65131 003 APR 16, 2003 APR NEWAMIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

>A>	AB	ALPHAPHARM	15MG	N76176 001	JUN 19, 2003	JUN	NEWA
>A>	AB		30MG	N76176 002	JUN 19, 2003	JUN	NEWA
>A>	AB		45MG	N76176 003	JUN 19, 2003	JUN	NEWA
>A>	AB	AMIDE PHARM	15MG	N76241 001	JUN 25, 2003	JUN	NEWA
>A>	AB		30MG	N76241 002	JUN 25, 2003	JUN	NEWA
>A>	AB		45MG	N76241 003	JUN 25, 2003	JUN	NEWA
>A>	AB	ANDRX PHARMS	15MG	N76336 001	JUN 20, 2003	JUN	NEWA
>A>	AB		30MG	N76336 002	JUN 20, 2003	JUN	NEWA
>A>	AB		45MG	N76336 003	JUN 20, 2003	JUN	NEWA
>A>	AB	EON	15MG	N76219 001	JUN 19, 2003	JUN	NEWA
>A>	AB		30MG	N76219 002	JUN 19, 2003	JUN	NEWA
>A>	AB		45MG	N76219 003	JUN 19, 2003	JUN	NEWA
>A>	AB	GENEVA PHARMS	15MG	N76189 001	JUN 19, 2003	JUN	NEWA
>A>	AB		30MG	N76189 002	JUN 19, 2003	JUN	NEWA
>A>	AB		45MG	N76189 003	JUN 19, 2003	JUN	NEWA
>A>	AB	MYLAN	15MG	N76122 001	JUN 19, 2003	JUN	NEWA
>A>	AB		30MG	N76122 002	JUN 19, 2003	JUN	NEWA
>A>	AB		45MG	N76122 003	JUN 19, 2003	JUN	NEWA

>A>	AB	PUREPAC PHARM	15MG	N76308 001	JUN 20, 2003	JUN	NEWA
>A>	AB		30MG	N76308 002	JUN 20, 2003	JUN	NEWA
>A>	AB		45MG	N76308 003	JUN 20, 2003	JUN	NEWA
>A>	AB	ROXANE	15MG	N76270 001	JUN 19, 2003	JUN	NEWA
>A>	AB		30MG	N76270 002	JUN 19, 2003	JUN	NEWA
>A>	AB		45MG	N76270 003	JUN 19, 2003	JUN	NEWA
	AB	TEVA	15MG	N76119 001	JAN 24, 2003	JAN	NEWA
	AB		30MG	N76119 002	JAN 24, 2003	JAN	NEWA
>A>	AB		45MG	N76119 003	JUN 19, 2003	JUN	NEWA
>A>	AB	WATSON LABS	15MG	N76312 001	JUN 19, 2003	JUN	NEWA
>A>	AB		30MG	N76312 002	JUN 19, 2003	JUN	NEWA
>A>	AB		45MG	N76312 003	JUN 19, 2003	JUN	NEWA
		REMERON					
	AB +	ORGANON	15MG	N20415 001	JUN 14, 1996	JAN	CFTG
	AB		30MG	N20415 002	JUN 14, 1996	JAN	CFTG
>D>			45MG	N20415 003	MAR 17, 1997	JUN	CFTG
>A>	AB	ORGANON USA INC	45MG	N20415 003	MAR 17, 1997	JUN	CFTG

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HCL

AB	TEVA	7.5MG	N76204 001	MAY 08, 2003	MAY	NEWA
AB		15MG	N76204 002	MAY 08, 2003	MAY	NEWA
	UNIVASC					
AB	SCHWARZ PHARMA	7.5MG	N20312 001	APR 19, 1995	MAY	CFTG
AB +		15MG	N20312 002	APR 19, 1995	MAY	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

>D>	BX +	ELAN PHARM	30MG	N21260 001	MAR 20, 2002	JUN	CAHN
>D>	BX +		60MG	N21260 002	MAR 20, 2002	JUN	CAHN
>D>	+		90MG	N21260 003	MAR 20, 2002	JUN	CAHN
>D>	+		120MG	N21260 004	MAR 20, 2002	JUN	CAHN
>A>	BX +	LIGAND	30MG	N21260 001	MAR 20, 2002	JUN	CAHN
>A>	BX +		60MG	N21260 002	MAR 20, 2002	JUN	CAHN
>A>	+		90MG	N21260 003	MAR 20, 2002	JUN	CAHN
>A>	+		120MG	N21260 004	MAR 20, 2002	JUN	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VIGAMOX

	+	ALCON	0.5%	N21598 001	APR 15, 2003	APR	NEWA
--	---	-------	------	------------	--------------	-----	------

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

BX	CLAY PARK LABS	2%	N50788 001	DEC 04, 2002	JAN	CTEC
BX	JOHNSON AND JOHNSON	2%	N50788 001	DEC 04, 2002	APR	CAHN

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT

+ ROCHE PALO 250MG N50722 001 MAY 03, 1995 FEB CAHN

SUSPENSION; ORAL

+ ROCHE PALO 200MG/ML N50759 001 OCT 01, 1998 FEB CAHN

TABLET; ORAL

+ ROCHE PALO 500MG N50723 001 JUN 19, 1997 FEB CAHN

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

+ ROCHE PALO 500MG/VIAL N50758 001 AUG 12, 1998 FEB CAHN

NABUMETONE

TABLET; ORAL

NABUMETONE

AB IVAX PHARMS 500MG N76009 001 JAN 24, 2003 JAN NEWA

AB 750MG N76009 002 JAN 24, 2003 JAN NEWA

>D> NAFTIFINE HYDROCHLORIDE

>D> CREAM; TOPICAL

>D> NAFTIN

>D> + ALLERGAN HERBERT 1% N19599 001 FEB 29, 1988 JUN DISC

>A> @ 1% N19599 001 FEB 29, 1988 JUN DISC

>D> GEL; TOPICAL

>D> + ALLERGAN HERBERT 1% N19356 001 JUN 18, 1990 JUN DISC

>A> @ 1% N19356 001 JUN 18, 1990 JUN DISC

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

@ KING PHARMS 10MG/ML N74471 001 MAR 19, 1998 MAY DISC

@ 20MG/ML N74471 002 MAR 19, 1998 MAY DISC

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

>D> AP ELKINS SINN 0.4MG/ML N70299 001 SEP 24, 1986 JUN DISC

>A> @ 0.4MG/ML N70299 001 SEP 24, 1986 JUN DISC

>D> AP ELKINS SINN PHARM 0.4MG/ML N70298 001 SEP 24, 1986 JUN DISC

>A> @ 0.4MG/ML N70298 001 SEP 24, 1986 JUN DISC

NALOXONE HCL

>D> AP ELKINS SINN 0.02MG/ML N71272 001 MAY 24, 1988 JUN DISC

>A> @ 0.02MG/ML N71272 001 MAY 24, 1988 JUN DISC

>D> AP 1MG/ML N71273 001 MAY 24, 1988 JUN DISC

>A> @ 1MG/ML N71273 001 MAY 24, 1988 JUN DISC

>D> AP 1MG/ML N71274 001 MAY 24, 1988 JUN DISC

>A> @ 1MG/ML N71274 001 MAY 24, 1988 JUN DISC

>D> AP 1MG/ML N71287 001 MAY 24, 1988 JUN DISC

>A> @ 1MG/ML N71287 001 MAY 24, 1988 JUN DISC

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

@ ORGANON USA INC

50MG/ML

N13132 001 JUN 12, 1986 MAY DISC

@

100MG/ML

N13132 002 JUN 12, 1986 MAY DISC

@

200MG/ML

N13132 003 JUN 12, 1986 MAY DISC

NANDROLONE DECANOATE

+ STERIS

50MG/ML

N86385 001 JAN 13, 1984 MAY CRLD

+

100MG/ML

N86598 001 JAN 13, 1984 MAY CRLD

+

200MG/ML

N88128 001 DEC 05, 1983 MAY CRLD

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

>D> AB + ELAN PHARM

EQ 375MG BASE

N20353 001 JAN 05, 1996 JUN CAHN

AB +

EQ 375MG BASE

N20353 001 JAN 05, 1996 APR CFTG

>D> AB +

EQ 500MG BASE

N20353 002 JAN 05, 1996 JUN CAHN

AB +

EQ 500MG BASE

N20353 002 JAN 05, 1996 MAR CFTG

>D> @

EQ 750MG BASE

N20353 003 JAN 05, 1996 JUN CAHN

>A> AB + ELAN PHARMA

EQ 375MG BASE

N20353 001 JAN 05, 1996 JUN CAHN

>A> AB +

EQ 500MG BASE

N20353 002 JAN 05, 1996 JUN CAHN

>A> @

EQ 750MG BASE

N20353 003 JAN 05, 1996 JUN CAHN

NAPROXEN SODIUM

AB ANDRX PHARMS

EQ 375MG BASE

N75416 002 APR 23, 2003 APR NEWA

AB

EQ 500MG BASE

N75416 001 AUG 27, 2002 MAR NEWA

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+ AGOURON

EQ 625MG BASE

N21503 001 APR 30, 2003 APR NEWA

NIFEDIPINE

CAPSULE; ORAL

ADALAT

>D> AB BAYER PHARMS

10MG

N19478 001 NOV 27, 1985 JUN DISC

>A> @

10MG

N19478 001 NOV 27, 1985 JUN DISC

>D> AB

20MG

N19478 002 SEP 17, 1986 JUN DISC

>A> @

20MG

N19478 002 SEP 17, 1986 JUN DISC

NITROFURANTOIN

TABLET; ORAL

FURADANTIN

@ PROCTER AND GAMBLE

50MG

N08693 001

APR DISC

@

100MG

N08693 002

APR DISC

NITROFURANTOIN

@ WATSON LAB

50MG

N80447 001

APR DISC

@ WHITEWORTH TOWN PLSN

100MG

N84085 002

APR DISC

NITROFURAZONE

OINTMENT; TOPICAL

FURACIN

@ SHIRE PHARM

0.2%

N05795 001

MAR DISC

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL*

NITROGLYCERIN			N75033 001	FEB 06, 1998	APR	CAHN
AB2	MYLAN TECHNOLOGIES	0.1MG/HR	N74609 001	AUG 30, 1996	APR	CAHN
AB2		0.2MG/HR	N74607 001	AUG 30, 1996	APR	CAHN
AB2		0.4MG/HR	N74559 001	AUG 30, 1996	APR	CAHN
AB2		0.6MG/HR				

INJECTABLE; INJECTION

TRIDIL

@ FAULDING

@

N18537 002	JUN 16, 1983	MAY	DISC
N18537 001		MAY	DISC

OINTMENT; TRANSDERMAL

NITROGLYCERIN

+ FOUGERA

2%

N87355 001	JUL 08, 1988	APR	CAHN
------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB TORPHARM

150MG

N76383 001	JAN 23, 2003	JAN	NEWA
------------	--------------	-----	------

AB

300MG

N76383 002	JAN 23, 2003	JAN	NEWA
------------	--------------	-----	------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP + ABBOTT

EQ 1MG BASE/ML

N07513 001		MAR	CFTG
------------	--	-----	------

NOREPINEPHRINE BITARTRATE

AP GENZIA SICOR PHARMS

EQ 1MG BASE/ML

N40455 001	MAR 03, 2003	MAR	NEWA
------------	--------------	-----	------

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

>A> AB + DURAMED PHARM BARR

5MG

N18405 001	APR 21, 1982	JUN	CAHN
------------	--------------	-----	------

>D> AB + WYETH PHARMS INC

5MG

N18405 001	APR 21, 1982	JUN	CAHN
------------	--------------	-----	------

AB +

5MG

N18405 001	APR 21, 1982	MAR	CAHN
------------	--------------	-----	------

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

@ MERCK

0.3%

N19757 001	JUN 17, 1991	MAY	DISC
------------	--------------	-----	------

NORGESTREL

TABLET; ORAL

OVRETTE

+ WYETH PHARMS INC

0.075MG

N17031 001		MAR	CAHN
------------	--	-----	------

OLANZAPINE

TABLET; ORAL

ZYPREXA

+ LILLY

5MG

20MG

N20592 002	SEP 30, 1996	MAY	CRLD
------------	--------------	-----	------

N20592 006	SEP 09, 1997	MAY	CRLD
------------	--------------	-----	------

* SEE SECTION 1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	LEK SVCS	10MG	N75757 001	JAN 28, 2003	JAN	NEWA
AB		20MG	N75757 002	JAN 28, 2003	JAN	NEWA
AB	MYLAN	10MG	N75876 001	MAY 29, 2003	MAY	NEWA
AB		20MG	N75876 002	MAY 29, 2003	MAY	NEWA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

AP	BEDFORD LABS	30MG/ML	N40463 001	MAR 04, 2003	MAR	NEWA
----	--------------	---------	------------	--------------	-----	------

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

+	WATSON LABS (UTAH)	3.9MG/24HR	N21351 002	FEB 26, 2003	FEB	NEWA
---	--------------------	------------	------------	--------------	-----	------

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

ALZA

5MG

N20897 001 DEC 16, 1998 MAY CRLD

10MG

N20897 002 DEC 16, 1998 MAY CRLD

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@	BAXTER HLTHCARE CORP	10USP UNITS/ML	N18243 001		MAY	CAHN
---	----------------------	----------------	------------	--	-----	------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP	+	GENSIA SICOR PHARMS	1MG/ML	N72759 001	JUL 31, 1990	MAY	CRLD
----	---	---------------------	--------	------------	--------------	-----	------

AP	+		2MG/ML	N72760 001	JUL 31, 1990	MAY	CRLD
----	---	--	--------	------------	--------------	-----	------

PAVULON

@ ORGANON

1MG/ML

N17015 002

MAY DISC

@

2MG/ML

N17015 001

MAY DISC

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PROTONIX IV

+	WYETH PHARMS INC	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	CAHN
---	------------------	-------------------	------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

PROTONIX

+	WYETH PHARMS INC	EQ 20MG BASE	N20987 002	JUN 12, 2001	MAR	CAHN
---	------------------	--------------	------------	--------------	-----	------

EQ 20MG BASE

N20987 002 JUN 12, 2001 APR CRLD

+

EQ 40MG BASE

N20987 001 FEB 02, 2000 MAR CAHN

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

AA	+	KING PHARMS	EQ 250MG BASE	N62310 001		MAY	CAHN
----	---	-------------	---------------	------------	--	-----	------

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS
SOMAVERT

+ PHARMACIA AND UPJOHN	10MG/VIAL	N21106 001	MAR 25, 2003	MAR	NEWA
+	15MG/VIAL	N21106 002	MAR 25, 2003	MAR	NEWA
+	20MG/VIAL	N21106 003	MAR 25, 2003	MAR	NEWA

PENICILLIN G POTASSIUM

TABLET; ORAL

>D>	PENICILLIN G POTASSIUM				
>D>	WYETH AYERST	200,000 UNITS	N60413 001	JUN	DISC
>A>	@	200,000 UNITS	N60413 001	JUN	DISC
>D>		250,000 UNITS	N60413 002	JUN	DISC
>A>	@	250,000 UNITS	N60413 002	JUN	DISC
>D>	+	400,000 UNITS	N60413 003	JUN	DISC
>A>	@	400,000 UNITS	N60413 003	JUN	DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

>D>	LEDERCILLIN VK				
>D>	AA LEDERLE	EQ 125MG BASE/5ML	N60136 001	JUN	DISC
>A>	@	EQ 125MG BASE/5ML	N60136 001	JUN	DISC
>D>	AA	EQ 250MG BASE/5ML	N60136 002	JUN	DISC
>A>	@	EQ 250MG BASE/5ML	N60136 002	JUN	DISC
>D>	AB LEDERLE	EQ 250MG BASE	N60134 001	JUN	DISC
>A>	@	EQ 250MG BASE	N60134 001	JUN	DISC
>D>	AB	EQ 500MG BASE	N60134 002	JUN	DISC
>A>	@	EQ 500MG BASE	N60134 002	JUN	DISC
>D>	PEN-VEE K				
>D>	AB WYETH AYERST	EQ 250MG BASE	N60006 002	JUN	DISC
>A>	@	EQ 250MG BASE	N60006 002	JUN	DISC
>D>	AB +	EQ 500MG BASE	N60006 003	JUN	DISC
>A>	@	EQ 500MG BASE	N60006 003	JUN	DISC

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

>D>	AP ELKINS SINN	300MG/VIAL	N73617 001	DEC 18, 1995	JUN	DISC
>A>	@	300MG/VIAL	N73617 001	DEC 18, 1995	JUN	DISC

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

>D>	AP + ABBOTT	50MG/ML	N83246 001		JUN	CTEC
>A>	+	50MG/ML	N83246 001		JUN	CTEC
>D>	SODIUM PENTOBARBITAL					
>D>	AP WYETH AYERST	50MG/ML	N83261 001		JUN	DISC
>A>	@	50MG/ML	N83261 001		JUN	DISC

PERMETHRIN

CREAM; TOPICAL
 PERMETHRIN
 AB CLAY PARK 5%

N76369 001 APR 21, 2003 APR NEWA

PERPHENAZINE

TABLET; ORAL
 PERPHENAZINE
 AB + IVAX PHARMS 16MG
 TRILAFON
 @ SCHERING 2MG
 @ 4MG
 @ 8MG
 @ 16MG

N89457 001 SEP 10, 1987 FEB CRLD
 N10775 001 FEB DISC
 N10775 002 FEB DISC
 N10775 003 FEB DISC
 N10775 004 FEB DISC

PHEENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
 PHEENTERMINE HCL
 AA ABLE 15MG
 AA AMBI PHARMS 30MG
 AA AMIDE PHARM 15MG
 AA 30MG

N40497 001 MAR 13, 2003 MAR NEWA
 N40083 001 MAR 07, 1997 MAY CAHN
 N40460 001 JAN 14, 2003 JAN NEWA
 N40448 001 JAN 22, 2003 JAN NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
 PHENERGAN VC
 @ WYETH AYERST 5MG/5ML;6.25MG/5ML
 PROMETH VC PLAIN
 AA + ALPHARMA 5MG/5ML;6.25MG/5ML

N08604 003 APR 02, 1984 APR DISC
 N88761 001 NOV 08, 1984 APR CRLD

PHENYTOIN

SUSPENSION; ORAL
 PHENYTOIN
 AB VISTAPHARM 125MG/5ML

N40342 001 JAN 31, 2001 MAR CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION
 DILANTIN
 @ PARKE DAVIS 50MG/ML
 PHENYTOIN
 + ELKINS SINN 50MG/ML
 PHENYTOIN SODIUM
 @ ABBOTT 50MG/ML
 @ 50MG/ML

N10151 001 MAR DISC
 N84307 001 MAR CRLD
 N89521 001 MAR 17, 1987 MAR DISC
 N89744 001 DEC 18, 1987 MAR DISC

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
 DILANTIN
 >D> PARKE DAVIS 30MG
 >A> + 30MG
 30MG

N84349 001 JUN CRLD
 N84349 001 JUN CRLD
 N84349 001 FEB CRLD

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

>A> AB BARR 100MG N40435 001 JUN 20, 2003 JUN NEWA

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

SALAGEN

MGI PHARMA INC

5MG

N20237 001 MAR 22, 1994 APR CRLD

+

7.5MG

N20237 002 APR 18, 2003 APR NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

>D> PIPRACIL N50545 002 JUN DISC
 >D> + WYETH PHARMS INC EQ 2GM BASE/VIAL N50545 002 JUN DISC
 >A> @ EQ 2GM BASE/VIAL N50545 002 JUN DISC
 + EQ 2GM BASE/VIAL N50545 002 MAR CAHN
 >D> EQ 2GM BASE/VIAL N62750 001 OCT 13, 1987 JUN DISC
 >A> @ EQ 2GM BASE/VIAL N62750 001 OCT 13, 1987 JUN DISC
 EQ 2GM BASE/VIAL N62750 001 OCT 13, 1987 MAR CAHN
 >D> + EQ 3GM BASE/VIAL N50545 003 JUN DISC
 >A> @ EQ 3GM BASE/VIAL N50545 003 JUN DISC
 + EQ 3GM BASE/VIAL N50545 003 MAR CAHN
 >D> EQ 3GM BASE/VIAL N62750 002 OCT 13, 1987 JUN DISC
 >A> @ EQ 3GM BASE/VIAL N62750 002 OCT 13, 1987 JUN DISC
 EQ 3GM BASE/VIAL N62750 002 OCT 13, 1987 MAR CAHN
 >D> + EQ 4GM BASE/VIAL N50545 004 JUN DISC
 >A> @ EQ 4GM BASE/VIAL N50545 004 JUN DISC
 + EQ 4GM BASE/VIAL N50545 004 MAR CAHN
 >D> EQ 4GM BASE/VIAL N62750 003 OCT 13, 1987 JUN DISC
 >A> @ EQ 4GM BASE/VIAL N62750 003 OCT 13, 1987 JUN DISC
 EQ 4GM BASE/VIAL N62750 003 OCT 13, 1987 MAR CAHN
 @ EQ 40GM BASE/VIAL N50545 006 SEP 30, 1985 MAR CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

ZOSYN

+ WYETH PHARMS INC EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL N50684 001 OCT 22, 1993 MAR CAHN
 + EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL N50684 002 OCT 22, 1993 MAR CAHN
 + EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL N50684 003 OCT 22, 1993 MAR CAHN
 + EQ 36GM BASE/VIAL;EQ 4.5GM
 BASE/VIAL N50684 004 OCT 22, 1993 MAR CAHN

ZOSYN IN PLASTIC CONTAINER

+ WYETH PHARMS INC EQ 40MG BASE/ML;EQ 5MG BASE/ML N50750 001 FEB 24, 1998 MAR CAHN
 + EQ 60MG BASE/ML;EQ 7.5MG BASE/ML N50750 002 FEB 24, 1998 MAR CAHN
 + EQ 4GM BASE/100ML;EQ 500MG
 BASE/100ML N50750 003 FEB 24, 1998 MAR CAHN

	<u>PIRBUTEROL ACETATE</u>						
	AEROSOL, METERED; INHALATION						
	MAXAIR						
	@ 3M	EQ 0.2MG BASE/INH	N19009 001	DEC 30, 1986	MAY	DISC	
	<u>POTASSIUM CHLORIDE</u>						
	TABLET, EXTENDED RELEASE; ORAL						
>A>	KLOR-CON M15						
>A>	UPSHER SMITH	15MEQ	N74726 003	JUN 06, 2003	JUN	NEWA	
	<u>PRALIDOXIME CHLORIDE</u>						
	INJECTABLE; INJECTION						
	PRALIDOXIME CHLORIDE						
	@ BAXTER HLTHCARE CORP	300MG/ML	N18799 001	DEC 13, 1982	MAR	CAHN	
	<u>PREDNICARBATE</u>						
	CREAM; TOPICAL						
	DERMATOP E EMOLLIENT						
	+ DERMIK LABS	0.1%	N20279 001	OCT 29, 1993	APR	CTNA	
	<u>PREDNISOLONE</u>						
	SYRUP; ORAL						
	PREDNISOLONE						
AA	AXIOM PHARM	15MG/5ML	N40287 001	MAY 28, 1999	MAY	CAHN	
AA	HI TECH PHARMA	15MG/5ML	N40401 001	FEB 27, 2003	FEB	NEWA	
AA	PHARM ASSOC	15MG/5ML	N40399 001	MAR 05, 2003	MAR	NEWA	
	PRELONE						
AA +	TEVA	15MG/5ML	N89081 001	FEB 04, 1986	MAY	CAHN	
	<u>PREDNISOLONE ACETATE</u>						
	SUSPENSION/DROPS; OPHTHALMIC						
>D>	ECONOPRED						
>D>	+ ALCON	0.125%	N17468 001		JUN	DISC	
>A>	@	0.125%	N17468 001		JUN	DISC	
	<u>PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM</u>						
	OINTMENT; OPHTHALMIC						
>D>	CETAPRED						
>D>	+ ALCON	0.25%;10%	N87771 001	AUG 06, 1993	JUN	DISC	
>A>	@	0.25%;10%	N87771 001	AUG 06, 1993	JUN	DISC	
	<u>PREDNISOLONE SODIUM PHOSPHATE</u>						
	SOLUTION; ORAL						
	PREDNISOLONE SODIUM PHOSPHATE						
AA	HI TECH PHARMA	EQ 5MG BASE/5ML	N75183 001	MAR 26, 2003	MAR	NEWA	
	<u>PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM</u>						
	SOLUTION/DROPS; OPHTHALMIC						
	SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE						
AT	ALCON	EQ 0.23% PHOSPHATE;10%	N73630 001	MAY 27, 1993	APR	CAHN	

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	VINTAGE PHARMS	20MG	N40392 001	FEB 12, 2003	FEB	NEWA
----	----------------	------	------------	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

>D>	AP	ELKINS SINN	100MG/ML	N89029 001	APR 17, 1986	JUN	DISC
>A>		@	100MG/ML	N89029 001	APR 17, 1986	JUN	DISC
>D>	AP		500MG/ML	N89030 001	APR 17, 1986	JUN	DISC
>A>		@	500MG/ML	N89030 001	APR 17, 1986	JUN	DISC

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N40505 001	MAY 30, 2003	MAY	NEWA
----	---------------------	----------------	------------	--------------	-----	------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

>D>	AP +	WYETH AYERST	25MG/ML	N08857 002		JUN	DISC
>A>		@	25MG/ML	N08857 002		JUN	DISC
		@	50MG/ML	N08857 003		APR	DISC

PROMETHAZINE HCL

>A>	AP	BAXTER HLTHCARE	25MG/ML	N83312 001		JUN	CAHN
>A>	AP		50MG/ML	N83312 002		JUN	CAHN
>D>	AP	ELKINS SINN	25MG/ML	N83312 001		JUN	CAHN
>D>	AP		50MG/ML	N83312 002		JUN	CAHN
	AP +	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	APR	CRLD
	AP +		50MG/ML	N40454 002	AUG 22, 2002	APR	CRLD
	AP	PHARMAFORCE	25MG/ML	N40515 001	MAR 19, 2003	MAR	NEWA

SUPPOSITORY; RECTAL

PHENERGAN

AB +	WYETH AYERST	50MG	N11689 001		FEB	CTEC
AB	WYETH PHARMS INC	12.5MG	N10926 002		MAR	CAHN
AB +		25MG	N10926 001		MAR	CAHN
AB +		50MG	N11689 001		MAR	CAHN

PROMETHAZINE HCL

AB	ABLE	12.5MG	N40504 001	APR 11, 2003	APR	NEWA	
AB		25MG	N40504 002	APR 11, 2003	APR	NEWA	
AB		50MG	N40449 001	FEB 27, 2003	FEB	NEWA	
>A>	AB	CLAY PARK	12.5MG	N40500 001	JUN 30, 2003	JUN	NEWA
>A>	AB		25MG	N40500 002	JUN 30, 2003	JUN	NEWA
	AB	G AND W LABS	12.5MG	N40428 002	MAR 31, 2003	MAR	NEWA
>A>	AB	PADDOCK	12.5MG	N40479 001	JUN 24, 2003	JUN	NEWA
>A>	AB		25MG	N40479 002	JUN 24, 2003	JUN	NEWA

SYRUP; ORAL

PHENERGAN PLAIN

>D>	AA +	WYETH AYERST	6.25MG/5ML	N08381 004	APR 18, 1984	JUN	DISC
>A>		@	6.25MG/5ML	N08381 004	APR 18, 1984	JUN	DISC

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH PLAIN

>D>	AA	ALPHARMA	6.25MG/5ML	N85953 001				
>A>	AA	+	6.25MG/5ML	N85953 001			JUN	CRLD
							JUN	CRLD
		TABLET; ORAL						
		PHENERGAN						
		WYETH PHARMS INC	12.5MG	N07935 002			MAR	CAHN
	BP		25MG	N07935 003			MAR	CAHN
	BP	+	50MG	N07935 004			MAR	CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

		@ BAXTER HLTHCARE CORP	20MG/ML	N12382 002			MAY	CAHN
--	--	------------------------	---------	------------	--	--	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

		WYETH PHARMS INC	60MG	N18553 004	MAR 18, 1987	MAR	CAHN	
	BX		80MG	N18553 002	APR 19, 1983	MAR	CTEC	
	BX		120MG	N18553 003	APR 19, 1983	MAR	CTEC	
		+	160MG	N18553 001	APR 19, 1983	MAR	CAHN	
		INNOPRAN XL						
	BX	RELIANT PHARMS	80MG	N21438 001	MAR 12, 2003	MAR	NEWA	
	BX		120MG	N21438 002	MAR 12, 2003	MAR	NEWA	
		INJECTABLE; INJECTION						
		INDERAL						
	AP	+ BAXTER HLTHCARE CORP	1MG/ML	N16419 001			MAY	CAHN
		PROPRANOLOL HCL						
	AP	SABEX 2002	1MG/ML	N76400 001	FEB 26, 2003	FEB	NEWA	
		TABLET; ORAL						
		INDERAL						
	AB	+ WYETH PHARMS INC	10MG	N16418 001			MAR	CAHN
	AB		20MG	N16418 003			MAR	CAHN
	AB		40MG	N16418 002			MAR	CAHN
	AB		60MG	N16418 009	OCT 18, 1982	MAR	CAHN	
	AB	+	80MG	N16418 004			MAR	CAHN
		@	90MG	N16418 010	OCT 18, 1982	MAR	CAHN	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

>D>	AP	ELKINS SINN	10MG/ML	N89474 001	NOV 05, 1986	JUN	DISC
>A>		@	10MG/ML	N89474 001	NOV 05, 1986	JUN	DISC
>D>	AP		10MG/ML	N89475 001	NOV 05, 1986	JUN	DISC
>A>		@	10MG/ML	N89475 001	NOV 05, 1986	JUN	DISC

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

REGONOL

>D>	@ ORGANON	5MG/ML		N17398 001		JUN	CAHN
	@	5MG/ML		N17398 001		MAY	DISC
>A>	@ SABEX 2002	5MG/ML		N17398 001		JUN	CAHN

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

AB	IMPAX LABS	60MG		N40502 001	APR 24, 2003	APR	NEWA
	@ US ARMY	30MG		N20414 001	FEB 05, 2003	FEB	NEWA

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

+	ASTRAZENECA	EQ 25MG BASE		N20639 001	SEP 26, 1997	MAR	CRLD
---	-------------	--------------	--	------------	--------------	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

AB	PFIZER PHARMS	EQ 5MG BASE		N19885 001	NOV 19, 1991	MAY	CFTG
AB		EQ 10MG BASE		N19885 002	NOV 19, 1991	MAY	CFTG
AB		EQ 20MG BASE		N19885 003	NOV 19, 1991	MAY	CFTG
AB +		EQ 40MG BASE		N19885 004	NOV 19, 1991	MAY	CFTG

QUINAPRIL HCL

AB	TEVA	EQ 5MG BASE		N75504 001	MAY 30, 2003	MAY	NEWA
AB		EQ 10MG BASE		N75504 002	MAY 30, 2003	MAY	NEWA
AB		EQ 20MG BASE		N75504 003	MAY 30, 2003	MAY	NEWA
AB		EQ 40MG BASE		N75504 004	NOV 20, 1998	MAY	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINAGLUTE

@ BERLEX LABS 324MG

N16647 001 MAR DISC

QUINIDINE GLUCONATE

BX +	MUTUAL PHARM	324MG		N89338 001	FEB 11, 1987	APR	CRLD
+		324MG		N89338 001	FEB 11, 1987	MAY	CTEC
+	WATSON LABS	324MG		N87810 001	SEP 29, 1982	MAR	CRLD
BX		324MG		N87810 001	SEP 29, 1982	APR	CRLD
	@	324MG		N87810 001	SEP 29, 1982	MAY	DISC

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDEX

>D>	AB +	WYETH PHARMS INC	300MG	N12796 002		JUN	DISC
>A>	@		300MG	N12796 002		JUN	DISC
	AB +		300MG	N12796 002		MAR	CAHN

QUINIDINE SULFATE

>D>	AB	COPLBY PHARM	300MG	N40045 001	JUN 30, 1994	JUN	CTEC
>A>	+		300MG	N40045 001	JUN 30, 1994	JUN	CTEC

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

a AVENTIS PHARMS

0.1MG;2MG

N12972 001

MAY DISC

METATENSIN #4

a AVENTIS PHARMS

0.1MG;4MG

N12972 002

MAY DISC

RILUZOLE

TABLET; ORAL

RILUTEK

AB + AVENTIS

50MG

N20599 001 DEC 12, 1995 JAN CFTG

RILUZOLE

AB IMPAX LABS

50MG

N76173 001 JAN 29, 2003 JAN NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HCL

AB AMIDE PHARM

100MG

N76375 001 JAN 14, 2003 JAN NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

JOHNSON AND JOHNSON

0.5MG

N21444 001 APR 02, 2003 APR NEWA

+

1MG

N21444 002 APR 02, 2003 APR NEWA

2MG

N21444 003 APR 02, 2003 APR NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

SB PHARMCO

EQ 2MG BASE

N21071 002 MAY 25, 1999 APR CAHN

EQ 4MG BASE

N21071 003 MAY 25, 1999 APR CAHN

+

EQ 8MG BASE

N21071 004 MAY 25, 1999 APR CAHN

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+ QOL MEDCL

8,500 IU/ML

N20772 001 APR 09, 1998 MAY CAHN

SECOBARBITAL SODIUM

INJECTABLE; INJECTION

SODIUM SECOBARBITAL

>D>

+ WYETH AYERST

50MG/ML

N83262 001

JUN DISC

>A>

a

50MG/ML

N83262 001

JUN DISC

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

>D>

+ SERONO

EQ 0.5MG BASE/VIAL

N20443 001 SEP 26, 1997 JUN DISC

>A>

a

EQ 0.5MG BASE/VIAL

N20443 001 SEP 26, 1997 JUN DISC

>D>

+

EQ 1MG BASE/VIAL

N20443 002 SEP 26, 1997 JUN DISC

>A>

a

EQ 1MG BASE/VIAL

N20443 002 SEP 26, 1997 JUN DISC

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

+ GENZYME 403MG N20926 001 OCT 30, 1998 APR CAHN

TABLET; ORAL

GENZYME 400MG N21179 001 JUL 12, 2000 APR CAHN

+ 800MG N21179 002 JUL 12, 2000 APR CAHN

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ WYETH PHARMS INC 1MG/ML N21083 001 SEP 15, 1999 MAR CAHN

TABLET; ORAL

WYETH PHARMS INC 1MG N21110 001 AUG 25, 2000 MAR CRLD

+ 2MG N21110 002 AUG 22, 2002 MAR NEWA

SODIUM IODIDE, I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ DRAXIMAGE 1-250mCi N21305 002 JAN 24, 2003 JAN NEWA

+ 1-500mCi N21305 003 JAN 24, 2003 JAN NEWA

SOLUTION; ORAL

SODIUM IODIDE I 131, KIT

+ DRAXIMAGE 1-250mCi/0.25ML N21305 002 JAN 24, 2003 FEB CDFR

+ 1-500mCi/0.5ML N21305 003 JAN 24, 2003 FEB CDFR

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

>D> AP ABBOTT 50MG/VIAL N70566 001 JUN 09, 1986 JUN CRLD

>A> AP + 50MG/VIAL N70566 001 JUN 09, 1986 JUN CRLD

SODIUM NITROPRUSSIDE

>D> AP + ELKINS SINN 50MG/VIAL N18581 001 JUL 28, 1982 JUN DISC

>A> @ 50MG/VIAL N18581 001 JUL 28, 1982 JUN DISC

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

BIO-TROPIN

@ BIO TECH GEN 4.8MG/VIAL N19774 001 MAY 25, 1995 MAR DISC

TEV-TROPIN

BX + BIO TECH GEN 5MG/ML N19774 002 JAN 04, 2002 FEB CTNA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE AF

@ BERLEX LABS 40MG N21151 006 APR 02, 2003 MAY DISC

40MG N21151 006 APR 02, 2003 APR NEWA

@ 60MG N21151 007 APR 02, 2003 MAY DISC

60MG N21151 007 APR 02, 2003 APR NEWA

@ 100MG N21151 005 MAR 14, 2003 MAY DISC

100MG N21151 005 MAR 14, 2003 MAR NEWA

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

>A>	+	GENSIA SICOR PHARMS	1GM/VIAL	N50577 001	MAY 07, 1982	JUN	CAHN
>D>	+	PHARMACIA AND UPJOHN	1GM/VIAL	N50577 001	MAY 07, 1982	JUN	CAHN

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

METASTRON

AP	+	AMERSHAM HLTH	1mCi/ML	N20134 001	JUN 18, 1993	JAN	CFTG
AP		STRONTIUM CHLORIDE SR-89					
AP		BIO NUCLEONICS	1mCi/ML	N75941 001	JAN 06, 2003	JAN	NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SEPTRA

@ MONARCH PHARMS

80MG/ML;16MG/ML

N18452 001 MAY DISC

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

AB		ASTRAZENECA	EQ 10MG BASE	N17970 001		FEB	CTEC
AB	+		EQ 20MG BASE	N17970 002	MAR 21, 1994	FEB	CTEC
		TAMOXIFEN CITRATE					
AB		AEGIS PHARMS	EQ 10MG BASE	N76398 001	MAR 31, 2003	MAR	NEWA
AB			EQ 20MG BASE	N76398 002	MAR 31, 2003	MAR	NEWA
AB		ANDRX PHARMS	EQ 10MG BASE	N76179 001	FEB 20, 2003	FEB	NEWA
AB			EQ 20MG BASE	N76179 002	FEB 20, 2003	FEB	NEWA
AB		BARR	EQ 10MG BASE	N70929 001	FEB 20, 2003	FEB	NEWA
AB			EQ 20MG BASE	N70929 002	FEB 20, 2003	FEB	NEWA
AB		IVAX PHARMS	EQ 10MG BASE	N75740 001	FEB 20, 2003	FEB	NEWA
AB			EQ 20MG BASE	N75740 002	FEB 20, 2003	FEB	NEWA
AB		MYLAN	EQ 10MG BASE	N74732 002	FEB 20, 2003	FEB	NEWA
AB			EQ 20MG BASE	N74732 001	FEB 20, 2003	FEB	NEWA
AB		PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAR 31, 2003	APR	CAHN
AB			EQ 20MG BASE	N74858 001	FEB 20, 2003	FEB	NEWA
AB		ROXANE	EQ 10MG BASE	N76027 001	FEB 20, 2003	FEB	NEWA
AB			EQ 20MG BASE	N76027 002	FEB 20, 2003	FEB	NEWA
AB		TEVA	EQ 10MG BASE	N74504 001	APR 28, 2003	APR	NEWA
AB			EQ 10MG BASE	N74539 001	MAR 31, 2003	MAR	NEWA
AB			EQ 10MG BASE	N75797 001	FEB 20, 2003	FEB	NEWA
AB			EQ 20MG BASE	N74504 002	APR 28, 2003	APR	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN MDP KIT

AP	+	DRAXIMAGE	N/A	N18035 001		MAR	CRLD
----	---	-----------	-----	------------	--	-----	------

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

@ CIS

N/A

N17684 001 MAY DISC

TESTOSTERONE

	GEL; TOPICAL					
	ANDROGEL					
BX +	UNIMED PHARMS	1%	N21015 001	FEB 28, 2000	APR	CTEC
	TESTIM					
BX +	AUXILIUM A2	1%	N21454 001	OCT 31, 2002	APR	CTEC
	TABLET, EXTENDED RELEASE; BUCCAL					
>A>	STRIANT					
>A>	+ COLUMBIA LABS	30MG	N21543 001	JUN 19, 2003	JUN	NEWA

TETRACYCLINE HYDROCHLORIDE

	CAPSULE; ORAL					
>D>	ACHROMYCIN V					
>A>	@ CLONMEL HLTHCARE	250MG	N50278 003		JUN	DISC
>A>	@	500MG	N50278 001		JUN	DISC
>D>	AB LEDERLE	250MG	N50278 003		JUN	DISC
>D>	AB +	500MG	N50278 001		JUN	DISC
	SUMYCIN					
>D>	AB APOTHECON	500MG	N60429 003		JUN	CRLD
>A>	AB +	500MG	N60429 003		JUN	CRLD
	TETRACYCLINE HCL					
AB	AXIOM PHARM	250MG	N60736 001		MAY	CAHN
AB		500MG	N60736 002		MAY	CAHN
>D>	FIBER, EXTENDED RELEASE; PERIODONTAL					
>D>	ACTISITE					
>D>	+ ALZA	12.7MG/FIBER	N50653 001	MAR 25, 1994	JUN	DISC
>A>	@	12.7MG/FIBER	N50653 001	MAR 25, 1994	JUN	DISC

THALIDOMIDE

	CAPSULE; ORAL					
	THALOMID					
	CELGENE	100MG	N20785 002	JAN 17, 2003	JAN	NEWA
	+	200MG	N20785 003	JAN 17, 2003	JAN	NEWA

THIAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION					
	THIAMINE HCL					
>D>	AP WYETH AYERST	100MG/ML	N80553 001		JUN	DISC
>A>	@	100MG/ML	N80553 001		JUN	DISC

THIETHYLPERAZINE MALEATE

>D>	SUPPOSITORY; RECTAL					
>D>	TORECAN					
>D>	+ NOVARTIS	10MG	N13247 001		JUN	DISC
>A>	@	10MG	N13247 001		JUN	DISC

THIOTHIXENE

	CAPSULE; ORAL					
	NAVANE					
AB	PFIZER	1MG	N16584 001		FEB	CAHN
AB		2MG	N16584 002		FEB	CAHN
AB +		5MG	N16584 003		FEB	CAHN

AB		10MG	N16584 004	FEB	CAHN
		20MG	N16584 005	FEB	CAHN
<u>THIOTHIXENE HYDROCHLORIDE</u>					
CONCENTRATE; ORAL					
AA	+	PFIZER	EQ 5MG BASE/ML	N16758 001	FEB CAHN
INJECTABLE; INJECTION					
		@ PFIZER	EQ 2MG BASE/ML	N16904 001	FEB CAHN
		+	EQ 10MG BASE/VIAL	N16904 002	FEB CAHN
<u>TIZANIDINE HYDROCHLORIDE</u>					
TABLET; ORAL					
TIZANIDINE HCL					
AB		BARR	EQ 2MG BASE	N76371 001	APR 09, 2003 APR NEWA
AB			EQ 4MG BASE	N76371 002	APR 09, 2003 APR NEWA
AB		MYLAN	EQ 2MG BASE	N76354 001	MAR 28, 2003 MAR NEWA
AB			EQ 4MG BASE	N76354 002	MAR 28, 2003 MAR NEWA
<u>TOLBUTAMIDE SODIUM</u>					
>D> INJECTABLE; INJECTION					
>D> ORINASE DIAGNOSTIC					
>D>		+	PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N12095 001 JUN DISC
>A>		@		EQ 1GM BASE/VIAL	N12095 001 JUN DISC
<u>TORSEMIDE</u>					
TABLET; ORAL					
TORSEMIDE					
AB		PAR PHARM	5MG	N76226 001	MAY 27, 2003 MAY NEWA
AB			10MG	N76226 002	MAY 27, 2003 MAY NEWA
AB			20MG	N76226 003	MAY 27, 2003 MAY NEWA
AB			100MG	N76226 004	MAY 27, 2003 MAY NEWA
AB		PLIVA PHARM IND	5MG	N76346 001	MAY 30, 2003 MAY NEWA
AB			10MG	N76346 002	MAY 30, 2003 MAY NEWA
AB			20MG	N76346 003	MAY 30, 2003 MAY NEWA
<u>TRAMADOL HYDROCHLORIDE</u>					
TABLET; ORAL					
TRAMADOL HCL					
AB		IVAX PHARMS	50MG	N75963 001	JUL 03, 2002 MAR CAHN
<u>TRIAMCINOLONE ACETONIDE</u>					
LOTION; TOPICAL					
TRIAMCINOLONE ACETONIDE					
AT		ALTANA	0.025%	N40467 001	APR 21, 2003 APR NEWA
AT			0.1%	N40467 002	APR 21, 2003 APR NEWA
<u>TRICHLORMETHIAZIDE</u>					
TABLET; ORAL					
METAHYDRIN					
		@ AVENTIS PHARMS	2MG	N12594 001	JUN 16, 1988 MAY DISC
		@	4MG	N12594 002	JUN 16, 1988 MAY DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

>D>		ARTANE		N06773 009		JUN	DISC
>D>	AA +	LEDERLE	2MG/5ML	N06773 009		JUN	DISC
>A>		@	2MG/5ML				
		TRIHEXYPHENIDYL HCL					
>D>	AA	PHARM VENTURES	2MG/5ML	N89514 001	APR 07, 1989	JUN	CRLD
>A>	AA +		2MG/5ML	N89514 001	APR 07, 1989	JUN	CRLD
		TABLET; ORAL					
>D>		ARTANE		N06773 005		JUN	DISC
>D>	AA +	LEDERLE	2MG	N06773 005		JUN	DISC
>A>		@	2MG	N06773 003		JUN	DISC
>D>	AA +		5MG	N06773 003		JUN	DISC
>A>		@	5MG				
		TRIHEXYPHENIDYL HCL					
>D>	AA	WATSON LABS	2MG	N84363 001		JUN	CRLD
>A>	AA +		2MG	N84363 001		JUN	CRLD
>D>	AA		5MG	N84364 001		JUN	CRLD
>A>	AA +		5MG	N84364 001		JUN	CRLD

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

@ MONARCH PHARMS

200MG

N17943 003 JUL 14, 1982 MAY DISC

TRIMETHOPRIM

+ TEVA

200MG

N71259 001 JUN 18, 1987 MAY CRLD

UREA, C-13

FOR SOLUTION; ORAL

HELICOSOL

@ METABOLIC SOLUTIONS

125MG/VIAL

N21092 001 DEC 17, 1999 MAY DISC

PYLORI-CHEK BREATH TEST

@ DEVICES

100MG/VIAL

N20900 001 FEB 04, 1999 MAR CAHN

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

>A> AP AM PHARM

EQ 100MG BASE/ML

N76539 001 JUN 26, 2003 JUN NEWA

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

>D> AA LILLY

EQ 250MG BASE/5ML

N61667 002 JUL 13, 1983 JUN CTEC

>A> +

EQ 250MG BASE/5ML

N61667 002 JUL 13, 1983 JUN CTEC

>D> VANCOLED

>D> AA LEDERLE

EQ 250MG BASE/5ML

N63321 002 OCT 15, 1993 JUN DISC

>A> @

EQ 250MG BASE/5ML

N63321 002 OCT 15, 1993 JUN DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

@ ORGANON

10MG/VIAL

N18776 002 APR 30, 1984 MAY DISC

<u>VECURONIUM BROMIDE</u>							
INJECTABLE; INJECTION							
VECURONIUM BROMIDE							
AP	+	BEDFORD	10MG/VIAL	N75549 001	JUN 13, 2000	MAY	CRLD
<u>VENLAFAXINE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
EFFEXOR XR							
		WYETH PHARMS INC	EQ 37.5MG BASE	N20699 001	OCT 20, 1997	MAR	CAHN
			EQ 75MG BASE	N20699 002	OCT 20, 1997	MAR	CRLD
	@		EQ 100MG BASE	N20699 003	OCT 20, 1997	MAR	CAHN
	+		EQ 150MG BASE	N20699 004	OCT 20, 1997	MAR	CRLD
TABLET; ORAL							
EFFEXOR							
	@	WYETH PHARMS INC	EQ 12.5MG BASE	N20151 001	DEC 28, 1993	MAR	CAHN
			EQ 25MG BASE	N20151 002	DEC 28, 1993	MAR	CRLD
			EQ 37.5MG BASE	N20151 006	DEC 28, 1993	MAR	CAHN
			EQ 50MG BASE	N20151 003	DEC 28, 1993	MAR	CAHN
			EQ 75MG BASE	N20151 004	DEC 28, 1993	MAR	CAHN
	+		EQ 100MG BASE	N20151 005	DEC 28, 1993	MAR	CAHN
<u>VIDARABINE</u>							
OINTMENT; OPHTHALMIC							
VIRA-A							
	@	PARKEDALE	3%	N50486 001		MAY	DISC
<u>VINORELBINE TARTRATE</u>							
INJECTABLE; INJECTION							
NAVELBINE							
AP	+	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N20388 001	DEC 23, 1994	FEB	CFTG
>A>	AP	ESI LEDERLE	EQ 10MG BASE/ML	N75992 001	JUN 10, 2003	JUN	NEWA
	AP	GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N76028 001	FEB 03, 2003	FEB	NEWA
<u>ZALEPLON</u>							
CAPSULE; ORAL							
SONATA							
>A>		JONES PHARMA	5MG	N20859 001	AUG 13, 1999	JUN	CAHN
>A>	+		10MG	N20859 002	AUG 13, 1999	JUN	CAHN
>D>		WYETH AYERST	5MG	N20859 001	AUG 13, 1999	JUN	CAHN
>D>	+		10MG	N20859 002	AUG 13, 1999	JUN	CAHN
<u>ZOLEDRONIC ACID</u>							
INJECTABLE; IV (INFUSION)							
ZOMETA							
	+	NOVARTIS	EQ 4MG BASE/5ML	N21223 002	MAR 07, 2003	MAR	NEWA

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

>D>	TYLENOL							
>D>	+ MCNEIL CONS SPECT	650MG		N19872 001	JUN 08, 1994	JUN	CTNA	
>A>	TYLENOL (CAPLET)							
>A>	+ MCNEIL CONS SPECT	650MG		N19872 001	JUN 08, 1994	JUN	CTNA	
>A>	TYLENOL (GELTAB)							
>A>	+ MCNEIL CONS SPECT	650MG		N19872 002	JAN 11, 2001	JUN	NEWA	

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMICON

	NOVARTIS	80MG;20MG		N72687 001	JUN 28, 1989	MAR	CAHN	
--	----------	-----------	--	------------	--------------	-----	------	--

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE

	@ CENT PHARMS	8MG;120MG		N19428 001	AUG 02, 1988	MAR	DISC	
--	---------------	-----------	--	------------	--------------	-----	------	--

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	@ LEK PHARMS	100MG		N75122 001	JUN 19, 1998	MAR	CAHN	
		200MG		N75122 002	JUN 19, 1998	MAR	CAHN	

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

	@ STERLING	0.25MG/INH		N16803 001		MAY	DISC	
--	------------	------------	--	------------	--	-----	------	--

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX

	ADAMS LABS	600MG		N21282 001	JUL 12, 2002	JAN	CRLD	
	+	1.2GM		N21282 002	DEC 18, 2002	JAN	NEWA	

IBUPROFEN

TABLET; ORAL

JUNIOR STRENGTH MOTRIN

>D>	+ MCNEIL	100MG		N20602 001	JUN 10, 1996	JUN	CRLD	
>A>		100MG		N20602 001	JUN 10, 1996	JUN	CRLD	

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HCL

>A>	LNK	2MG		N76497 001	JUN 10, 2003	JUN	NEWA	
-----	-----	-----	--	------------	--------------	-----	------	--

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM ADVANCED

	+ MCNEIL CONS SPECT	2MG;125MG		N21140 001	NOV 30, 2000	JAN	CRLD	
--	---------------------	-----------	--	------------	--------------	-----	------	--

<u>LORATADINE</u>							
	SYRUP; ORAL						
	CLARITIN						
	+ SCHERING	1MG/ML		N20641 002	NOV 27, 2002	APR	CRLD
		1MG/ML		N20641 002	NOV 27, 2002	MAR	NEWA
	TABLET; ORAL						
	+ SCHERING	10MG		N19658 002	NOV 27, 2002	APR	CRLD
		10MG		N19658 002	NOV 27, 2002	MAR	NEWA
	LORATADINE						
	GENEVA PHARMS	10MG		N75209 001	JAN 21, 2003	JAN	NEWA
	TABLET, ORALLY DISINTEGRATING; ORAL						
	ALAVERT						
	WYETH CONS	10MG		N21375 001	DEC 19, 2002	APR	CRLD
	CLARITIN REDITABS						
	+ SCHERING	10MG		N20704 002	NOV 27, 2002	APR	CRLD
		10MG		N20704 002	NOV 27, 2002	MAR	NEWA
	LORATADINE						
	WYETH CONS	10MG		N75822 001	FEB 10, 2003	FEB	NEWA
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>							
	TABLET, EXTENDED RELEASE; ORAL						
	CLARITIN-D						
	+ SCHERING	5MG;120MG		N19670 002	NOV 27, 2002	APR	CRLD
		5MG;120MG		N19670 002	NOV 27, 2002	MAR	NEWA
	CLARITIN-D 24 HOUR						
	+ SCHERING	10MG;240MG		N20470 002	NOV 27, 2002	APR	CRLD
		10MG;240MG		N20470 002	NOV 27, 2002	MAR	NEWA
	LORATADINE AND PSEUDOEPHEDRINE HCL						
	ANDRX PHARMS	10MG;240MG		N75706 001	FEB 21, 2003	FEB	NEWA
	LORATADINE AND PSEUDOEPHEDRINE SULFATE						
	IMPAX LABS	5MG;120MG		N76050 001	JAN 30, 2003	JAN	NEWA
<u>MICONAZOLE NITRATE</u>							
	CREAM; TOPICAL, VAGINAL						
	MONISTAT 3 COMBINATION PACK						
>A>	+ PERSONAL PRODS	2%,4%		N21261 003	JUN 17, 2003	JUN	NEWA
>D>	MONISTAT 3 COMBINATION PACK						
>D>	+ PERSONAL PRODS	2%,4%		N21261 001	FEB 02, 2001	JUN	CTNA
>A>	MONISTAT 3 COMBINATION PACK (PREFILLED)						
>A>	+ PERSONAL PRODS	2%,4%		N21261 001	FEB 02, 2001	JUN	CTNA
<u>MINOXIDIL</u>							
	SOLUTION; TOPICAL						
	MINOXIDIL EXTRA STRENGTH (FOR MEN)						
	MORTON GROVE	5%		N75438 001	FEB 27, 2003	FEB	NEWA
>A>	<u>OMEPRAZOLE MAGNESIUM</u>						
>A>	TABLET, DELAYED RELEASE; ORAL						
>A>	PRILOSEC						
>A>	+ ASTRAZENECA	EQ 20MG BASE		N21229 001	JUN 20, 2003	JUN	NEWA

PERMETHRIN

LOTION; TOPICAL

NIX

+ INSIGHT PHARMS

1%

N19918 001 MAY 02, 1990 MAR CAHN



**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE '03

NO JUNE 2003 APPROVALS

THE UNIVERSITY OF CHICAGO

PHYSICS DEPARTMENT

[The remainder of the page contains extremely faint, illegible text, likely bleed-through from the reverse side of the paper.]

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

Orphan Products Designations and Approvals List
June 2003

Generic Name/ Trade Name (if present):	Date Designated = DD Date Approved= MA	Indication Designated:	Sponsor and Address
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003 MA:	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	BioMedicines, Inc. 2000 Powell Street Suite 1640 Emeryville CA 94608
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003 MA:	Treatment of mitochondrial disease	Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham MA 02453
4,5-dibromorhodamine 123 Theralux Irradiation Device	DD: 4/10/2003 MA:	Treatment of chronic myelogenous leukemia	Celmed BioSciences Inc. 2310 boul Alfred-Nobel 2310 boul Alfred-Nobel Saint-Laurent, Quebec Canada H4S 2A4
a-(3-aminophthalimido) Actimid	DD: 1/15/2003 MA: MA:	Treatment of multiple myeloma	Celgene Corporation 7 Powder Horn Drive Warren NJ 07059
a-Galactosidase A Corporation Plant-Produced Human a-Glactosidase	DD: 1/21/2003 MA:	Treatment of Fabry's disease	Large Scale Biology 3333 Vacaville Parkway Suite 1000 Vacaville CA 95688
alendronate Fosamax	DD: 3/31/2003 MA:	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
alteplase University Activase University Jefferson 1-109	DD: 1/27/2003 MA:	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Daniel F. Hanley, MD Johns Hopkins Johns Hopkins 600 N. Wolfe St., Baltimore MD 21287

Orphan Products Designations and Approvals List

June 2003

AMG 531			DD: 3/27/2003
thrombocytopenic			Treatment of immune
		purpura.	Amgen, Inc.
Drive			One Amgen Center
91320-1799	MA:		Thousand Oaks CA
anti-CD23 IgG1, kappa monoclonal	DD: 2/12/2003	Treatment of chronic lymphocytic	IDEC Pharmaceuticals,
Inc.		leukemia	
antibody	MA:		3030 Callan Road
			San Diego CA 92121
Anti-CEA Sheep-human chimeric	DD: 5/21/2003	Treatment of pancreatic cancer	KS Biomedix Ltd
monoclonal antibody labeled			Ground Floor, 1 Occam
Court	MA:		
w/iodine-131 (KAb201)			Surrey Research Park
7HJ UK			Guilford, Surrey, GU2
antisense 20-mer	DD: 3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc
phosphorothioate oligonucleotide			2 Meridan Road
[complementary to the coding			
region of R2 component of the			
human ribonucleotide reductase			
mRNA]			
GTI-2040	MA:		Toronto, Ontario
	MA:		M9W427 CANADA
arsenic trioxide	DD: 5/13/2003	Treatment of chronic lymphocytic	Cell Therapeutics, Inc.
Trisenox		leukemia	501 Elliott avenue West
	MA:		501 Elliott avenue West
			Suite 400
			Seattle WA 98119
arsenic trioxide	DD: 6/13/2003	Treatment of liver cancer	Cell Therapeutics, Inc.
Trisenox			501 Elliott Avenue West
	MA:		Suite 400
			Seattle WA 98119
bifidobacterium longum infantis	DD: 1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health
Limited			
35624	MA:		Guardwell, Kinsale
			County Cork, Ireland

Orphan Products Designations and Approvals List

June 2003

bortezomib Pharmaceuticals, Inc. VELCADE	DD: 1/15/2003 MA:	To treat multiple myeloma	Millennium 75 Sidney Street Cambridge MA 02139
Capsaicin Park 4117	DD: 5/2/2003 MA:	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc. San Carlos Business 981F Industrial Road San Carols CA 94070-
cinacalcet Drive 91320-1799	DD: 5/12/2003 MA:	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc. One Amgen Center Thousand Oaks CA
Defibrotide (CO)	DD: 5/21/2003 MA:	For the treatment of hepatic veno-occlusive disease	Gentium SpA Piazza XX Settembre, 2 22079 Villa Guardia ITALY
dextran 1 3B5	DD: 3/21/2003 MA:	Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600 Toronto, Ontario M4P
DHA-paclitaxel Boulevard Taxoprexin Boulevard 19406	DD: 5/1/2003 MA:	Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance 2200 Renaissance Suite 450 King of Prussia PA
diferuloylmethane LLC	DD: 6/13/2003 MA:	Treatment of cystic fibrosis	Seer Pharmaceuticals, P. O. Box 138 Southport CT 06890
diphenylcyclophenone	DD: 6/13/2003 MA: MA:	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr. 1900 Patterson Street Suite 104

Orphan Products Designations and Approvals List

June 2003

			Nashville TN 37203
Factor XIII [A2] homodimer, recombinant DNA origin East	DD: 5/21/2003	Treatment of congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue
	MA:		Seattle WA 98102
ferric hexacyanoferrate (II) "Prussian Blue"	DD: 6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG Weissfrauenstr.9 D-60287 Frankfurt GERMANY
	MA:		
Human Anti-tumor Necrosis factor alpha monoclonal antibody Parkway	DD: 1/16/2003	Treatment of uveitis of the posterior segment of non-infectious etiology, and	Centocor, Inc. 200 Great Valley
1307	MA:	uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Malvern PA 19355-
infiximab Remicade Parkway	DD: 5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc. 200 Great Valley
1307	MA:		Malvern PA 19355-
infiximab Remicade Parkway	DD: 5/6/2003	Treatment of giant cell arteritis	Centocor, Inc. 200 Great Valley
1307	MA:		Malvern PA 19355-
INGN 201 Inc. ADVEXIN	DD: 1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, 2250 Holcombe Blvd Houston TX 77030
	MA:		
	MA:		
iron(III)-hexacyanoferrate(II) Pharmzeutische KG	DD: 5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch- Fabrik GMBH & Co, Goerzallee 253 Goerzallee 253 D-14167 Berlin, Federal Germany
Radiogardase-Cs / Antidotum Republic of	MA: MA:		

Orphan Products Designations and Approvals List

June 2003

Mafosfamide (formerly Oncology)	DD: 1/21/2003 MA: MA:	Treatment of neoplastic meningitis	Baxter Oncology GmbH ASTA Medica Daimlerstrasse 40 60314 frankfurt/Main Germany
MaxAdFVIII Corporation 1113	DD: 3/3/2003 MA:	Treatment of Hemophilia A	GenStar Therapeutics 10865 Altman Row Suite 200 San Diego CA 92121-
motexafin gadolinium Xcytrin 4521	DD: 1/27/2003 MA: MA:	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc. 999 East Arques Avenue 999 East Arques Avenue Sunnyvale CA 94085-
myristoylated recombinant SCR1-3 of human complement reseptor Pk, type I APT070 Saffron Walden,	DD: 5/21/2003 MA: MA:	Prevention of delayed graft function in solid organ transplant	Adprotech, Ltd. Chesterford Research Little Chesterford, Essex, CB10 1XK UK
polyinosinic-polycytidilic acid NW Poly-ICLC NW 3450	DD: 3/3/2003 MA: MA:	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Ribopharm, Inc. 3203 Cleveland Ave., 3203 Cleveland Ave., Washington DC 20008-
Protaxel Court	DD: 5/21/2003 MA:	Treatment of ovarian cancer	Biophysica, Inc. 3333 North Torrey Pines Suite 100 La Jolla CA 92037
recombinant adeno-associated Technologies Corp. virus alpha 1-antitrypsin vector rAAV-AAT	DD: 1/27/2003 MA: MA:	Treatment of alpha 1-antitrypsin deficiency	Applied Genetic 12085 Research Drive Suite 110 Alachua FL 32615

Orphan Products Designations and Approvals List

June 2003

recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003 MA:	Treatment of angioedema	Dyax Corp 300 Technology Square Cambridge MA 02139
Recombinant T-cell receptor Square Road	DD: 5/2/2003 MA: MA:	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and glycoprotein residues 35-55 autoreactive to myelin oligodendrocyte	Virogenomics, Inc. 9020 SW Washington Suite 380 Tigard, OR 97223-4332
repertaxin	DD: 1/27/2003 MA:	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila Italy
repository corticotropin or Pharmaceuticals, Inc. adrenocorticotrophic hormone H.P. Acthar Gel 1217	DD: 5/21/2003 MA: MA:	Treatment of infantile spasms	Questcor 3260 Whipple Road Union City CA 94587-
resiniferatoxin	DD: 5/13/2003 MA: DASS/PPCS/NIDCR/NIH	Treatment of intractable pain at end-stage disease	Andrew J. Mannes, Md Bldg 10/Rm 2N236 - 10 Convent Drive Bethesda MD 20892
Ribavirin USP Road REBETOL Road	DD: 4/4/2003 MA:	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation 2000 Galloping Hill 2000 Galloping Hill Kenilworth NJ 07033
Sodium pyruvate	DD: 3/31/2003 MA:	Treatment of cystic fibrosis	Cellular Sciences, Inc. 84 Park Avenue P. O. Box 968 Flemington NJ 08822
suberoylanilide hydroxamic acid Road 6717	DD: 6/12/2003 MA:	Treatment of multiple myeloma	Aton Pharma, Inc. 777 Old Saw Mill River Tarrytown NY 10591-

Orphan Products Designations and Approvals List

June 2003

Tezacitabine	DD: 1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Chiron Corporation 4560 Horton Street Emeryville CA 94608-
2916	MA:		
Tretinoin	DD: 4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc. 34 Commerce Way 34 Commerce Way Woburn MA 01801
ATRA-IV	MA:		



**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2003 ADDITIONS



PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020560 004	ALENDRONATE SODIUM; FOSAMAX	6015801	JUL 17, 2018	U-353 NS		OCT 20, 2003
		4621077	AUG 06, 2007	U-114 D-61		OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		6008207	JUN 06, 2015		PED	APR 20, 2004
		6090410	DEC 02, 2012		PED	APR 20, 2004
		5994329	JUL 17, 2018			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U-114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 16, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019			
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
		4661491	MAY 27, 2006			
		6149940	AUG 22, 2017			
>ADD>	ALFUZOSIN HYDROCHLORIDE; UROXATRAL	5424471	JUL 31, 2012	U-353 NCE		JUN 12, 2008
>ADD>		5954703	OCT 31, 2017	U-289		
021434 001	ALPRAZOLAM; XANAX XR	5424471	JUL 31, 2012	U-353 NDF		JAN 17, 2006
021434 002	ALPRAZOLAM; XANAX XR	5954703	OCT 31, 2017	U-289 NDF		JAN 17, 2006
021434 003	ALPRAZOLAM; XANAX XR			NDF		JAN 17, 2006
021434 004	ALPRAZOLAM; XANAX XR			NDF		JAN 17, 2006
020221 002	AMIFOSTINE; ETHYOL					
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE; LEVULIAN					

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	020364 002 020364 003 020364 004 020364 005	AMLODIPINE BESYLATE; LOTREL AMLODIPINE BESYLATE; LOTREL AMLODIPINE BESYLATE; LOTREL AMLODIPINE BESYLATE; LOTREL	4410520 4410520*PED 4410520 4410520*PED 4410520 4410520*PED 4410520 4410520*PED	AUG 11, 2003 FEB 11, 2004 AUG 11, 2003 FEB 11, 2004 AUG 11, 2003 FEB 11, 2004 AUG 11, 2003 FEB 11, 2004			
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021303 001 021303 006 021303 002 021303 004 021303 003 021303 005 040422 005 040422 006 040422 007 021549 001	AMPHETAMINE ASPARTATE; ADDERALL XR 10 AMPHETAMINE ASPARTATE; ADDERALL XR 15 AMPHETAMINE ASPARTATE; ADDERALL XR 20 AMPHETAMINE ASPARTATE; ADDERALL XR 25 AMPHETAMINE ASPARTATE; ADDERALL XR 30 AMPHETAMINE ASPARTATE; ADDERALL XR 5 AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE APREPIANT; EMEND	5719147 5538982 6048859 6096742 6235735 5719147 5538982 6048859 6096742 6235735 4734416 5006528 4734416 5006528 4734416 5006528 4734416 5006528 4346227 4346227*PED 5030447 5030447*PED 5180589 5180589*PED 5622985 5622985*PED	JUN 29, 2012 JUL 23, 2013 JUN 29, 2012 JUL 01, 2018 JUN 29, 2012 JUN 29, 2012 JUL 23, 2013 JUN 29, 2012 JUN 29, 2012 JUL 01, 2018 JUN 29, 2012 MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2005 APR 20, 2006 JUL 09, 2008 JAN 09, 2009 JUL 09, 2009 JAN 09, 2009 APR 22, 2014 OCT 22, 2014			
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021436 001 021436 002 021436 003 021436 004 021436 005 021436 006 021387 001	ARTIPRAZOLE; ABILIFY ARTIPRAZOLE; ABILIFY ARTIPRAZOLE; ABILIFY ARTIPRAZOLE; ABILIFY ARTIPRAZOLE; ABILIFY ARTIPRAZOLE; ABILIFY ASPIRIN; PRAVIGARD PAC	5719147 5538982 6048859 6096742 6235735 5719147 5538982 6048859 6096742 6235735 4734416 5006528 4734416 5006528 4734416 5006528 4734416 5006528 4346227 4346227*PED 5030447 5030447*PED 5180589 5180589*PED 5622985 5622985*PED	JUN 29, 2012 JUL 23, 2013 JUN 29, 2012 JUL 01, 2018 JUN 29, 2012 JUN 29, 2012 JUL 23, 2013 JUN 29, 2012 JUN 29, 2012 JUL 01, 2018 JUN 29, 2012 MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2005 APR 20, 2006 JUL 09, 2008 JAN 09, 2009 JUL 09, 2009 JAN 09, 2009 APR 22, 2014 OCT 22, 2014			
						NCE	MAR 26, 2008
						PC	SEP 15, 2003
						PC	SEP 15, 2003
						NCE	MAR 26, 2008
						NS	JUN 20, 2005
						PED	DEC 20, 2005
						U-335	
						U-335	

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PEP EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 021411 003	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
>ADD> 021411 004	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5658590**PED	JUL 11, 2015	U-494	PC	MAY 26, 2008
>ADD> 021411 005	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5658590**PED	JAN 11, 2015	U-494	NCE	NOV 26, 2007
>ADD> 021411 006	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5658590**PED	JAN 11, 2015	U-494	PC	MAY 26, 2008
>ADD> 021470 001	AZELAIC ACID; FINACEA	5658590**PED	JUL 11, 2015	U-494	PC	MAY 26, 2008
>ADD> 019851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
>ADD> 019851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520**PED	FEB 11, 2004			
>ADD> 019851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520**PED	AUG 11, 2003			
>ADD> 019851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520**PED	FEB 11, 2004			
>ADD> 020033 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
>ADD> 020033 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520**PED	FEB 11, 2004			
>ADD> 020033 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
>ADD> 020033 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520**PED	FEB 11, 2004			
>ADD> 021055 001	BEKAROTENE; TARGRETIN	5780676	JUL 14, 2015	U-509		
>ADD> 021056 001	BEKAROTENE; TARGRETIN	5780454	OCT 28, 2014	U-510		
>ADD> 021602 001	BORTEZOMIB; VELCADE	6083903	OCT 28, 2014	U-515	NCE	MAY 13, 2008
>ADD> 021262 001	BRIMONIDINE TARTRATE; ALPHAGAN P	6297217	OCT 28, 2014	U-515		
>ADD> 076260 001	BRIMONIDINE TARTRATE; BRIMONIDINE TARTRATE	6562873	JUL 10, 2021			
>ADD> 075766 001	CALCITRIOL; CALCITRIOL	6562873**PED	JAN 10, 2022			
>ADD> 075766 002	CALCITRIOL; CALCITRIOL					
>ADD> 075823 001	CALCITRIOL; CALCITRIOL					
>ADD> 075823 002	CALCITRIOL; CALCITRIOL					
>ADD> 075836 001	CALCITRIOL; CALCITRIOL					
>ADD> 075836 002	CALCITRIOL; CALCITRIOL					
>ADD> 021160 002	CALCIUM ACETATE; PHOSLO	6576665	APR 03, 2021			
>ADD> 021160 003	CALCIUM ACETATE; PHOSLO GELCAPS	6576665	APR 03, 2021			
>ADD> 021485 002	CARBIDOPA; STALEVO 100	5446194	AUG 29, 2012		NCE	OCT 19, 2004
>ADD>		5135950	OCT 31, 2010			
>ADD>		4963590	NOV 27, 2007			
>ADD>		6500867	JUN 29, 2020			
>ADD>		5112861	MAY 12, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021485 003 CARBIDOPA; STALEVO 150	5446194 5135950 4963590 6500867 5112861 5466194 5135950 4963590	AUG 29, 2012 OCT 31, 2010 NOV 27, 2007 JUN 29, 2020 MAY 12, 2009 AUG 29, 2012 OCT 31, 2010 NOV 27, 2007	NCE			OCT 19, 2004
>ADD> >ADD> >ADD> >ADD>	021485 001 CARBIDOPA; STALEVO 50	5466194 5135950 4963590 6500867 5112861 512861 4789724 4757128	AUG 29, 2012 OCT 31, 2010 NOV 27, 2007 JUN 29, 2020 MAY 12, 2009 AUG 01, 2006 AUG 01, 2006	NCE			OCT 19, 2004
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	020637 001 CARMUSTINE; GLIADEL	4525358 4525358*PED 6469009 6489329	JUN 25, 2007 DEC 25, 2007 JUL 13, 2019 APR 08, 2016	I-382			FEB 25, 2006
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	020297 001 CARVEDILOL; COREG 020297 002 CARVEDILOL; COREG 020297 003 CARVEDILOL; COREG 020297 004 CARVEDILOL; COREG 021150 001 CETIRIZINE HYDROCHLORIDE; ZYRTEC-D 12 HOUR	4670444 6504030 4525358 4525358*PED 6469009 6489329	DEC 09, 2003 JUN 10, 2019 JUN 25, 2007 DEC 25, 2007 JUL 13, 2019 APR 08, 2016	I-388 I-388 I-388 I-388 I-388			MAR 27, 2006 MAR 27, 2006 MAR 27, 2006 MAR 27, 2006 MAR 27, 2006
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021159 001 CICLOPIROX; IOPROX 021473 001 CIPROFLOXACTIN; CIPRO XR 020839 001 CLOPIDOGREL BISULFATE; PLAVIX 019758 001 CLOZAPINE; CLOZARIL 019758 002 CLOZAPINE; CLOZARIL 021141 001 COLESEVELAM HYDROCHLORIDE; WELCHOL 021176 001 COLESEVELAM HYDROCHLORIDE; WELCHOL 017821 001 CYCLOBENZAPRINE HYDROCHLORIDE; FLEXERIL 021165 001 DESLORATADINE; CLARINEX	4659716 4863931 4804666 5595997 6100274 4659716*PED 4804666*PED 4863931*PED 5595997*PED 6100274*PED	APR 21, 2004 SEP 15, 2008 FEB 14, 2006 DEC 30, 2014 JUL 07, 2019 OCT 21, 2004 AUG 14, 2006 MAR 15, 2009 JUN 30, 2015 JAN 07, 2020	D-78 NCE NCE NCE NCE NCE NCE NCE NCE NCE			FEB 03, 2006 FEB 21, 2006 JUN 21, 2007 DEC 21, 2006 DEC 21, 2006 DEC 21, 2006 DEC 21, 2006 DEC 21, 2006 DEC 21, 2006 DEC 21, 2006
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021312 001 DESLORATADINE; CLARINEX 021392 001 DILTIAZEM HYDROCHLORIDE; CARDIZEM LA 021392 002 DILTIAZEM HYDROCHLORIDE; CARDIZEM LA	5288505 5529791 5288505 5529791	JUN 26, 2011 JUN 25, 2013 JUN 26, 2011 JUN 25, 2013	NCE NDF NDF NDF			DEC 21, 2006 JUN 21, 2007 FEB 06, 2006 FEB 06, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021392 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM IA	5288505	JUN 26, 2011	NDP	NDP	FEB 06, 2006
021392 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM IA	5529791	JUN 25, 2013	NDP	NDP	FEB 06, 2006
021392 005	DILTIAZEM HYDROCHLORIDE; CARDIZEM IA	5288505	JUN 26, 2011	NDP	NDP	FEB 06, 2006
021392 006	DILTIAZEM HYDROCHLORIDE; CARDIZEM IA	5529791	JUN 25, 2013	NDP	NDP	FEB 06, 2006
020401 006	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013	U-248	NCE	MAR 13, 2008
021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	6511678	DEC 18, 2018	U-248	NCE	MAR 13, 2008
021168 002	DIVALPROEX SODIUM; DEPAKOTE ER	4874794	APR 28, 2014	U-248	NCE	MAR 13, 2008
020941 001	DOCOSANOL; ABBREVA	6555133	APR 06, 2019	U-248	NCE	MAR 13, 2008
020972 001	EPAVIRENZ; SUSTIVA	6555133	APR 06, 2019	U-248	NCE	MAR 13, 2008
020972 002	EPAVIRENZ; SUSTIVA	6555133	APR 06, 2019	U-248	NCE	MAR 13, 2008
020972 003	EPAVIRENZ; SUSTIVA	5663169	SEP 02, 2014	U-248	NCE	MAR 13, 2008
021360 001	EPAVIRENZ; SUSTIVA	6500867	JUN 29, 2020	U-248	NCE	MAR 13, 2008
021481 001	ENFUVRITIDE; FUZEON	5112861	MAY 12, 2009	U-248	NCE	MAR 13, 2008
021437 001	EPLERENONE; INSPRA	5464933	JUN 07, 2013	U-248	NCE	MAR 13, 2008
021437 002	EPLERENONE; INSPRA	6133418	JUN 07, 2013	U-248	NCE	MAR 13, 2008
021437 003	EPLERENONE; INSPRA	6475491	JUN 07, 2013	U-248	NCE	MAR 13, 2008
019386 004	ESMOLOL HYDROCHLORIDE; BREVIBLOC	6534093	DEC 08, 2019	U-3	NCE	MAR 13, 2008
019386 004	ESMOLOL HYDROCHLORIDE; BREVIBLOC	6534093	DEC 08, 2019	U-3	NCE	MAR 13, 2008
019386 006	ESMOLOL HYDROCHLORIDE; BREVIBLOC	6528540	JAN 12, 2021	U-3	NCE	MAR 13, 2008
019386 006	ESMOLOL HYDROCHLORIDE; BREVIBLOC	4593119	JUN 03, 2003	U-3	NCE	MAR 13, 2008
019386 005	ESMOLOL HYDROCHLORIDE; BREVIBLOC DOUBLE STR	6310094	JAN 12, 2021	U-3	NCE	MAR 13, 2008
019386 005	ESMOLOL HYDROCHLORIDE; BREVIBLOC DOUBLE STR	6528540	JAN 12, 2021	U-3	NCE	MAR 13, 2008
021367 001	ESTRADIOL ACETATE; REMRING	4593119	JUN 03, 2003	U-508	NP	MAR 20, 2006
021367 002	ESTRADIOL ACETATE; REMRING	6310094	JAN 12, 2021	U-508	NP	MAR 20, 2006
020527 001	ESTROGENS, CONJUGATED; PREMPRO	6528540	JAN 12, 2021	U-508	NP	MAR 20, 2006
020527 003	ESTROGENS, CONJUGATED; PREMPRO	4593119	JUN 03, 2003	U-508	NP	MAR 20, 2006
020527 004	ESTROGENS, CONJUGATED; PREMPRO	6310094	JAN 12, 2021	U-508	NP	MAR 20, 2006
020527 005	ESTROGENS, CONJUGATED; PREMPRO	5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
021180 001	ETHINYL ESTRADIOL; ORTHO EVRA	RE36247	MAY 02, 2006	U-514	D-79	MAR 12, 2006
021180 001	ETHINYL ESTRADIOL; ORTHO EVRA	5547948	JAN 17, 2015	U-514	D-79	MAR 12, 2006
021180 001	ETHINYL ESTRADIOL; ORTHO EVRA	5210081	FEB 26, 2012	U-514	D-81	MAR 12, 2006
021180 001	ETHINYL ESTRADIOL; ORTHO EVRA	5876746	JUN 07, 2015	U-514	D-81	MAR 12, 2006
021180 001	ETHINYL ESTRADIOL; ORTHO EVRA	5972377	JUN 07, 2015	U-514	D-81	MAR 12, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020747 001	PENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006	U-43	NPP	MAY 20, 2006
020747 002	PENTANYL CITRATE;ACTIQ	5785989	SEP 05, 2006	U-43	PED	NOV 20, 2006
020747 003	PENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006	U-43	PED	NOV 20, 2006
020747 004	PENTANYL CITRATE;ACTIQ	5785989	SEP 05, 2006	U-43	NPP	MAY 20, 2006
020747 005	PENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006	U-43	PED	NOV 20, 2006
020747 006	PENTANYL CITRATE;ACTIQ	5785989	SEP 05, 2006	U-43	NPP	MAY 20, 2006
019813 001	PENTANYL DURAGESIC	4588580	JUL 23, 2004	U-43	PED	NOV 20, 2006
019813 002	PENTANYL DURAGESIC	4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
019813 003	PENTANYL DURAGESIC	4588580	JUL 23, 2004	U-43	PED	NOV 20, 2006
019813 004	PENTANYL DURAGESIC	4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
020625 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
		5578610	NOV 26, 2013	U-192	M-25	MAY 12, 2006
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5932247	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014	U-192		
		5738872*PED	AUG 28, 2015			
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		
		5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015			MAY 12, 2006
		6037353	MAR 14, 2017	U-138	PED	NOV 12, 2006
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014	U-139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		
020872 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632*PED	NOV 11, 2012	U-468		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020872 002	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015		M-25	MAY 12, 2006
		6037353	MAR 14, 2017	U-138	PED	NOV 12, 2006
		6113942	FEB 28, 2015	U-138		
		6187791	MAY 11, 2012	U-468		
		6399632	MAY 11, 2012	U-139		
		5578610*	MAY 26, 2014			
		5855912*	AUG 28, 2015			
		5932247*	AUG 28, 2015			
		6037353*	SEP 14, 2017			
		6113942*	AUG 28, 2015			
		6187791*	NOV 11, 2012			
		6399632*	NOV 11, 2012			
		020872 004	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U-139
5932247	FEB 28, 2015				PED	AUG 25, 2003
5855912	FEB 28, 2015				M-25	MAY 12, 2006
6037353	MAR 14, 2017			U-138	PED	NOV 12, 2006
6113942	FEB 28, 2015			U-138		
6187791	MAY 11, 2012			U-468		
6399632	MAY 11, 2012			U-139		
5578610*	MAY 26, 2014					
5855912*	AUG 28, 2015					
5932247*	AUG 28, 2015					
6037353*	SEP 14, 2017					
6113942*	AUG 28, 2015					
6187791*	NOV 11, 2012					
6399632*	NOV 11, 2012					
020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D			5578610	NOV 26, 2013	U-138
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		6037353	MAR 14, 2017	U-138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015	U-138		
		6187791	MAY 11, 2012	U-468		
		6399632	MAY 11, 2012			
		5578610*	MAY 26, 2014			
		5855912*	AUG 28, 2015			
		6037353*	SEP 14, 2017			
		6113942*	AUG 28, 2015			
		6187791*	NOV 11, 2012			
		6399632*	NOV 11, 2012			
		6046183	MAR 20, 2011			
		4357324	FEB 24, 2003			
4357324*	AUG 24, 2003					
020180 001	FINASTERIDE; PROSCAR					
020038 001	FLUDARABINE PHOSPHATE; FLUDARA					

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020549 003	FLUTICASONE PROPIONATE; FLOVENT	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 001	FLUTICASONE PROPIONATE; FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 002	FLUTICASONE PROPIONATE; FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 003	FLUTICASONE PROPIONATE; FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
>ADD>	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-413		
>ADD>	FLUVASTATIN SODIUM; LESCOL XL	5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>	FORMOTEROL FUMARATE; FORADIL	5354772	OCT 11, 2011	U-413		
>ADD>	FORMOTEROL FUMARATE; FORADIL	6488027	MAR 08, 2019	U-109		
019915 002	POSINOPRIL SODIUM; MONOPRIL	4337201	DEC 04, 2002		I-342	SEP 25, 2004
		5006344	JUL 10, 2009		NPP	JUN 27, 2006
019915 003	POSINOPRIL SODIUM; MONOPRIL	5006344*PED	JAN 10, 2010			
		4337201	DEC 04, 2002			
019915 004	POSINOPRIL SODIUM; MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020286 001	POSINOPRIL SODIUM; MONOPRIL-HCT	5006344*PED	JAN 10, 2010			
		4337201	DEC 04, 2002			
020286 002	POSINOPRIL SODIUM; MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
>ADD>	GATIFLOXACIN; ZYMAR	5006344*PED	JAN 10, 2010			
>ADD>	GATIFLOXACIN; ZYMAR	4337201	DEC 04, 2002			
>ADD>	GEMIFLOXACIN MESYLATE; FACTIVE	4337201	DEC 04, 2002			
>ADD>	GEMIFLOXACIN MESYLATE; FACTIVE	5006344*PED	JAN 10, 2010			
>ADD>	GEMIFLOXACIN MESYLATE; FACTIVE	4337201*PED	JUN 04, 2003			
>ADD>	GEMIFLOXACIN MESYLATE; FACTIVE	5880283	DEC 05, 2015			
>ADD>	GEMIFLOXACIN MESYLATE; FACTIVE	4980470	DEC 15, 2009			
021493 001	GATIFLOXACIN; ZYMAR	5633262	JUN 15, 2015		NDF	MAR 28, 2006
>ADD>	GATIFLOXACIN; ZYMAR	5776944	JUN 15, 2015		NCE	DEC 17, 2004
>ADD>	GATIFLOXACIN; ZYMAR	5962468	JUN 15, 2015		NCE	MAY 05, 2008
>ADD>	GATIFLOXACIN; ZYMAR	6262071	SEP 21, 2019			
>ADD>	GATIFLOXACIN; ZYMAR	6331550	SEP 21, 2019			
>ADD>	GATIFLOXACIN; ZYMAR	6340689	SEP 14, 2019			
>ADD>	GATIFLOXACIN; ZYMAR	6455540	SEP 21, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PEX EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021282 002	5091190	SEP 05, 2009	U-111		
>ADD>	021532 002	5545413	JUL 21, 2008	U-111		
>ADD>	021532 003	5091190	SEP 05, 2009	U-111		
>ADD>	021532 005	5545413	JUL 21, 2008	U-111		
>ADD>	020453 001	4612008	SEP 16, 2003			
>ADD>	021455 001	5024843	SEP 05, 2009			
>ADD>	021321 001	5082668	SEP 16, 2003			
>ADD>		5091190	SEP 05, 2009			
>ADD>		5545413	JUL 21, 2008			
>ADD>		5591454	JAN 07, 2014			
>ADD>		6372252	APR 28, 2020			
>ADD>		5616599	APR 01, 2014			
>ADD>		5616599	APR 01, 2014			
>ADD>		5616599	APR 01, 2014			
>ADD>		4794106	AUG 28, 2006			
>ADD>		6248726	JUN 19, 2018			
>ADD>		4761237	AUG 02, 2005			
>ADD>		4886789	DEC 12, 2006			
>ADD>		6077836	JUN 20, 2017			
>ADD>		5521184	MAY 28, 2013			
>ADD>		5521184	MAY 28, 2013			
>ADD>		5521184	MAY 28, 2013			
>ADD>		4364921	MAR 06, 2005			
>ADD>		4364921	MAR 06, 2005			
>ADD>		5110493	MAY 05, 2009			
>ADD>		5110493*PED	NOV 05, 2009			
>ADD>		5047407*PED	MAY 17, 2010			
>ADD>		5047407	NOV 17, 2009			
>ADD>		5047407	NOV 17, 2009			
>ADD>		5047407	NOV 17, 2009			
>ADD>		5047407*PED	MAY 17, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021004 001	LAMIVUDINE; EPIVIR-HBV	5047407	NOV 17, 2009		I-387	JAN 17, 2006
020241 001	LAMOTRIGINE; LAMICTAL	5047407*PED	MAY 17, 2010		I-387	JAN 17, 2006
020241 002	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 003	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 004	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 005	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 006	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020764 001	LAMOTRIGINE; LAMICTAL CD				I-387	JAN 17, 2006
020764 002	LAMOTRIGINE; LAMICTAL CD				I-387	JAN 17, 2006
020764 003	LAMOTRIGINE; LAMICTAL CD				I-395	JUN 13, 2006
020764 004	LAMOTRIGINE; LAMICTAL CD				I-395	JUN 13, 2006
020905 001	LEFLUNOMIDE; ARAVA				I-395	JUN 13, 2006
020905 002	LEFLUNOMIDE; ARAVA				NP	FEB 13, 2006
020905 003	LEFLUNOMIDE; ARAVA				I-393	MAY 23, 2006
021488 001	LEUPROLIDE ACETATE; ELIGARD	5362755	NOV 08, 2011	U-332	I-393	MAY 23, 2006
020837 001	LEVABUTEROL HYDROCHLORIDE; XOPENEX				I-393	MAY 23, 2006
020634 001	LEVOFLOXACIN; LEVAQUIN				I-393	MAY 23, 2006
020634 002	LEVOFLOXACIN; LEVAQUIN				I-393	MAY 23, 2006
020634 003	LEVOFLOXACIN; LEVAQUIN				I-393	MAY 23, 2006
020635 001	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				I-393	MAY 23, 2006
020635 002	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				I-393	MAY 23, 2006
020635 003	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				I-393	MAY 23, 2006
021199 001	LEVOFLOXACIN; QUIXIN	5503407	DEC 20, 2010		I-387	JAN 17, 2006
021301 001	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 002	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 003	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 004	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 005	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 006	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 007	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 008	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 009	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 010	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022		I-387	JAN 17, 2006
021301 011	LEVOTHYROXINE SODIUM; LEVOXYL	5589180	MAR 17, 2009	U-485	I-387	JAN 17, 2006
021301 012	LEVOTHYROXINE SODIUM; LEVOXYL	5411738	MAY 02, 2012		I-387	JAN 17, 2006
020612 001	LIDOCAINE; LIDODERM	5827529	OCT 27, 2015		U-486	
		5709869	MAR 17, 2009		U-485	
		5601838	MAY 02, 2012		U-488	
021130 001	LINEZOLID; ZYVOX				NPP	DEC 19, 2005
021130 002	LINEZOLID; ZYVOX				NPP	DEC 19, 2005
021131 001	LINEZOLID; ZYVOX				NPP	DEC 19, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021132 001	LINEZOLID; ZYVOX	6521651	NOV 01, 2017		NPP	DEC 19, 2005
021226 001	LOPINAVIR; KALETRA	4659716	APR 21, 2004	U-142		
019658 002	LO RATADINE; CLARITIN	4659716*PED	OCT 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		4659716	APR 21, 2004	U-142		
		4659716*PED	OCT 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		6132758	JUN 01, 2018			
020641 002	LO RATADINE; CLARITIN	4659716	APR 21, 2004	U-142		
		4659716*PED	OCT 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
020704 002	LO RATADINE; CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
		4659716*PED	OCT 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		4659716	APR 21, 2004	U-142		
		4659716*PED	OCT 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
019670 002	LO RATADINE; CLARITIN-D	4659716	APR 21, 2004	U-142		
		4659716*PED	OCT 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
020470 002	LO RATADINE; CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U-142		
		4659716*PED	OCT 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		5314697	OCT 23, 2012			
		5314697*PED	APR 23, 2013			
>ADD>	075209 001				PC	JUL 21, 2003
>ADD>	075822 001				PC	AUG 09, 2003
>ADD>	075706 001				PC	NOV 29, 2003
>ADD>	076050 001				PC	JUL 30, 2003
>ADD>	020386 001				PC	SEP 17, 2005
>ADD>	020386 002				I-383	SEP 17, 2005
>ADD>	020386 003				I-383	SEP 17, 2005
>ADD>	021410 001				NCE	MAY 25, 2004
>ADD>	021410 002				NCE	MAY 25, 2004
>ADD>	021410 003				NCE	MAY 25, 2004
>ADD>	021202 004				NDF	OCT 13, 2003
>ADD>	021259 002				NDF	APR 03, 2004
>ADD>	019962 003				NDF	APR 03, 2004
>ADD>	076119 001				PC	JUN 16, 2003
>ADD>	076119 002				PC	JUN 16, 2003
>ADD>	076204 001				PC	SEP 21, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
076204 002	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL	4990517	JUN 30, 2009		PC	SEP 21, 2003
021085 001	MOXIFLOXACTIN HYDROCHLORIDE;AVELOX	5607942	MAR 04, 2014	U-298	I-385	FEB 28, 2006
021277 001	MOXIFLOXACTIN HYDROCHLORIDE;AVELOX IN SODIUM CHL	4990517	JUN 30, 2009	U-298		FEB 28, 2006
021598 001	MOXIFLOXACTIN HYDROCHLORIDE;VIGAMOX	5607942	MAR 04, 2014		NDF PED	APR 15, 2006 OCT 15, 2006
021204 001	NATEGLINIDE;STARLIX	4990517	DEC 30, 2009			
021204 002	NATEGLINIDE;STARLIX	5849752	DEC 30, 2009			
020636 001	NEVIRAPINE;VIRAMUNE	5607942	MAR 04, 2014			
>ADD>		5849752	DEC 05, 2016			
>ADD>		4990517	SEP 17, 2019			
>ADD>		5366972	NOV 22, 2011			
>ADD>		5366972	MAY 22, 2012			
>ADD>		5366972	NOV 22, 2011	U-167		
>ADD>		5366972	MAY 22, 2012			
>ADD>		5366972	NOV 22, 2011			
020933 001	NEVIRAPINE;VIRAMUNE	5366972	MAY 22, 2012			
021330 001	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010			
021330 002	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010			
020076 004	NICOTINE;HABITROL	4597961	MAY 21, 2008			
>ADD>		5016652	JAN 23, 2005	U-56		
>ADD>		4597961	MAY 21, 2008			
>ADD>		4597961	JAN 23, 2005			
020076 005	NICOTINE;HABITROL	5016652	MAY 21, 2008			
>ADD>		4597961	MAY 21, 2008			
>ADD>		5016652	JAN 23, 2005	U-56		
020076 006	NICOTINE;HABITROL	4597961	MAY 21, 2008			
>ADD>		5016652	MAY 21, 2008			
>ADD>		4946853	AUG 07, 2007	U-56		
019983 003	NICOTINE;PROSTEP	4946853	AUG 07, 2007			
019983 004	NICOTINE;PROSTEP	4946853	AUG 07, 2007			
020845 002	NITRIC OXIDE;INOMAX	5873359	JAN 23, 2013			
020845 003	NITRIC OXIDE;INOMAX	5873359	JAN 23, 2013			
>ADD>		4382892	SEP 02, 2003	U-297		
>ADD>		4551456	NOV 14, 2003			
019921 001	OFLOXACIN;OCUFLOX	4551456	NOV 14, 2003			
>ADD>		4382892	SEP 02, 2003	U-80	ODE PED	MAY 22, 2003 NOV 22, 2003
>ADD>		4551456	NOV 14, 2003			
021286 002	OLMESARTAN MEDOXOMIL;BENEVAS	4551456	MAY 14, 2004			
021286 001	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U-80		
021286 003	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U-500		
>ADD>		5616599	APR 01, 2014	U-500		
021229 001	OMEPRazole MAGNESIUM;PRLOSEC	4738974	APR 19, 2014	U-500	RTO	JUN 20, 2006
>ADD>		5900424	MAY 04, 2016			
>ADD>		4786505	APR 20, 2007			
>ADD>		4853230	APR 20, 2007			
>ADD>		5690960	NOV 25, 2014			
>ADD>		5817338	OCT 06, 2015			
>ADD>		5753265	JUN 07, 2015			
>ADD>		6403616	NOV 15, 2019			
>ADD>		6428810	NOV 03, 2019			
>ADD>		4786505	OCT 20, 2007			
>ADD>		4853230	OCT 20, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

A-16

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020007 003	ONDANSETRON HYDROCHLORIDE; ZOPRAN PRESERVATIVE	4695578	JAN 25, 2005	U-44		
020776 001	OXAPROZIN POTASSIUM; DAYPRO ALTA	4753789	JUN 24, 2006			
017577 001	OXYBUTYNIN CHLORIDE; DITROPAN	6030643	MAY 16, 2017	U-497		
018211 001	OXYBUTYNIN CHLORIDE; DITROPAN				NPP	APR 15, 2006
020897 001	OXYBUTYNIN CHLORIDE; DITROPAN XL				PED	OCT 15, 2006
020897 002	OXYBUTYNIN CHLORIDE; DITROPAN XL				NPP	APR 15, 2006
020897 003	OXYBUTYNIN CHLORIDE; DITROPAN XL				PED	APR 15, 2006
021351 002	OXYBUTYNIN CHLORIDE; DITROPAN XL				NPP	APR 15, 2006
020936 001	OXYBUTYNIN CHLORIDE; DITROPAN XL				PED	OCT 15, 2006
020936 002	OXYBUTYNIN CHLORIDE; DITROPAN XL				NPP	APR 15, 2006
020936 003	OXYBUTYNIN CHLORIDE; DITROPAN XL				PED	APR 15, 2006
021106 001	PEGVISOMANT; SOMAVERT	6548084	JUL 19, 2016		NDP	FEB 26, 2006
021106 002	PEGVISOMANT; SOMAVERT	6548084*PED	JAN 19, 2017			
021106 003	PEGVISOMANT; SOMAVERT	6548084	JUL 19, 2016			
		6548084*PED	JAN 19, 2017			
		6548084	JUL 19, 2016			
		6548084*PED	JAN 19, 2017			
		6548084	JUL 19, 2016			
		6548084*PED	JAN 19, 2017			
		6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
		5849535	SEP 21, 2015			
		5958879	SEP 27, 2011	U-507		
		5681809	SEP 27, 2011	U-507		
		6057292	SEP 21, 2015	U-507		
		5849535	SEP 21, 2015			
		5958879	SEP 27, 2011	U-507		
		5350836	SEP 27, 2011	U-507		
		5681809	SEP 27, 2011	U-507		
		6573378	SEP 24, 2010	U-507		
		6579981	JUN 17, 2020	U-501		
		6469015	OCT 22, 2019	U-501		
>ADD>	PENCICLOVIR SODIUM; DENAVIR					
020629 001	PENCICLOVIR SODIUM; DENAVIR					
>ADD>	PERGOLIDE MESYLATE; PERGOLIDE MESYLATE					
076061 001	PERGOLIDE MESYLATE; PERGOLIDE MESYLATE					
076061 002	PERGOLIDE MESYLATE; PERGOLIDE MESYLATE					
076061 003	PERGOLIDE MESYLATE; PERGOLIDE MESYLATE					
>ADD>	PIGLITAZONE HYDROCHLORIDE; ACTOS					
021073 001	PIGLITAZONE HYDROCHLORIDE; ACTOS					
021073 002	PIGLITAZONE HYDROCHLORIDE; ACTOS					
021073 003	PIGLITAZONE HYDROCHLORIDE; ACTOS					
>ADD>	PIGLITAZONE HYDROCHLORIDE; ACTOS					
021073 003	PIGLITAZONE HYDROCHLORIDE; ACTOS	4687777	JAN 17, 2011		PC	MAY 31, 2003
		4687777	JAN 17, 2011		PC	MAY 31, 2003
		4687777	JAN 17, 2011		PC	MAY 31, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	074726 003 POTASSIUM CHLORIDE; KIOR-CON M15	6500454	DEC 31, 2022		PC	DEC 24, 2003
>ADD>	021438 001 PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
>ADD>	021438 002 PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL	5403856	APR 04, 2012	U-71	NP	MAR 12, 2006
>ADD>	019901 001 RAMIPRIL; ALTACE	5403856	APR 01, 2012	U-71		
>ADD>	019901 002 RAMIPRIL; ALTACE	5403856	APR 01, 2012	U-71		
>ADD>	019901 003 RAMIPRIL; ALTACE	5403856	APR 04, 2012	U-71		
>ADD>	019901 004 RAMIPRIL; ALTACE	5403856	APR 04, 2012	U-71		
>ADD>	020903 001 RIBAVIRIN; REBETOL	6524570	NOV 01, 2016	U-499	M-26	MAR 06, 2005
>ADD>	020903 002 RIBAVIRIN; REBETOL	6524570*PED	MAY 01, 2017	U-499	M-26	MAR 06, 2005
>ADD>	021444 001 RISPERSION; RISPERSIONAL	4804663	DEC 29, 2007	U-516	M-15	MAR 03, 2005
>ADD>	021444 001 RISPERSION; RISPERSIONAL	5648093	JUL 15, 2004	U-516	M-15	MAR 03, 2005
>ADD>	021444 002 RISPERSION; RISPERSIONAL	6224905	JUN 10, 2017	U-516	M-15	MAR 03, 2005
>ADD>	021444 003 RISPERSION; RISPERSIONAL	4804663	DEC 29, 2007	U-516	M-15	MAR 03, 2005
>ADD>	021444 003 RISPERSION; RISPERSIONAL	5648093	DEC 29, 2007	U-516	M-15	MAR 03, 2005
>ADD>	021444 003 RISPERSION; RISPERSIONAL	6224905	JUN 10, 2017	U-516	M-15	MAR 03, 2005
>ADD>	021071 002 ROSIGLITAZONE MALEATE; AVANDIA	4562829	MAY 01, 2004	U-503	I-384	FEB 27, 2006
>ADD>	021071 003 ROSIGLITAZONE MALEATE; AVANDIA	4562829	MAY 01, 2004	U-503	I-384	FEB 27, 2006
>ADD>	021071 004 ROSIGLITAZONE MALEATE; AVANDIA	4562829	MAY 01, 2004	U-503	I-384	FEB 27, 2006
>ADD>	019414 001 RUBIDIUM CHLORIDE RB-82; CARDIOGEN-82	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	019839 001 SERTRALINE HYDROCHLORIDE; ZOLOFT	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	019839 002 SERTRALINE HYDROCHLORIDE; ZOLOFT	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	019839 003 SERTRALINE HYDROCHLORIDE; ZOLOFT	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	019839 004 SERTRALINE HYDROCHLORIDE; ZOLOFT	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	019839 005 SERTRALINE HYDROCHLORIDE; ZOLOFT	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	020926 001 SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	021179 001 SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	021179 002 SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 13, 2013		I-261	FEB 07, 2006
>ADD>	019766 001 SIMVASTATIN; ZOCOR	5100899	JUN 06, 2009	U-290	I-390	APR 16, 2006
>ADD>	019766 002 SIMVASTATIN; ZOCOR	5212155	MAY 18, 2010	U-291	I-390	APR 16, 2006
>ADD>	019766 003 SIMVASTATIN; ZOCOR	5308847	MAY 03, 2011	U-292	I-390	APR 16, 2006
>ADD>	019766 004 SIMVASTATIN; ZOCOR	5403833	APR 04, 2012	U-293	I-390	APR 16, 2006
>ADD>	019766 005 SIMVASTATIN; ZOCOR	5403833	APR 04, 2012	U-293	I-390	APR 16, 2006
>ADD>	021083 001 SIROLIMUS; RAPAMUNE	5100899	JUN 06, 2009	U-290	I-386	APR 11, 2006
>ADD>	021110 001 SIROLIMUS; RAPAMUNE	5212155	MAY 18, 2010	U-291	I-386	APR 11, 2006
>ADD>	021110 001 SIROLIMUS; RAPAMUNE	5308847	MAY 03, 2011	U-292	I-386	APR 11, 2006
>ADD>	021110 001 SIROLIMUS; RAPAMUNE	5403833	APR 04, 2012	U-293	I-386	APR 11, 2006
>ADD>	021110 002 SIROLIMUS; RAPAMUNE	5989591	MAR 11, 2018	U-293	I-386	APR 11, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020231 001	SODIUM FLUORIDE; COLGATE TOTAL	5288480	JUL 16, 2008		ODE	OCT 31, 2004
>ADD>						
020280 007	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 001	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 002	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 003	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 005	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 008	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 009	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 010	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 011	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 012	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 013	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
021148 001	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014		ODE	OCT 31, 2004
021148 002	SOMATROPIN RECOMBINANT; NORDITROPIN	5849700	DEC 15, 2015	U-340		
021148 003	SOMATROPIN RECOMBINANT; NORDITROPIN	5849704	DEC 15, 2015	U-340		
021148 004	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014			
021148 005	SOMATROPIN RECOMBINANT; NORDITROPIN	5849700	DEC 15, 2015	U-340		
021151 006	SOTALOL HYDROCHLORIDE; BETAPACE AF	5849704	DEC 15, 2015		NP	FEB 22, 2003
021151 007	SOTALOL HYDROCHLORIDE; BETAPACE AF	5633352	MAY 27, 2014		NP	FEB 22, 2003
020413 001	STAVUDINE; ZERIT	5849704	DEC 15, 2015		NP	FEB 22, 2003
021453 001	STAVUDINE; ZERIT XR	4978655	JUN 24, 2008		NP	AUG 22, 2003
021453 002	STAVUDINE; ZERIT XR	4978655*PED	DEC 24, 2008	U-248	NDF	DEC 31, 2005
021453 003	STAVUDINE; ZERIT XR	4978655*PED	DEC 24, 2008	U-248	NDF	DEC 31, 2005
021453 004	STAVUDINE; ZERIT XR	4978655*PED	DEC 24, 2008	U-248	NDF	DEC 31, 2005
020600 001	TAZAROTENE; TAZORAC	4978655	JUN 24, 2008	U-248	NDF	JUL 01, 2005
020600 002	TAZAROTENE; TAZORAC	4978655*PED	DEC 24, 2008	U-248	NDF	DEC 31, 2005
020749 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	5914334	JUN 07, 2014	U-517		JUL 01, 2006
021124 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	6258830	JUN 07, 2014	U-517		JUL 01, 2006
020489 001	TESTOSTERONE; ANDRODERM	6121314	MAY 18, 2012	U-504		JUL 01, 2006
020489 001	TESTOSTERONE; ANDRODERM	4863970	NOV 14, 2006	U-504		JUL 01, 2006
		4983395	NOV 12, 2007	U-490		JUL 01, 2006
		5152997	DEC 11, 2010			
		5164190	DEC 11, 2010			
		4849224	NOV 12, 2007			
		4855294	SEP 06, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020489 002	TESTOSTERONE; ANDRODERM	48492224	NOV 12, 2007			
		4855294	SEP 06, 2008			
		4863970	NOV 14, 2006			
		4983395	NOV 12, 2007			
		5152997	DEC 11, 2010			
		5164190	DEC 11, 2010	U-490		
>ADD>	021543 001	TESTOSTERONE; STRIANT			NP	JUN 19, 2006
>ADD>	021454 001	TESTOSTERONE; TESTIM			NP	OCT 31, 2005
>ADD>	020785 001	THALIDOMIDE; THALOMID				
>ADD>	020785 002	THALIDOMIDE; THALOMID				
>ADD>	020785 003	THALIDOMIDE; THALOMID				
>ADD>	020505 001	TOPIRAMATE; TOPAMAX	6561977	OCT 23, 2020	U-371	
>ADD>	020505 002	TOPIRAMATE; TOPAMAX	6561976	AUG 28, 2018	U-371	
>ADD>	020505 003	TOPIRAMATE; TOPAMAX	6561977	OCT 23, 2020	U-371	
>ADD>	020505 004	TOPIRAMATE; TOPAMAX	6561976	AUG 28, 2018	U-371	
>ADD>	020505 005	TOPIRAMATE; TOPAMAX	6045501	AUG 28, 2018	U-371	
>ADD>	020505 006	TOPIRAMATE; TOPAMAX	6315720	OCT 23, 2020	U-442	
>ADD>	020844 001	TOPIRAMATE; TOPAMAX SPRINKLE	6561977	OCT 23, 2020	U-371	
>ADD>	020844 002	TOPIRAMATE; TOPAMAX SPRINKLE	6561976	AUG 28, 2018	U-371	
>ADD>	020844 003	TOPIRAMATE; TOPAMAX SPRINKLE	6045501	AUG 28, 2018	U-371	
>ADD>	021108 001	TRAVOPROST; TRAVATAN	6315720	OCT 23, 2020	U-442	
>ADD>	020550 001	TRATTINOIN; RENOVA	6531141	MAR 07, 2020	M-23	FEB 13, 2006
>ADD>	020550 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX				
>ADD>	020699 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	4612008	SEP 16, 2003	U-366	
>ADD>	020699 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6146662	AUG 14, 2007	U-366	
>ADD>	020699 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	4612008	SEP 16, 2003	U-366	
>ADD>	020699 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6146662	AUG 14, 2007	U-366	
>ADD>	020552 001	VERAPAMIL HYDROCHLORIDE; COVERA-HS	4626538	JUN 06, 2008		
>ADD>	020552 002	VERAPAMIL HYDROCHLORIDE; COVERA-HS	4626538	JUN 06, 2008		
>ADD>	020859 001	ZALEPLON; SONATA				
>ADD>	020859 002	ZALEPLON; SONATA				

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 23RD EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

PATENT & EXCLUSIVITY ABBREVIATIONS

RTO RX TO OTC SWITCH OR OTC USE

EXCLUSIVITY DOSING SCHEDULE

D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
 D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
 D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
 D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

EXCLUSIVITY INDICATION

I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
 I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
 I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
 I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
 I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
 I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN \geq 2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
 I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
 I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
 I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
 I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
 I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
 I-391 INTENTIONALLY LEFT BLANK
 I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
 I-393 CHRONIC BACTERIAL PROSTATITIS
 I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
 I-395 TO IMPROVE PHYSICAL FUNCTION

EXCLUSIVITY MISCELLANEOUS

- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01

PATENT USE

- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS



Approved Drug Products, ADP SUBSCRIPTION ORDER FORM

Order Processing
Code: **8392**

Easy Secure Internet:
bookstore.gpo.gov

Toll Free: 866 512-1800
Phone: 202 512-1800
Fax: 202 512-2250

Mai: Superintendent of Documents
PO Box 371954
Pittsburgh, PA 15250-7954

YES, enter my subscription(s) as follows:

_____ subscription(s) of the *Approved Drug products with Therapeutic Equivalence Evaluations, ADP*, and the monthly Cumulative Supplements, for \$108.00 per year. The total cost of my order is \$____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.



Personal name _____

(Please type or print)

Company name _____

Street address _____

City, State, Zip code _____

Daytime phone including area code _____

Check method of payment:

Check payable to Superintendent of Documents

SOD Deposit Account

--	--	--	--	--	--	--	--	--	--

 —

VISA MasterCard Discover/NOVUS American Express

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

(expiration date)

--	--	--	--

Thank you for your order!

Purchase Order Number _____

Authorizing signature _____

02/03